ADVANCED GLYCATION END PRODUCTS (AGES)

Advanced glycation end products

Key players in skin aging?

Aging is the progressive accumulation of damage to an organism over time leading to disease and death. Aging research has been very intensive in the last years aiming at characterizing the pathophysiology of aging and finding possibilities to fight age-related diseases. Various theories of aging have been proposed. In the last years advanced glycation end products (AGEs) have received particular attention in this context. AGEs are formed in high amounts in diabetes but also in the physiological organism during aging. They have been etiologically implicated in numerous diabetes- and age-related diseases. Strategies inhibiting AGE accumulation and signaling seem to possess a therapeutic potential in these pathologies. However, still little is known on the precise role of AGEs during skin aging. In this review the existing literature on AGEs and skin aging will be reviewed. In addition, existing and potential anti-AGE strategies that may be beneficial on skin aging will be discussed.

Introduction

Aging is defined as the progressive accumulation of damage over time, leading to disturbed function on the cellular, tissue and organ level and eventually to disease and death. Aging is a complex, multifactorial process where genetic, endogenous and environmental factors play a role.1

Skin is the largest organ of the human body and also the boundary between an organism and environment. As such, skin is subjected not only to the internal aging process but also to various external stressors, leading to distinct structural changes and affecting not only its youthful appearance, but also its various physiological functions. Aged skin shows disturbed skin permeability, angiogenesis, lipid and sweat production, immune function and vitamin D synthesis, manifesting among others as impaired wound healing, atrophy, vulnerability to external stimuli and development of several benign and malignant diseases (reviewed in Zouboulis et al.).2

Endogenously aged skin refers to changes reflecting the internal aging process of the organism and is being observed mainly in ultraviolet (UV) light-protected skin areas, such as the inner side of the arms. Macroscopically it is recognized by fine wrinkles, loss of elasticity, reduced epidermal and dermal thickness, while microscopically epidermal atrophy, decreased mitotic rate of basal keratinocytes, decreased proliferative capacity and cellular senescence, atrophy of the dermal extracellular matrix and change of the physiological properties of the connective tissue are typical characteristics.24 Exogenously aged skin or photoaged skin is the skin where endogenous aging processes are being aggravated by external stressors, mainly UV irradiation,2,5 but also by tobacco,6 chemicals and pollution.2,4 Apart from many similarities with endogenously aged skin, extrinsic aged skin is also characterized by a thickened epidermis and a hyperplasia of elastic tissue (solar elastosis).2,4

Until today, more than 300 theories of aging have been proposed, among them the theory of cellular senescence, decreased proliferative capacity and telomere shortening, mitochondrial DNA single mutations, the free radical theory and others, none of which can fully explain all changes observed in aging.711 According to the inflammatory theory of aging, a common characteristic of skin aging factors is their ability to induce or maintain proinflammatory changes and trigger a local inflammatory response which through subsequent immune responses, matrix metalloproteinase (MMP) activation and proinflammatory cytokine production contributes to the structural changes observed in aged skin.12

In the recent years, the role of advanced glycation end products (AGEs) has been increasingly discussed in skin aging, and the potential of anti-AGE strategies has received high interest from pharmaceutical companies for the development of novel anti-aging cosmeceutical compounds.

The aim of this work is to critically review the existing literature on AGEs and provide evidence that they play an important role in the pathogenesis of skin aging. Furthermore, existing and potential strategies against the deleterious effects of AGEs on skin aging will be discussed.

Biochemistry of AGEs

Glycation is the non-enzymatic reaction between reducing sugars, such as glucose, and proteins, lipids or nucleic acids.13 Glycation has to be distinguished from glycosylation, which is an enzymatic reaction. Since its first description by Maillard in 1912 and its involvement in food browning during thermal processing by Hodge 50 years later, its presence in living systems and involvement in various pathologies of the human body, including aging and diabetes, have been an intensive field of research.14,15

Formation of AGEs is a complicated molecular process involving simple and more complex multistep reactions. During the classical Maillard reaction electrophilic carbonyl groups of glucose or other reactive sugars react with free amino groups of amino acids (especially of basic lysine or arginine residues), forming a non-stable Schiff base.16 Further rearrangement leads to formation of a more stable ketoamine (Amadori product) (Fig. 1).13,16 Schiff bases and Amadori products are reversible reaction products. However, they can react irreversibly with amino acid residues of peptides or proteins to form protein adducts or protein crosslinks.13,16 Alternatively, they can undergo further oxidation, dehydration, polymerization and oxidative breakdown reactions to give rise to numerous other AGEs.13,17 Oxygen, reactive oxygen species (ROS) and redox active transition metals accelerate AGE formation. When an oxidative step is involved, the products are called advanced glycoxidation end products.13,17

Figure 1. Schematic presentation of the Maillard reaction. Reactive carbonyl groups of a reducing sugar react with neutrophilic free amino groups of proteins to form a reversible Schiff base. Through rearrangement a more stable Amadori product is formed. Dependent on the nature of these early glycation end products, protein adducts or protein crosslinks are formed.

AGEs are a very heterogeneous group of molecules. Since the discovery of the first glycated protein, glycated hemoglobin in diabetes, numerous other AGEs have been detected. Some of them have characteristic autofluorescent properties, which simplifies their identification in situ or in vivo.13 To date, numerous AGEs have been identified. Table 1 lists the most commonly found ones in the skin.1728

Table 1. Detected AGEs in skin*

Carboxymethyl-lysine (CML) was first described by Ahmed and represents the most prevalent AGE in vivo.29,30 It is a non-fluorescent protein adduct. Mechanisms of its formation include oxidative degradation of Amadori products or direct addition of glyoxal to lysine. It seems to be the major epitope of the commonly used polyclonal anti-AGE antibodies.30

Pentosidine was first isolated and characterized by Sell and Monnier. It is composed of an arginine and a lysine residue crosslinked to a pentose.31 Pentosidine is a fluorescent glycoxidation product and forms protein-protein crosslinks.16

Dicarbonyl compounds like 3-deoxyglucosome, methylglyoxal and glyoxal derive from oxidative degradation or autooxidation of Amadori products and other pathways.13,32 These dicarbonyl compounds are very reactive molecules leading to protein crosslinks.13 Other in vivo characterized AGEs include glucosepane, carboxymethyl-hydroxy-lysine, carboxyethyl-lysine (CEL), fructose-lysine, methylglyoxal-derived hydroimidazolones and pyrraline, which form non-fluorescent protein adducts, while glyoxal-lysine dimer (GOLD) and methylglyoxal-lysine dimer (MOLD) form non-fluorescent protein crosslinks.13,17

AGEs can be exogenously ingested (through food consumption) or be endogenously produced. Endogenous AGE formation is increased in diabetes; however, AGEs are also formed at lower rates by normal metabolic processes of the organism.33 Environmental factors, such as diet and smoking influence the rate of AGE formation.34 Moreover, it seems that the level of circulating AGEs levels are genetically determined, as shown in a cohort study of healthy monozygotic and heterozygotic twins.35

The content of AGEs in the organism is not only defined by the rate of their formation but also by the rate of their removal. Many cells have developed intrinsic detoxifying pathways against accumulation of AGEs.36 The glutathione-dependent glyoxalase system, comprising of glyoxalase (Glo) I and II, has a key role in the defense against glycation.37 This system uses reduced glutathione (GSH) to catalyze the conversion of glyoxal, methylglyoxal and other α-oxoaldehydes to the less toxic D-lactate.37 Other enzymatic systems include fructosyl-amine oxidases (FAOXs) and fructosamine kinases, relatively new classes of enzymes which recognize and break Amadori products.38 However, FAOXs or “amadoriases” have been found to be expressed only in bacteria, yeast and fungi but not in mammals. They oxidatively break Amadori products but act mostly on low molecular weight compounds.39 On the contrary, fructosamine kinases are expressed in various genomes including humans.38 These intracellular enzymes phosphorylate and destabilize Amadori products leading to their spontaneous breakdown.39Fructosamine-3-kinase (FN3K), one of the most studied enzymes in this system, is almost ubiquitary expressed in human tissues including the skin. Thus, it plays an important role in the intracellular breakdown of Amadori products.40

Receptors for AGEs

AGEs not only exert their deleterious actions due to their biological properties per se, but also through their interaction with specific receptors. Receptor for AGEs (RAGE) is a multiligand member of the immunoglobulin superfamily of cell surface receptors, encoded by a gene on chromosome 6 near the major histocompatibility complex III. It is a pattern recognition receptor binding in addition to AGEs various other molecules such as S-100/calgranulins, high motility group protein B1 (amphoterine), β-amyloid peptides and β-sheet fibrils.33,41 The binding of ligands to RAGE stimulates various signaling pathways including the mitogen-activated protein kinases (MAPKs) extracellular signal-regulated kinases (ERK) 1 and 2, phosphatidyl-inositol 3 kinase, p21Ras, stress-activated protein kinase/c-Jun-N-terminal kinase and the janus kinases.33,41 Stimulation of RAGE results in activation of the transcription factor nuclear factor kappa-B (NFκB) and subsequent transcription of many proinflammatory genes.41,42Interestingly, RAGE-induced activation of NFκB is characterized by a sustained and self-perpetuating action, through induction of positive feedback loops and overwhelming of the autoregulatory negative feedback loops. RAGE activation leads to new synthesis of the transcriptionally active subunit p65, which overwhelms the newly synthesized inhibitor IκBα. Moreover NFκB increases further expression of RAGE, which itself further stimulates NFκB, forming a vicious cycle of self-renewing and perpetuating proinflammatory signals.41 RAGE activation can directly induce oxidative stress by activating nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase (NOX), decreasing activity of superoxide dismutase (SOD), catalase and other pathways, and indirectly by reducing cellular antioxidant defenses, like GSH and ascorbic acid.41,43,44 The reduction of GSH leads furthermore to decreased activity of Glo I, the major cellular defense system against methylglyoxal, therefore supporting further production of AGEs.37 RAGE is almost ubiquitary expressed in the organism, typically at low levels, and its expression is upregulated under various pathologic conditions.41,45 In the skin, RAGE expression was observed in both epidermis and dermis, and it was increased in sun-exposed compared with UV irradiation-protected areas. Keratinocytes, fibroblasts, dendritic cells and to a lesser extent endothelial cells and lymphocytes express RAGE.45 Not only in vivo, but also in vitro, various skin cells types have been shown to express RAGE (Table 2).43,4551

Table 2. Expression of human RAGE in skin and skin cells*

RAGE is the most studied receptor for advanced glycation end products. Another group of cell surface receptors, AGER1, AGER2 and AGER3 seem to regulate endocytosis and degradation of AGEs, thus counteracting the effects of RAGE.52 AGER1 has been further shown to counteract AGEs-induced oxidative stress via inhibition of RAGE signaling.53,54 Soluble RAGE (sRAGE) is a truncated splice variant of RAGE containing the ligand-binding domain but not the transmembrane domain and has been found in plasma. sRAGE is a soluble extracellular protein without signaling properties and it is considered as a natural decoy receptor of RAGE.55

Role of AGEs During Skin Aging

Cutaneous accumulation of AGEs is a feature of skin aging

As mentioned above, AGEs can be directly formed in the organism or be exogenously ingested. Accumulation of AGEs has been detected in various tissues during aging and diabetes, including articular collagen, skeletal and smooth vascular muscles or glomerular basement membranes.5658 Accordingly, deposited AGEs in these tissues have been implicated in various diabetes- or age-associated pathologies such as diabetic angiopathy, age- and diabetes-associated macular degeneration and osteoarthritis.5662

Skin, due to its easy accessibility, offers an excellent opportunity for minimal invasive or even non-invasive investigation of glycation, taking advantage of the characteristic autofluorescent properties of AGEs. Accumulation of AGEs in the skin has been therefore thoroughly studied and is detected not only in diabetes as expected but also during chronological aging.20,63,64 Glycation-associated skin autofluorescence was shown to correlate with chronological aging in a large number of healthy subjects.65

It is a general perception today that AGE accumulation is dependent on protein turnover rate; therefore long-lived proteins are thought to be mainly modified by glycation.66 Collagen types I and IV, exhibiting a slow turnover rate of about 10 y, and other dermal long-lived proteins like fibronectin mainly suffer from glycation during intrinsic chronological aging.19,20 The appearance of glycated collagen is first observed at the age of 20. It accumulates with a yearly rate of about 3,7% reaching a 30–50% increase at 80 y of age.20,67 CML was recently histochemically detected in human epidermis from healthy donors.18 The upper epidermal layers were mostly involved (stratum spinosum, granulosum and corneum) and the authors identified cytokeratin 10 (CK10) (expressed by differentiated keratinocytes) as a target protein for CML modification. The amount of CML in younger donors seemed to be weak in comparison to the older ones. The latter study had restrictions, as the size of the sample was small and heterogeneous, but indicates a potential involvement of AGEs in epidermal physiology and a possible involvement of more short-lived proteins in glycation chemistry. Moreover, in an in vitro reconstructed organ skin model, both epidermis and dermis, as well as their functions, were modified by glycation.68

AGEs also seem to highly accumulate in extrinsically aged skin. Until now, the deleterious effects of UV irradiation have been mainly attributed to proinflammatory changes, apoptosis, oxidative damage, mutagenesis and induction of MMPs.2,5 However, it has been shown that in young individuals, where typically no significant accumulation of AGEs in sun-protected skin is observed, sun-exposed areas display an increased deposition of these substances.20,69 Accumulation of AGEs was mainly found in sites of solar elastosis in sun-exposed skin, showing that UV irradiation may also precipitate the formation of AGEs in vivo.20,23 It is tempting to speculate that formation of AGEs in sun-exposed skin may be one additional mechanism mediating the various structural and functional modifications during photoaging.

Moreover, smoking, a typical aggravating factor of skin aging, accelerates formation of AGEs and increases their deposition in various tissues including skin.70,71 Another important environmental factor for aging is diet. The content of AGEs in food is highly dependent on the method of preparation, like cooking time and temperature. Fried food contains in general far higher amounts of AGEs than boiled or steamed food.72 Approximately 10–30% of ingested AGEs are absorbed in the circulation.73 Dietary AGEs directly correlate with serum levels of AGEs and inflammatory markers in healthy human subjects, respectively.73

It has been widely accepted that AGEs, once formed, can be only removed when the modified proteins degrade. However it has now become apparent that in the organism various enzymatic systems seem to be involved in the degradation or removal of AGEs. As mentioned above, Glo I is an enzyme responsible for the removal of reactive α-dicarbonyl compounds. Interestingly, decreased activity of such defense systems against AGEs has been reported during aging.44 These age-related changes may further increase the extent of deposited AGEs in a living organism over time.

Consequences of AGE deposition in skin

AGEs can be formed intracellularly and extracellularly. Their presence in biological molecules modifies their biomechanical and functional properties. Proteins, lipids and nucleic acids can be targets of advanced glycation, modifying enzyme-substrate interactions, protein-DNA interactions, protein-protein interactions, DNA regulation and epigenetic modulation, thus interfering with numerous physiological functions of the organism. Moreover, AGEs are themselves reactive molecules which through interaction with their receptors activate various molecular pathways in vivo, thus becoming involved in inflammation, immune response, cell proliferation and gene expression (Fig. 2).

Figure 2. Effects of AGEs on skin. AGEs are formed intracellularly and extracellularly. They can react with proteins, lipids and nucleic acids in almost all skin cells as well as on intracellular or extracellular proteins. Through alteration of the physicochemical properties of dermal proteins, decreased cell proliferation, increased apoptosis and senescence, induction of oxidative stress and proinflammatory mediators as well as other pathways, AGEs contribute to the overall picture of skin aging. Triangles represent AGEs. Abbreviations: jak/stat, januskinase/signal transducers and activators of transcription; MCP-1, monocyte chemotactic protein-1; all other abbreviations are already explained in the text.

1. Extracellular matrix proteins

Extracellular matrix (ECM) proteins have been regarded as one of the major target structures for glycation. The most abundant collagen type in the skin is type I, whereas collagen IV is being found in the basal membrane. Collagen is one of the strongest proteins. In the skin, it is not only used as a supportive framework for mechanical support for cells and tissues, but represents an active component being able to interact with cells and affect various cellular functions such as migration, differentiation and proliferation.

Collagen glycation impairs its function in various ways. Intermolecular crosslinks of adjacent collagen fibers change its biomechanical properties leading to stiffness and decreased flexibility, thus increasing its susceptibility to mechanical stimuli.74 The change of its charge and the formation of AGEs on side chains of collagen affect its contact sites with cells and other matrix proteins and inhibit its ability to react with them.75 The precise aggregation of monomers into the triple helix may be affected as well as the association of collagen IV with laminin in the basal membrane.16 Modified collagen resists degradation by MMPs, thus inhibiting its removal and replacement by newly synthesized and functional one.62Accordingly, tissue permeability and turnover is impaired.16,76

Other extracellular matrix proteins suffering from advanced glycation are elastin and fibronectin, contributing further to dermal dysfunction.19,20,23 Of note, CML-modified elastin has been found almost exclusively in sites of actinic elastosis and not in sun-protected skin, underlining its potential role in photoaging. Indeed, UV irradiation stimulates glycation of elastin in the presence of sugars. Moreover, CML-modified elastin assembled in large and irregular structures, has decreased elasticity and is resistant to proteolytic degradation.77

It has been shown that in vitro glycated skin samples have impaired biomechanical properties.78 In vivo, decreased skin elasticity characterizes diabetic subjects in comparison to healthy controls.79

2. Intracellular proteins

Intermediate filaments such as vimentin in fibroblasts and CK10 in keratinocytes have been found to be modified by AGEs.18,22 Cytoskeletal proteins are important in providing stability of the cytoskeleton and are crucially involved in numerous cellular functions such as migration and cellular division. Various other intracellular proteins including enzymes and growth factors may be targets of non-enzymatic modification by sugars. Glycated basic fibroblast growth factor (bFGF) displays impaired mitogenic activity in endothelial cells.80 Glycation of enzymes of the ubiquitin-proteasome system and of the lysosomal proteolytic system has been shown to inhibit their action.81 Antioxidant and other protective enzymes such as Cu-Zn-SOD can be inactivated.82 Other intracellular components, such as DNA and lipids can be glycated with detrimental effects on their function.13,83

3. Receptors for AGEs: RAGE

AGEs do not only act by altering the physicochemical properties of glycated proteins. Interestingly, AGEs may bind to their cell surface receptor, RAGE, initiating a cascade of signals influencing cell cycle and proliferation, gene expression, inflammation and extracellular matrix synthesis (reviewed in Bierhaus et al.).41 As mentioned above, RAGE is broadly expressed in human skin and in epidermal keratinocytes, dermal fibroblasts and endothelial cells in vitro. It is highly found in sites of solar elastosis, and its expression is induced by advanced glycation end products and proinflammatory cytokines like TNFα.45 In skin cells RAGE has been shown to decrease cell proliferation, induce apoptosis and increase MMPs production.47 Many of these effects involve NFκB signaling.47

4. Effects of AGEs on resident skin cells

AGEs have been shown to affect various functions of skin cells in vitro (Table 3). They decrease proliferation and enhance apoptosis of human dermal fibroblasts, an effect which is at least partly RAGE-dependent and correlates with the activation of NFκB and caspases.87 In keratinocytes, AGEs decrease cell viability and migration and induce the expression of proinflammatory mediators.84 Moreover, AGEs are able to induce premature senescence in human dermal fibroblasts and in normal human keratinocytes in vitro.86,89,90 Collagen and ECM protein synthesis have been also found to be decreased, while the expression of MMPs is induced.47 Dicarbonyls such as glyoxal and methylglyoxal impair the signaling of epidermal growth factor receptor (EGFR), a receptor controlling various cellular functions such as proliferation, differentiation, motility and survival, by formation of EGFR crosslinks, blocking of phosphorylation and impaired activation of ERKs and phospholipase C.92 Various other growth factors or proteins significant for cellular functions, like bFGF, may be glycated inhibiting their functions.80 In the context of extrinsic aging, AGEs seem to render cells more sensitive to external stimuli, as UVA irradiated fibroblasts and keratinocytes exhibit decreased viability after exposure to AGEs.85,93

Table 3. Effects of AGEs/RAGE on skin morphology and physiology during aging*

5. The role of oxidative stress

Oxidative stress has been widely accepted to mediate the deleterious effects of solar radiation in the skin during photoaging. Interestingly, in vitro exposure of AGEs to UVA irradiation leads to formation of ROS, such as superoxide anion, hydrogen peroxide and hydroxyl radicals.93 AGEs can lead to ROS formation in cells by various ways. They can stimulate NOX to induce production of superoxide anion or they can compromise cellular antioxidant defense systems, e.g. inactivation of Cu-Zn-SOD by cross-linking and site-specific fragmentation of this molecule.82 Moreover, AGEs are themselves very reactive molecules. As early as during their crosslinking reactions they can act as electron donors leading to formation of superoxide anions.94 Glycation of proteins creates active enzyme-like centers (cation-radical sites of crosslinked proteins) able to catalyze one-electron oxidation-reduction reactions leading to ROS generation with or without presence of oxygen or transition metals such as iron and copper.94-,96

Finally, autofluorescent AGEs, such as pentosidine, can act as endogenous photosensitizers leading to increased ROS formation after UVA irradiation of human skin.97 UV irradiation of human keratinocytes and fibroblasts in the presence of AGEs led to increased ROS formation and decreased proliferation in vitro.85

6. Skin AGEs as biomarkers of aging

As AGEs have been etiologically implicated in aging and aging-related pathologies, the idea of using them as biomarkers is appealing. AGEs in the skin have been initially measured by western blots (WB) with polyclonal antibodies or by autofluorescence measurements of skin biopsies, thus restricting the wide use of these measurements. An AGE-Reader (DiagnOptics B.V., Groningen, The Netherlands) has been introduced some years ago as a new, non-invasive method to measure in vivo the skin content of AGEs based on their characteristic autofluorescence.98100

Until now it has been shown that skin autofluorescence positively correlates with various diabetes- and age-related complications such as micro- and macrovascular complications, renal disease, cardiovascular events, overall mortality, age-related macular degeneration and chronic renal disease.99,101,102 Skin glycation has been proposed as a prognostic factor for the development of diabetic complications.103Lately it was shown that skin autofluorescence increases with chronological aging and correlates with skin deposition of AGEs, making this method a potential tool in investigating the effect of various anti-aging products of the cosmetic industry.104

Anti-AGE Strategies: Current Knowledge and Future Perspectives

Since the emergence of AGEs as an important pathogenetic factor in diabetes and aging the development of strategies against AGEs has been in the center of scientific interest. Substances able to prevent or inhibit formation of AGEs, as well as agents able to break already formed AGEs or those antagonizing their signaling have been identified. Some of them are already being tested in clinical trials.105,106

1. Substances preventing or inhibiting AGE formation

Aminoguanidine was one of the first substances identified limiting the formation of AGEs.107Aminoguanidine is a nucleophilic hydrazine and its anti-AGE properties result from trapping of early glycation products such as carbonyl intermediate compounds. It has no effects on more advanced stages of glycation. Despite its potential effects in attenuating various diabetes- and age-related complications in animal models, its use in clinical practice is limited due to adverse effects in clinical trials with diabetic patients.108 In an in vitro skin aging model it could attenuate collagen glycation, however its effects against AGE-induced collagen modification in vivo have been contradictory.109111 Studies on topical application of aminoguanidine in the skin are lacking.

Pyridoxamine, a naturally occurring vitamin B6 isoform, seems to be another tool in the fight against AGEs. Pyridoxamine traps reactive carbonyl intermediates, scavenges ROS and in addition inhibits post-Amadori stages of AGEs formation.112 It has shown promising results in a phase II clinical trial against diabetic nephropathy.113 Oral intake of pyridoxamine resulted in potent inhibition of skin collagen CML formation in diabetic rats.111 However, its potential against skin aging remains to be shown.

2. “AGE breakers”

Chemical substances and enzymes able to recognize and break the Maillard reaction crosslinks have been identified. Such chemical AGE breakers are dimethyl-3-phenayl-thiazolium chloride (ALT-711), N-phenacylthiazolium and N-phenacyl-4,5-dimethylthiazolium.113 They have been developed to chemically break the prototypical Maillard reaction crosslink via a thiazolium structure.113 Promising results against cardiovascular complications in diabetes and aging have been reported, although their actual ability to cleave existing protein crosslinks in tissues has been questioned.114117 In the rat ALT-711 showed some promising results on skin hydration.113

Interference with intrinsic AGE-detoxifying enzymes like FAOXs, FN3K and the enzymatic system of Glo is another interesting strategy to remove AGEs, as enzymes recognize specific substrates and may be associated with fewer side effects.37,38,118 There are a lot of data supporting the significance of these enzyme systems in aging. As noted above decreased Glo I activity and increased accumulation of AGEs with age have been shown in many tissues and animals.37 Overexpression of Glo I significantly inhibits hyperglycemia-induced intracellular formation of AGEs in bovine aortic endothelial cells and in mouse mesangial cells by reduction of intracellular oxidative stress and apoptosis.119,120 A potential in vivo beneficial effect of Glo I against AGEs could be also shown in transgenic rats.121 Interestingly, it has been recently shown that Glo I is transcriptionally controlled by Nrf2, and that pharmacological Nrf2 activators increase Glo I mRNA and protein levels as well as its activity.122 The pharmacological induction of such enzymes could represent a novel future strategy against AGEs. Fructosamine phosphokinases are relatively new enzymes and currently under investigation, and until now no inductors or activators of their expression have been found.40 FAOXs on the other hand are not expressed in mammals, and their potential use in humans by enzymatic engineering remains to be discovered.39

3. Nutriceuticals

Since oxidation steps are crucially involved in formation of many AGEs, substances with antioxidative or metal chelating properties, may also have antiglycating activities.123 Thus, a lot of interest has been directed to nutrients and vitamins, so called “nutriceuticals,” as natural tools against AGEs.106,124

Accordingly, an increasing list of natural antioxidants and chelating agents such as ascorbic acid, α-tocopherol, niacinamide, pyridoxal, sodium selenite, selenium yeast, trolox, rivoflavin, zink and manganese has been shown to inhibit glycation of albumin in vitro.125 Alpha-lipoic acid was able to reverse tail tendon collagen glycation in fructose-fed rats, an effect which was attributed to its endogenous antioxidant action, its ability to recycle ascorbic acid, α-tocopherol and GSH as well as to its positive influence on glucose uptake and glycaemia.126 Green tea, vitamins C and E and a combination of N-acetylcystein with taurine and oxerutin could inhibit skin collagen glycation in mice.124,127 Another compound, the green tea-derived polyphenol and flavonoid epigallocatechin-3-gallate revealed also promising in vitro effects by antagonizing AGE-induced proinflammatory changes.128 In healthy human subjects, supplementation of vitamin C significantly decreased serum protein glycation.129

Many spices and herbs were shown to inhibit glycation of albumin in vitro, among them ginger, cinnamon, cloves, marjoram, rosemary and tarragon.130 Their protective effects correlated with their phenolic content. Recently, in vivo beneficial effects of some of these compounds were shown in zebrafish.131

Other promising compounds include blueberry extract and naturally occurring flavonoids, such as luteolin, quercetin and rutin, which can inhibit various stages of AGE formation.132,133 Recently, blueberry extract, an AGE-inhibitor and C-xyloside, a glycosaminoglycan synthesis stimulator, were tested for 12 weeks in female diabetic subjects. This treatment resulted in significant improvement of skin firmness, wrinkles and hydration although it failed to show a significant decrease in the cutaneous content of AGEs.132

4. Caloric restriction and dietary measures

As nutrition is an important factor in skin aging, dietary caloric restriction may be effective in preventing accumulation of AGEs in the human body. In mice restriction of caloric intake increases lifespan and delays many age-related dysfunctions by altering stress response and influencing the expression of various metabolic and biosynthetic genes.134 Dietary restriction could significantly decrease the levels of AGEs in rat and mice skin collagen.135,136 Skin collagen glycation and glycoxidation inversely correlated with lifespan whereas caloric restriction led to decreased accumulation of AGEs and increased lifespan.137Dietary restriction may not be a pragmatic option in humans; however a restriction in intake of dietary “glycotoxins” may be more feasible. As outlined above these dietary glycotoxins derive from nutrition. In humans dietary glycotoxins significantly increase concentrations of systemic inflammatory mediators like TNFα, interleukin (IL)-6 and C-reactive protein and are thus considered as diabetogenic, nephrotoxic and proatherogenic.59,138,139 Dietary intake of AGEs correlates with serum AGEs and can induce systemic oxidative stress, increase RAGE expression, decrease antioxidant levels and shorten lifespan in mice.54 A diet with a low content in AGEs could reduce circulating AGEs and inflammatory biomarkers in patients with diabetes and renal failure thus seeming to be an important supportive therapy in diabetes.140,141 In mice low dietary AGEs had beneficial effects in wound healing and other diabetes mellitus-associated pathologies.142 There are no studies investigating the effects of AGE-poor diets on skin aging in humans. However, it has been shown that skin collagen glycation positively correlates with blood glucose levels in diabetes and that intensive treatment can reduce the levels of skin glycation, implicating that a diet low in AGEs may have a beneficial effect on skin glycation.143,144

5. Targeting RAGE

Another potential strategy against excessive accumulation of AGEs could be the antagonism of RAGE.145Possible approaches include gene knock-down of RAGE by siRNA or anti-sense and antagonism of RAGE with putative small molecular inhibitors against RAGE-induced signaling.50,145 Promising effects in various systems have been shown in vitro and in vivo with neutralizing anti-RAGE antibodies.41 Since serum concentrations of sRAGE negatively correlate with AGE-induced pathologies, neutralization of AGEs by these decoy receptors of RAGE may be considered as another potential anti-AGE strategy. Potential protective effects of sRAGE have been shown in various diabetes and inflammatory models.41,44,45,146Interestingly, sRAGE could also attenuate impaired wound healing in diabetic mice. Therefore, studies will be needed to investigate an analogous effect on skin aging.147

6. Others

Molecular chaperones like carnosine have lately shown promise in improving skin appearance in various studies at least in part by reducing the amounts of skin AGEs.148150

Conclusion

There is ample evidence that AGEs play an important role in skin aging. There are also numerous studies investigating potential substances against excessive accumulation of AGEs in tissues. Some of these studies have already shown protective effects against diabetic complications. As controlled human studies investigating the effects of these anti-AGE strategies against skin aging are largely missing, this is a hot field for future research.

SCIENTIFIC STUDIES:

  1. Increase in the Advanced Glycation end product pentosidine in Bruch’s membrane with age.
  2. Chelating activity of Advanced Glycation end-product inhibitors
  3. The Advanced Glycation end product , N∊-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions
  4. Advanced Glycation end product interventions reduce diabetes-accelerated atherosclerosis
  5. Recent progress in Advanced Glycation and diabetic vascular disease: role of Advanced Glycation end product receptors
  6. Improved arterial compliance by a novel Advanced Glycation end-product crosslink breaker
  7. Plasma levels of pentosidine in diabetic patients: an Advanced Glycation end product .
  8. The effect of Advanced Glycation end-product formation upon cell-matrix interactions
  9. Advanced Glycation end product ligands for the receptor for Advanced Glycation end products : biochemical characterization and formation kinetics
  10. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of Advanced Glycation end product formation
  11. Immunological detection of a novel Advanced Glycation end-product
  12. Advanced Glycation end product Cross‐Linking: Pathophysiologic Role and Therapeutic Target in Cardiovascular Disease
  13. Advanced Glycation end product recognition by the receptor for AGEs
  14. Dietary glycotoxins correlate with circulating Advanced Glycation end product levels in renal failure patients
  15. Therapeutic potential of breakers of Advanced Glycation end product –protein crosslinks
  16. High serum level of pentosidine, an Advanced Glycation end product (AGE) , is a risk factor of patients with heart failure
  17. Inhibitors of Advanced Glycation end product formation and neurovascular dysfunction in experimental diabetes
  18. Effect of Advanced Glycation end product intake on inflammation and aging: a systematic review
  19. N. epsilon.-(Carboxymethyl) lysine is a dominant Advanced Glycation end product (AGE) antigen in tissue proteins
  20. Advanced Glycation end product receptor‐mediated cellular dysfunction
  21. Immunohistochemical detection of imidazolone, a novel Advanced Glycation end product , in kidneys and aortas of diabetic patients.
  22. Advanced Glycation end product -induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells
  23. Advanced Glycation end product level, diabetes, and accelerated cognitive aging
  24. Clearance of pentosidine, an Advanced Glycation end product , by different modalities of renal replacement therapy
  25. Advanced Glycation end-product cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process
  26. Advanced Glycation end product precursors impair epidermal growth factor receptor signaling
  27. ELISA of pentosidine, an Advanced Glycation end product , in biological specimens
  28. Inhibition of Advanced Glycation end product formation on collagen by rutin and its metabolites
  29. Oxidative stress, Advanced Glycation end product , and coronary artery calcification in hemodialysis patients
  30. Glucosepane: a poorly understood Advanced Glycation end product of growing importance for diabetes and its complications
  31. … transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel Advanced Glycation end product inhibitor, OPB-9195
  32. Advanced Glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings
  33. Advanced Glycation end product accumulation: a new enemy to target in chronic kidney disease?
  34. … and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and Advanced Glycation end product
  35. Increased pentosidine, an Advanced Glycation end product , in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory …
  36. Skin Advanced Glycation end product accumulation and muscle strength among adult men
  37. Role of oxidative stress in Advanced Glycation end product -induced mesangial cell activation
  38. Characterization of the Advanced Glycation end-product receptor complex in human vascular endothelial cells
  39. Inhibition of NADPH oxidase prevents Advanced Glycation end product –mediated damage in diabetic nephropathy through a protein kinase C-α–dependent pathway
  40. Advanced Glycation end product (AGE) –mediated induction of tissue factor in cultured endothelial cells Is dependent on RAGE
  41. Significance of fructose-induced protein oxidation and formation of Advanced Glycation end product
  42. Advanced Glycation end product -induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in …
  43. Glycationand Advanced Glycation end-product formation with icodextrin and dextrose
  44. Identification of Nω-carboxymethylarginine as a novel acid-labile Advanced Glycation end product in collagen
  45. Advanced Glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis
  46. Contribution of the Advanced Glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar …
  47. Blockade of Advanced Glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice
  48. Advanced Glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor
  49. … suppresses Advanced Glycation end product –induced monocyte chemoattractant protein–1 expression in mesangial cells by reducing Advanced Glycation end product
  50. Role of hyperglycemia-induced Advanced Glycation end product (AGE) accumulation in atherosclerosis
  51. Pathological implications of receptor for Advanced Glycation end-product (AGER) gene polymorphism
  52. Effect of an Advanced Glycation end product -restricted diet and exercise on metabolic parameters in adult overweight men
  53. Advanced Glycation end product associated skin autofluorescence: a mirror of vascular function?
  54. Serum carboxymethyl–lysine, an Advanced Glycation end product , is associated with increased aortic pulse wave velocity in adults
  55. Role of the Maillard reaction in aging of tissue proteins: Advanced Glycation end product -dependent increase in imidazolium cross-links in human lens …
  56. Decreased endogenous secretory Advanced Glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications
  57. Accumulation of carbonyls accelerates the formation of pentosidine, an Advanced Glycation end product : carbonyl stress in uremia.
  58. Dietary Advanced Glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review
  59. Role of receptor for Advanced Glycation end-products and signalling events in Advanced Glycation end-product-induced monocyte chemoattractant protein-1 …
  60. Genistein inhibits Advanced Glycation end product formation by trapping methylglyoxal
  61. Connective tissue growth factor plays an important role in Advanced Glycation end product –induced tubular epithelial-to-mesenchymal transition: implications for …
  62. Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus Advanced Glycation end-product formation
  63. Tissue-Advanced Glycation end product concentration in dialysis patients
  64. Inhibition of Advanced Glycation end product formation by medicinal plant extracts correlates with phenolic metabolites and antioxidant activity
  65. Role of receptor for Advanced Glycation end‐product (RAGE) and the JAK/STAT‐signaling pathway in AGE‐induced collagen production in NRK‐49F cells
  66. Advanced Glycation end product precursors impair ABCA1-dependent cholesterol removal from cells
  67. Skin autofluorescence, a marker for Advanced Glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease
  68. Advanced Glycation end product homeostasis: exogenous oxidants and innate defenses
  69. Quercetin inhibits Advanced Glycation end product formation by trapping methylglyoxal and glyoxal
  70. Agents that block Advanced Glycation end product (AGE) -RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular …
  71. Advanced Glycation end-product Nɛ-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes
  72. Recombinant Advanced Glycation end product receptor pharmacokinetics in normal and diabetic rats
  73. Relationship of an Advanced Glycation end product , plasma carboxymethyl-lysine, with slow walking speed in older adults: the InCHIANTI study
  74. Advanced Glycation end product (AGE) accumulation on Bruch’s membrane: links to age-related RPE dysfunction
  75. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular Advanced Glycation end-product accumulation
  76. Argpyrimidine, a methylglyoxal-derived Advanced Glycation end-product in familial amyloidotic polyneuropathy
  77. Role of Advanced Glycation end product (AGE) -induced receptor (RAGE) expression in diabetic vascular complications
  78. Pigment epithelium-derived factor protects cultured retinal pericytes from Advanced Glycation end product -induced injury through its antioxidative properties
  79. Involvement of Advanced Glycation end product -induced asymmetric dimethylarginine generation in endothelial dysfunction
  80. Antihyperglycemic activity and inhibition of Advanced Glycation end product formation by Cuminum cyminum in streptozotocin induced diabetic rats
  81. ERK and Akt signaling pathways are involved in Advanced Glycation end product -induced autophagy in rat vascular smooth muscle cells
  82. The serum concentration of the Advanced Glycation end-product Nε-(carboxymethyl) lysine is increased in uremia
  83. Elevated serum levels of N ε-carboxymethyl-lysine, an Advanced Glycation end product , are associated with proliferative diabetic retinopathy and macular …
  84. Impact of oxidative stress biomarkers and carboxymethyllysine (an Advanced Glycation end product ) on prostate cancer: a prospective study
  85. Regulation of Advanced Glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells
  86. Blockade of receptor for Advanced Glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice
  87. Reduction of Advanced Glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients
  88. Advanced Glycation end-product accumulation and associated protein modification in type II skeletal muscle with aging
  89. Effect of Moringa oleifera on Advanced Glycation end-product formation and lipid metabolism gene expression in HepG2 cells
  90. The Advanced Glycation end‐product Nϵ‐carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes‐associated risk and its …
  91. Advanced Glycation end product (AGE) -induced proliferation of HEL cells via receptor for AGE-related signal pathways
  92. Pigment epithelium-derived factor inhibits Advanced Glycation end product -induced retinal vascular hyperpermeability by blocking reactive oxygen species …
  93. AdvancedGlycation-end-product-induced formation of immunoproteasomes: involvement of RAGE and Jak2/STAT1
  94. The Contribution of Advanced Glycation end product (AGE) accumulation to the decline in motor function
  95. Effect of pseudophosphorylation and cross-linking by lipid peroxidation and Advanced Glycation end product precursors on tau aggregation and filament …
  96. Low Advanced Glycation end product diet improves the lipid and inflammatory profiles of prediabetic subjects
  97. Inhibition of Advanced Glycation end-product formation by high antioxidant-leveled spices commonly used in European cuisine
  98. Role of microRNA-214–targeting phosphatase and tensin homolog in Advanced Glycation end product -induced apoptosis delay in monocytes
  99. Advanced Glycation end product (AGE) -receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages
  100. Olive leaf extracts are a natural source of Advanced Glycation end product inhibitors
  101. Metabolization of the Advanced Glycation end product N-ε-Carboxymethyllysine (CML) by Different Probiotic E. coli Strains
  102. Increased receptor for Advanced Glycation end product expression in the human alcoholic prefrontal cortex is linked to adolescent drinking
  103. Increased serum levels of the specific Advanced Glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 …
  104. Confocal Raman microscopy can quantify Advanced Glycation end product (AGE) modifications in Bruch’s membrane leading to accurate, nondestructive prediction of …
  105. Implication of receptor for Advanced Glycation end product (RAGE) in pulmonary health and pathophysiology
  106. Receptor for Advanced Glycation end product (RAGE) upregulation in human gingival fibroblasts incubated with nornicotine
  107. Clinical studies of Advanced Glycation end product inhibitors and diabetic kidney disease
  108. Methylglyoxal induces Advanced Glycation end product (AGEs)formation and dysfunction of PDGF receptor‐β: implications for diabetic atherosclerosis
  109. Type IV collagen is transcriptionally regulated by Smad1 under Advanced Glycation end product (AGE) stimulation
  110. Advanced Glycation end product (AGE) modified proteins in tears of diabetic patients
  111. Plasma carboxymethyl‐lysine, an Advanced Glycation end product , and all‐cause and cardiovascular disease mortality in older community‐dwelling adults
  112. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the Advanced Glycation end product cross-link breaker ALT-711 via a protein kinase C-α …
  113. Dietary protein intake and circulating Advanced Glycation end product /receptor for Advanced Glycation end product concentrations in the Health, Aging, and Body …
  114. Advanced Glycation end products induce the expression of interleukin-6 and interleukin-8 by receptor for Advanced Glycation end product -mediated activation of …
  115. Serum carboxymethyl-lysine, an Advanced Glycation end product , is associated with arterial stiffness in older adults
  116. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing Advanced Glycation end product –receptor axis
  117. Combination therapy with the Advanced Glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or …
  118. Effects of alagebrium, an Advanced Glycation end‐product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL …
  119. Anti-inflammatory effects of the Advanced Glycation end product inhibitor LR-90 in human monocytes
  120. Diastolic dysfunction of aging is independent of myocardial structure but associated with plasma Advanced Glycation end-product levels
  121. Ability of resveratrol to inhibit Advanced Glycation end product formation and carbohydrate-hydrolyzing enzyme activity, and to conjugate methylglyoxal
  122. Fat mass is inversely associated with serum carboxymethyl-lysine, an Advanced Glycation end product , in adults
  123. Receptor for Advanced Glycation end product -dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-β-mediated cortical synaptic …
  124. COX‐2 and iNOS are critical in Advanced Glycation end product ‐activated chondrocytes in vitro
  125. Mdia1 is crucial for Advanced Glycation end product -induced endothelial hyperpermeability
  126. Potential clinical utility of Advanced Glycation end product cross-link breakers in age-and diabetes-associated disorders
  127. … effect of OPB-9195 [(±)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on Advanced Glycation end product and Advancedlipoxidation end product
  128. Mangostanaxanthones III and IV: Advanced Glycation end-product inhibitors from the pericarp of Garcinia mangostana
  129. Inhibition of protein glycoxidation and Advanced Glycation end-product formation by barnyard millet (Echinochloa frumentacea) phenolics
  130. Effect of metformin administration on plasma Advanced Glycation end product levels in women with polycystic ovary syndrome
  131. Increased pentosidine, an Advanced Glycation end product , in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric …
  132. Diphlorethohydroxycarmalol attenuates methylglyoxal-induced oxidative stress and Advanced Glycation end product formation in human kidney cells
  133. Glucagon-like peptide-1 protects hippocampal neurons against Advanced Glycation end product -induced tau hyperphosphorylation
  134. Green tea polyphenol epigallocatechin-3-gallate inhibits Advanced Glycation end product -induced expression of tumor necrosis factor-α and matrix …
  135. Regulation of Advanced Glycation end product (AGE) -receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease
  136. Inhibition of Advanced Glycation end-product formation on eye lens protein by rutin
  137. Inhibition of Advanced Glycation end product formation by cymene–A common food constituent
  138. Relationship between Advanced Glycation end‐product accumulation and low skeletal muscle mass in Japanese men and women
  139. Nε-(Carboxymethyl)lysine-Receptor for Advanced Glycation end product Axis Is a Key Modulator of Obesity-Induced Dysregulation of Adipokine Expression and …
  140. Advanced Glycation end product accumulation is associated with low skeletal muscle mass, weak muscle strength, and reduced bone density: the Nagahama Study
  141. Soluble receptor for Advanced Glycation end product : a biomarker for acute coronary syndrome
  142. Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major Advanced Glycation end product , in adults: the Energetics Study
  143. Anti-Advanced Glycation end-product and free radical scavenging activity of plants from the Yucatecan flora
  144. Beneficial effect of Corni Fructus, a constituent of Hachimi-jio-gan, on Advanced Glycation end-product-mediated renal injury in streptozotocin-treated diabetic rats
  145. Advanced Glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling
  146. Increased concentration of pentosidine, an Advanced Glycation end product , and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy
  147. … dimethylarginine generation in the kidney of Streptozotocin-induced diabetic rats by blocking Advanced Glycation end product –induced protein arginine …
  148. Advanced Glycation end-product (AGE) -damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis
  149. Molecular basis of maillard amide-Advanced Glycation end product (AGE) formation in vivo
  150. Accumulation of argpyrimidine, a methylglyoxal-derived Advanced Glycation end product , increases apoptosis of lens epithelial cells both in vitro and in vivo
  151. Tissue Advanced Glycation end product deposition after kidney transplantation
  152. Sitagliptin augments protective effects of GLP-1 against Advanced Glycation end product receptor axis in endothelial cells
  153. Stilbene glucoside from Polygonum multiflorum Thunb.: a novel natural inhibitor of Advanced Glycation end product formation by trapping of methylglyoxal
  154. Role of Advanced Glycation end product receptors in the pathogenesis of diabetic retinopathy
  155. A comparative study of sulphated polysaccharide effects on Advanced Glycation end-product uptake and scavenger receptor class A level in macrophages
  156. Complement C3a, CpG oligos, and DNA/C3a complex stimulate IFN-α production in a receptor for Advanced Glycation end product -dependent manner
  157. Ginseng improves cognitive deficit via the RAGE/NF-κB pathway in Advanced Glycation end product -induced rats
  158. Long-term administration of Advanced Glycation end-product stimulates the activation of NLRP3 inflammasome and sparking the development of renal injury
  159. Circulating soluble receptor of Advanced Glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease
  160. Increased glyoxalase I levels inhibit accumulation of oxidative stress and an Advanced Glycation end product in mouse mesangial cells cultured in high glucose
  161. Age-related increase in an Advanced Glycation end product in penile tissue
  162. The Advanced Glycation end product methylglyoxal-derived hydroimidazolone-1 and early signs of atherosclerosis in childhood diabetes
  163. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of Advanced Glycation end-product, tissue factor and TNF-α
  164. Aspirin inhibits the formation of pentosidine, a cross-linking Advanced Glycation end product , in collagen
  165. The Advanced Glycation end product Nepsilon-(carboxymethyl) lysine is increased in serum from children and adolescents with type 1 diabetes.
  166. … uptake of methylglyoxal-modified serum albumin. Competition with Advanced Glycation end product -modified serum albumin at the Advanced Glycation end product
  167. Recombinant antibody color resulting from Advanced Glycation end product modifications
  168. Advanced Glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes.
  169. The Advanced Glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis
  170. Pioglitazone inhibits Advanced Glycation end product -induced matrix metalloproteinases and apoptosis by suppressing the activation of MAPK and NF-κB
  171. Pathological roles of Advanced Glycation end product receptors SR‐A and CD36
  172. Pyridoxamine, an inhibitor of Advanced Glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice
  173. The neuroprotective role of metformin in Advanced Glycation end product treated human neural stem cells is AMPK-dependent
  174. Phase I clinical studies of the Advanced Glycation end-product (AGE) -breaker TRC4186
  175. Impairment of glyoxalase-1, an Advanced Glycation end-product detoxifying enzyme, induced by inflammation in age-related osteoarthritis
  176. Plasma S100A12 and soluble receptor of Advanced Glycation end product levels and mortality in chronic kidney disease Stage 5 patients
  177. Sulforaphane inhibits Advanced Glycation end product –induced pericyte damage by reducing expression of receptor for Advanced Glycation end products
  178. Interactions of the Advanced Glycation end product inhibitor pyridoxamine and the antioxidant α-lipoic acid on insulin resistance in the obese Zucker rat
  179. AGER gene polymorphisms and soluble receptor for Advanced Glycation end product in patients with idiopathic pulmonary fibrosis
  180. Proteomic analysis defines altered cellular redox pathways and Advanced Glycation end-product metabolism in glomeruli of db/db diabetic mice
  181. Effects of scavenger receptors-1 class A stimulation on macrophage morphology and highly modified Advanced Glycation end product -protein phagocytosis
  182. Levels of soluble Advanced Glycation end product -receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot
  183. The effect of an Advanced Glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial
  184. Diabetes impairs hippocampal function via Advanced Glycation end product mediated new neuron generation in animals with diabetes-related depression
  185. Siphonaxanthin, a carotenoid from green algae, suppresses Advanced Glycation end product -induced inflammatory responses
  186. Profiling of methylglyoxal blood metabolism and Advanced Glycation end-product proteome using a chemical probe
  187. Constituents with α-glucosidase and Advanced Glycation end-product formation inhibitory activities from Salvia miltiorrhiza Bge.
  188. Inhibition of Advanced Glycation end-product formation and antioxidant activity by extracts and polyphenols from Scutellaria alpina L. and S. altissima L.
  189. Are Advanced Glycation end‐product‐modified proteins of pathogenetic importance in fibromyalgia?
  190. The Advanced Glycation end product Nε-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney …
  191. Advanced Glycation end product accumulation in subjects with open-angle glaucoma with and without Exfoliation
  192. Differential contribution of possible pattern‐recognition receptors to Advanced Glycation end product –induced cellular responses in macrophage‐like RAW264. 7 cells
  193. 1 h Postload Glycemia is associated with low endogenous secretory receptor for Advanced Glycation end product levels and early markers of cardiovascular disease
  194. The diabetic milieu modulates the Advanced Glycation end product -receptor complex in the mesangium by inducing or upregulating galectin-3 expression.
  195. Inhibition of Advanced Glycation end-product formation by Origanum majorana L. in vitro and in streptozotocin-induced diabetic rats
  196. Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in Advanced Glycation end-product-induced cellular mitogenesis in …
  197. Blockade of receptor for Advanced Glycation end product attenuates pulmonary reperfusion injury in mice
  198. Blockade of Advanced Glycation end product formation attenuates bleomycin-induced pulmonary fibrosis in rats
  199. Quercetin inhibits Advanced Glycation end product formation via chelating metal ions, trapping methylglyoxal, and trapping reactive oxygen species
  200. Red blood cell adhesion in diabetes mellitus is mediated by Advanced Glycation end product receptor and is modulated by nitric oxide
  201. An expeditious synthesis of pentosidine, an Advanced Glycation end product
  202. Proteomic studies on receptor for Advanced Glycation end product variants in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease
  203. Advanced Glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia
  204. Efficacy of alogliptin, a dipeptidyl peptidase‐4 inhibitor, on glucose parameters, the activity of the Advanced Glycation end product (AGE) –receptor for AGE (RAGE) …
  205. An Advanced Glycation end product (AGE) -rich diet promotes Nε-carboxymethyl-lysine accumulation in the cardiac tissue and tendons of rats
  206. Advanced Glycation end-product pentosidine accumulates in various tissues of rats with high fructose intake.
  207. Pigment epithelium-derived factor inhibits Advanced Glycation end product -elicited mesangial cell damage by blocking NF-κB activation
  208. The association between various smoking behaviors, cotinine biomarkers and skin autofluorescence, a marker for Advanced Glycation end product
  209. Dehydroepiandrosterone administration counteracts oxidative imbalance and Advanced Glycation end product formation in type 2 diabetic patients
  210. Advanced Glycation end product (AGE) accumulation in the skin is associated with depression: the maastricht study
  211. Danshensu ameliorates the cognitive decline in streptozotocin-induced diabetic mice by attenuating Advanced Glycation end product -mediated neuroinflammation
  212. Irbesartan inhibits Advanced Glycation end product (AGE) -induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression
  213. Microglial receptor for Advanced Glycation end product -dependent signal pathway drives β-amyloid-induced synaptic depression and long-term depression …
  214. Receptor for Advanced Glycation end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia/reperfusion injury
  215. Toxicological evaluation of Advanced Glycation end product Nε-(carboxymethyl) lysine: Acute and subacute oral toxicity studies
  216. Receptor for Advanced Glycation end-product antagonist reduces blood–brain barrier damage after intracerebral hemorrhage
  217. Angiotensin II augments Advanced Glycation end product -induced pericyte apoptosis through RAGE overexpression
  218. Serum‐soluble receptor for Advanced Glycation end product levels in patients with amyotrophic lateral sclerosis
  219. Microbiome–metabolomics analysis of the impacts of long-term dietary advancedGlycation-end-product consumption on C57BL/6 mouse fecal microbiota and …
  220. Mutagenesis and Repair Induced by the DNA Advanced Glycation end product N2-1-(Carboxyethyl)-2′-deoxyguanosine in Human Cells
  221. Advanced Glycation end-product 2 and Porphyromonas gingivalis lipopolysaccharide increase sclerostin expression in mouse osteocyte-like cells
  222. A novel monoclonal antibody targeting carboxymethyllysine, an Advanced Glycation end product in atherosclerosis and pancreatic cancer
  223. Autoantibody against N (epsilon)-(carboxymethyl) lysine: an Advanced Glycation end product of the Maillard reaction.
  224. Glucagon-like peptide-1 (GLP-1) inhibits Advanced Glycation end product (AGE) -induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing …
  225. Circulating soluble receptor for Advanced Glycation end product identifies patients with bicuspid aortic valve and associated aortopathies
  226. Increased serum endogenous secretory receptor for Advanced Glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function
  227. Advanced Glycation end-product cross-linking inhibits biomechanical plasticity and characteristic failure morphology of native tendon
  228. Effect of Advanced Glycation end product on paraoxonase 2 expression: Its impact on endoplasmic reticulum stress and inflammation in HUVECs
  229. Morpho-mechanical intestinal remodeling in type 2 diabetic GK rats—is it related to Advanced Glycation end product formation?
  230. Autophagy protects Advanced Glycation end product -induced apoptosis and expression of MMP-3 and MMP-13 in rat chondrocytes
  231. Advanced Glycation end product (AGE) : Characterization of the products from the reaction between D‐glucose and serum albumin
  232. Identification of a novel Advanced Glycation end product derived from lactaldehyde
  233. Efficacy of adjunctive photodynamic therapy on the clinical periodontal, HbA1c and Advanced Glycation end product levels among mild to moderate chronic …
  234. Korean red ginseng extract alleviates Advanced Glycation end product -mediated renal injury
  235. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits Advanced Glycation end-product (AGE) -induced monocyte chemoattractant protein-1 expression in …
  236. Serum carboxymethyl-lysine, a dominant Advanced Glycation end product , is associated with chronic kidney disease: the Baltimore longitudinal study of aging
  237. Soluble receptor for Advanced Glycation end product ameliorates chronic intermittent hypoxia induced renal injury, inflammation, and apoptosis via P38/JNK …
  238. … inhibits inflammation via phospho-P38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-κB pathways in Advanced Glycation end product -stimulated …
  239. Effect of age and menopause on serum concentrations of pentosidine, an Advanced Glycation end product
  240. Attenuating effects of Ganoderma lucidum polysaccharides on myocardial collagen cross-linking relates to Advanced Glycation end product and antioxidant enzymes …
  241. Targeting the AGE‐RAGE axis improves renal function in the context of a healthy diet low in Advanced Glycation end‐product content
  242. Imidazolone, a novel Advanced Glycation end product , is present at high levels in kidneys of rats with streptozotocin‐induced diabetes
  243. The relationship of glycaemic level to Advanced Glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster
  244. Polymorphism screening of four genes encoding Advanced Glycation end-product putative receptors: association study with nephropathy in type 1 diabetic patients
  245. Non-invasive skin autofluorescence, blood and urine assays of the Advanced Glycation end product (AGE) pentosidine as an indirect indicator of AGE content …
  246. Evaluation of autofluorescent property of hemoglobin-Advanced Glycation end product as a long-term glycemic index of diabetes
  247. Dietary genistein inhibits methylglyoxal-induced Advanced Glycation end product formation in mice fed a high-fat diet
  248. Advanced Glycation end-product expression is upregulated in the gastrointestinal tract of type 2 diabetic rats
  249. Advanced Glycation end product Inhibition by Alkaloids from Ocotea paranapiacabensis for the Prevention of Skin Aging
  250. Curcumin inhibits Advanced Glycation end product ‑induced oxidative stress and inflammatory responses in endothelial cell damage via trapping …
  251. Regulation of inducible nitric oxide synthase expression in Advanced Glycation end product –stimulated RAW 264.7 cells: the role of heme oxygenase-1 and …
  252. Immunogenicity of DNA-Advanced Glycation end product fashioned through glyoxal and arginine in the presence of Fe3+: its potential role in prompt recognition of …
  253. Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against Advanced Glycation end product -induced neuronal insult: Studies in vivo …
  254. Inhibitors of Advanced Glycation end product -associated protein cross-linking
  255. Relation between development of nephropathy and the p22phox C242T and receptor for Advanced Glycation end product G1704T gene polymorphisms in type 2 …
  256. Arginine side-chain modification that occurs during copper-catalysed azide–alkyne click reactions resembles an Advanced Glycation end product
  257. Concentrations of pentosidine, an Advanced Glycation end-product, in umbilical cord blood
  258. Effect on the mechanical properties of type I collagen of intra-molecular lysine-arginine derived Advanced Glycation end-product cross-linking
  259. Exercise training initiated in late middle age attenuates cardiac fibrosis and Advanced Glycation end-product accumulation in senescent rats
  260. Effect of diabetes and aminoguanidine therapy on renal Advanced Glycation end-product binding
  261. Biocatalytic Reversal of Advanced Glycation end product Modification.
  262. Decreased Soluble Receptor of Advanced Glycation end product Levels Correlated with Inflammation in Silicosis
  263. Atrial fibrillation coincides with the Advanced Glycation end product Nε-(carboxymethyl) lysine in the atrium
  264. Skin autofluorescence as a measure of Advanced Glycation end product levels is associated with carotid atherosclerotic plaque burden in an elderly population
  265. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for Advanced Glycation end product (AGE) -related disorders
  266. Carnosine prevents testicular oxidative stress and Advanced Glycation end product formation in D‐galactose‐induced aged rats
  267. AntiGlycationeffect of various vegetables: Inhibition of Advanced Glycation end product formation in glucose and human serum albumin reaction system
  268. Advanced Glycation end product formation in human cerebral cortex increases with Alzheimer-type neuropathologic changes but is not independently associated with …
  269. Pigment epithelium-derived factor (PEDF) ameliorates Advanced Glycation end product (AGE) -induced hepatic insulin resistance in vitro by suppressing Rac-1 …
  270. Advanced Glycation end products accelerate ischemia/reperfusion injury through receptor of Advancedend product /nitrative thioredoxin inactivation in cardiac …
  271. … exfoliated deciduous teeth ameliorate diabetic nephropathy in vivo and in vitro by inhibiting Advanced Glycation end product -activated epithelial-mesenchymal …
  272. Advanced Glycation end product deposits in climatic droplet keratopathy
  273. Dietary Advanced Glycation end-product consumption leads to mechanical stiffening of murine intervertebral discs
  274. Advanced Glycation end product 3 (AGE3) suppresses the mineralization of mouse stromal ST2 cells and human mesenchymal stem cells by increasing TGF-β …
  275. Role of moesin, Src, and ROS in Advanced Glycation end product ‐induced vascular endothelial dysfunction
  276. Advanced Glycation end product in diabetic rat skeletal muscle in vivo
  277. Use of skin Advanced Glycation end product levels measured using a simple noninvasive method as a biological marker for the diagnosis of neuropsychiatric diseases
  278. Effect of Advanced Glycation end product –modified albumin on tissue factor expression by monocytes: role of oxidant stress and protein tyrosine kinase activation
  279. Psoralea corylifolia L. Seed Extract Attenuates Methylglyoxal-Induced Insulin Resistance by Inhibition of Advanced Glycation end product Formation
  280. Diabetic kidney disease: a role for Advanced Glycation end-product receptor 1 (AGE-R1)?
  281. Advanced Glycation end product -induced peroxisome proliferator-activated receptor γ gene expression in the cultured mesangial cells
  282. Correlation between diabetic retinopathy severity and elevated skin autofluorescence as a marker of Advanced Glycation end-product accumulation in type 2 diabetic …
  283. Food restriction prevents Advanced Glycation end product accumulation and retards kidney aging in lean rats
  284. Advanced Glycation end product receptor interactions on microvascular cells occur within caveolin‐rich membrane domains
  285. Inhibiting receptor for Advanced Glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on …
  286. Homoisoflavanones from Polygonatum odoratum rhizomes inhibit Advanced Glycation end product formation
  287. Oxidative stress mediates protein kinase C activation and Advanced Glycation end product formation in a mesangial cell model of diabetes and high protein diet
  288. Beneficial effect of traditional chinese medicinal formula Danggui-Shaoyao-San on Advanced Glycation end-product-mediated renal injury in streptozotocin …
  289. Cardiomyocyte mitochondrial respiration is reduced by receptor for Advanced Glycation end-product signaling in a ceramide-dependent manner
  290. Exosomes derived from mesenchymal stromal cells pretreated with Advanced Glycation end product -bovine serum albumin inhibit calcification of vascular …
  291. Reaction time in healthy elderly is associated with chronic low-grade inflammation and Advanced Glycation end product
  292. Carboxymethyl-lysine, an Advanced Glycation end product , and decline of renal function in older community-dwelling adults
  293. High levels of urinary pentosidine, an Advanced Glycation end product , in children with acute exacerbation of atopic dermatitis: relationship with oxidative stress
  294. Gly82Ser polymorphism of the receptor for Advanced Glycation end-product (RAGE) potential high risk in patients with colorectal cancer
  295. Intra-molecular lysine-arginine derived Advanced Glycation end-product cross-linking in Type I collagen: A molecular dynamics simulation study
  296. S 100 A 9 promotes human lung fibroblast cells activation through receptor for Advanced Glycation end‐product‐mediated extracellular‐regulated kinase 1/2, mitogen …
  297. Localization of identified Advanced Glycation end‐product structures, Nε=(carboxymethyl) lysine and pentosidine, in age‐related inclusions in human brains
  298. Astaxanthin and Corni Fructus protect against diabetes-induced oxidative stress, inflammation, and Advanced Glycation end product in livers of streptozotocin-induced …
  299. Drugs of abuse that mediate Advanced Glycation end product formation: a chemical link to disease pathology
  300. Beneficial effect of Azadirachta indica on Advanced Glycation end-product in streptozotocin-diabetic rat
  301. … effects of the hexane extract from Piper auritum leaves in vitro and beneficial activity on oxidative stress and Advanced Glycation end-product-mediated renal injury in …
  302. Accumulation of the Advanced Glycation end product carboxymethyl lysine in breast cancer is positively associated with estrogen receptor expression and unfavorable …
  303. Lung level of HMBG1 is elevated in response to Advanced Glycation end product ‐enriched food in vivo
  304. New therapies for Advanced Glycation end product nephrotoxicity: current challenges
  305. Circulating soluble receptor for Advanced Glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD)
  306. Circulating levels of soluble receptor for Advanced Glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent …
  307. Bridging Advanced Glycation end product , receptor for Advanced Glycation end product and nitric oxide with hormonal replacement/estrogen therapy in …
  308. Circulating Advanced Glycation end product levels in rats rapidly increase with acute renal failure
  309. Clinical implications of Nε‐(carboxymethyl)lysine, Advanced Glycation end product , in children and adolescents with type 1 diabetes
  310. Autophagy plays a protective role in Advanced Glycation end product -induced apoptosis in cardiomyocytes
  311. Serum carboxymethyl-lysine, a dominant Advanced Glycation end product , is increased in women with gestational diabetes mellitus
  312. Advanced Glycation end product free adducts are cleared by dialysis
  313. Inhibition of Advanced Glycation end product formation by Pu-erh tea ameliorates progression of experimental diabetic nephropathy
  314. Chemoenzymatic synthesis of heparan sulfate mimetic glycopolymers and their interactions with the receptor for Advanced Glycation end-product
  315. The Advanced Glycation end-product Nɛ-(carboxymethyl) lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis
  316. Skin Advanced Glycation end product accumulation is poorly reflected by glycemic control in type 2 diabetic patients (ZODIAC-9)
  317. Advanced Glycation end product 3 (AGE3) increases apoptosis and the expression of sclerostin by stimulating TGF-β expression and secretion in osteocyte-like MLO …
  318. A novel inhibitor of Advanced Glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes
  319. Modulation of the cellular expression of circulating Advanced Glycation end-product receptors in type 2 diabetic nephropathy
  320. Myricetin inhibits Advanced Glycation end product (AGE) -induced migration of retinal pericytes through phosphorylation of ERK1/2, FAK-1, and paxillin in vitro and in …
  321. Immunodistribution of amyloid beta protein (Aβ) and Advanced Glycation end-product receptors (RAGE) in choroid plexus and ependyma of resuscitated patients
  322. Differential effects of α-tocopherol and N-acetyl-cysteine on Advanced Glycation end product -induced oxidative damage and neurite degeneration in SH-SY5Y …
  323. Loratadine alleviates Advanced Glycation end product -induced activation of NLRP3 inflammasome in human chondrocytes
  324. Expression and significance of high-mobility group protein B1 (HMGB1) and the receptor for Advanced Glycation end-product (RAGE) in knee osteoarthritis
  325. An Advanced Glycation end product (AGE) -receptor for AGEs (RAGE) axis restores adipogenic potential of senescent preadipocytes through modulation of …
  326. Altered serum glyceraldehyde-derived Advanced Glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia
  327. Amadori albumin and Advanced Glycation end-product formation in peritoneal dialysis using icodextrin
  328. Protective effect of extractive and biotechnological chondroitin in insulin amyloid and Advanced Glycation end product ‐induced toxicity
  329. Advanced Glycation end-product (AGE) induces apoptosis in human retinal ARPE-19 cells via promoting mitochondrial dysfunction and activating the Fas-FasL …
  330. Catalpol ameliorates Advanced Glycation end product ‐induced dysfunction of glomerular endothelial cells via regulating nitric oxide synthesis by inducible nitric oxide …
  331. Elevated serum carboxymethyl-lysine, an Advanced Glycation end product , predicts severe walking disability in older women: The Women’s Health and Aging …
  332. Advanced Glycation end product Nε‐carboxymethyllysine induces endothelial cell injury: the involvement of SHP‐1‐regulated VEGFR‐2 dephosphorylation
  333. Renal proximal tubular metabolism of protein-linked pentosidine, an Advanced Glycation end product
  334. … -Weight Polyphenol Derived from Lychee Fruit, Attenuates Diabetes-Induced Renal Damage through the Advanced Glycation end product –Related Pathway in db/db …
  335. Vitamin D attenuates human gingival fibroblast inflammatory cytokine production following Advanced Glycation end product interaction with receptors for AGE
  336. Effects of monascin on anti-inflammation mediated by Nrf2 activation in Advanced Glycation end product -treated THP-1 monocytes and methylglyoxal-treated Wistar …
  337. Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an Advanced Glycation end product , in uremia
  338. Endoplasmic reticulum stress plays a role in the Advanced Glycation end product -induced inflammatory response in endothelial cells
  339. Relationship between Advanced Glycation end-product accumulation in the skin and pulmonary function
  340. Differential effect of estrogen receptor alpha and beta agonists on the receptor for Advanced Glycation end product expression in human microvascular …
  341. Receptor for Advanced Glycation end product expression in experimental diabetic retinopathy
  342. Clinical potential of Advanced Glycation end-product inhibitors in diabetes mellitus
  343. Accelerated Formation of Nϵ-(carboxymethyl) Lysine, an Advanced Glycation end product , by Glyoxal and 3-Deoxyglucosone in Cultured Rat Sensory Neurons
  344. An emerging role of glucagon-like peptide-1 in preventing advancedGlycation-end-product-mediated damages in diabetes
  345. Benazepril, an angiotensin‐converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting Advanced Glycation end‐product …
  346. Longistatin in tick saliva blocks Advanced Glycation end-product receptor activation
  347. The inhibitory effect of the catechin structure on Advanced Glycation end product formation in alcoholic media
  348. Early plasma soluble receptor for Advanced Glycation end‐product levels are associated with bronchiolitis obliterans syndrome
  349. Detection and determination of glyceraldehyde-derived pyridinium-type Advanced Glycation end product in streptozotocin-induced diabetic rats
  350. Structure of a synthetic glucose derived Advanced Glycation end product that is immunologically cross-reactive with its naturally occurring counterparts
  351. Soluble receptor for Advanced Glycation end-product (sRAGE)/pentosidine ratio: a potential risk factor determinant for type 2 diabetic retinopathy
  352. Diabetes mellitus exacerbates Advanced Glycation end product accumulation in the veins of end-stage renal failure patients
  353. Dietary Intake of Nε-carboxymethyl-lysine, a Major Advanced Glycation end product , is Not Associated with Increased Risk of Mortality in Japanese Adults in the …
  354. Circulating soluble receptor for Advanced Glycation end-product levels are decreased in patients with calcific aortic valve stenosis
  355. N‐Phenacylthiazolium Bromide Inhibits the Advanced Glycation end product (AGE) –AGE Receptor Axis to Modulate Experimental Periodontitis in Rats
  356. Pigment epithelium-derived factor (PEDF) inhibits Advanced Glycation end product (AGE) -induced C-reactive protein expression in hepatoma cells by …
  357. Advanced Glycation end product (AGE) inhibitors and their therapeutic implications in diseases.
  358. Pyridoxamine alleviates mechanical allodynia by suppressing the spinal receptor for Advanced Glycation end product -nuclear factor-κ B/extracellular signal-regulated …
  359. Accumulation of methylglyoxal increases the Advanced Glycation end-product levels in DRG and contributes to lumbar disk herniation-induced persistent pain
  360. Protective effect of ISO‑1 against Advanced Glycation end product aggravation of PC12 cell injury induced by Aβ1‑40
  361. Effect of nitric oxide-cGMP-dependent protein kinase activation on Advanced Glycation end-product–induced proliferation in renal fibroblasts
  362. Sitagliptin ameliorates Advanced Glycation end-product (AGE) -induced degradation of extracellular matrix in human primary chondrocytes
  363. Second generation 2-aminoimidazole based Advanced Glycation end product inhibitors and breakers
  364. Phosphorylation of low density lipoprotein receptor-related protein 6 is involved in receptor for Advanced Glycation end product -mediated β-catenin stabilization in a …
  365. Effects of Advanced Glycation end-product inhibition and cross-link breakage in diabetic rats
  366. Increased pentosidine, an Advanced Glycation end‐product, in urine and tissue reflects disease activity in inflammatory bowel diseases
  367. Inhibition of Advanced Glycation end-product formation by Origanum majorana L. in vitro and in streptozotocin-induced diabetic rats
  368. Advanced Glycation end product Accumulation is Associated with Lower Cognitive Performance in an Older General Population: The Nagahama Study
  369. Advanced Glycation end-product levels in subtotally nephrectomized rats: beneficial effects of angiotensin II receptor 1 antagonist losartan
  370. Neuronal and glial Advanced Glycation end product [Nε-(carboxymethyl)lysine] in Alzheimer’s disease brains
  371. Advanced Glycation end-product induces fractalkine gene upregulation in normal rat glomeruli
  372. Amyloid β2-microglobulin is modified with imidazolone, a novel Advanced Glycation end product , in dialysis-related amyloidosis
  373. Advanced Glycation end product -mediated matrix metallo-proteinase-9 and apoptosis via renin-angiotensin system in type 2 diabetes
  374. Advanced Glycation end product -induced proliferation in NRK-49F cells is dependent on the JAK2/STAT5 pathway and cyclin D1
  375. Therapeutic potentials of unicellular green alga Chlorella in Advanced Glycation end product (AGE) -related disorders
  376. Nifedipine, a calcium channel blocker, inhibits Advanced Glycation end product (AGE) -elicited mesangial cell damage by suppressing AGE receptor (RAGE) …
  377. Dietary Genistein Reduces Methylglyoxal and Advanced Glycation end product Accumulation in Obese Mice Treated with High-Fat Diet
  378. Beta carotene protects H9c2 cardiomyocytes from Advanced Glycation end product -induced endoplasmic reticulum stress, apoptosis, and autophagy via the …
  379. Receptor for Advanced Glycation end-product (RAGE) gene polymorphism 2245G/A is associated with pro-inflammatory, oxidative-Glycationmarkers and sRAGE in …
  380. Advanced Glycation end product (AGE) -induced hepatic stellate cell activation via autophagy contributes to hepatitis C-related fibrosis
  381. Pioglitazone alleviates inflammation in diabetic mice fed a high‐fat diet via inhibiting Advanced Glycation end‐product‐induced classical macrophage activation
  382. Model studies of Advanced Glycation end product modification of heterograft biomaterials: The effects of in vitro glucose, glyoxal, and serum albumin on collagen …
  383. Advanced Glycation end product (AGE) -AGE receptor (RAGE) system upregulated connexin43 expression in rat cardiomyocytes via PKC and Erk MAPK pathways
  384. Circulating levels and dietary intake of the Advanced Glycation end-product marker carboxymethyl lysine in chronic kidney disease patients on conservative …
  385. Antibodies against Advanced Glycation end product Nɛ-(carboxymethyl) lysine in healthy controls and diabetic patients
  386. Advanced Glycation end‐product‐induced mitogenesis and collagen production are dependent on angiotensin II and connective tissue growth factor in NRK‐49F cells
  387. Impaired permeability and antimicrobial barriers in type 2 diabetes skin are linked to increased serum levels of Advanced Glycation end‐product
  388. Age dependent accumulation patterns of Advanced Glycation end product receptor (RAGE) ligands and binding intensities between RAGE and its ligands …
  389. Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in Advanced Glycation end product (AGE) -exposed fibroblasts via …
  390. The Advanced Glycation end product -lowering agent ALT-711 is a low-affinity inhibitor of thiamine diphosphokinase
  391. Amyloid-beta mediates the receptor of Advanced Glycation end product -induced pro-inflammatory response via toll-like receptor 4 signaling pathway in retinal …
  392. The effects of a maternal Advanced Glycation end product -rich diet on somatic features, reflex ontogeny and metabolic parameters of offspring mice
  393. Panax notoginseng saponins alleviates Advanced Glycation end product ‑induced apoptosis by upregulating SIRT1 and antioxidant expression levels in HUVECs
  394. Inhibitory effects of Siegesbeckia orientalis extracts on Advanced Glycation end product formation and key enzymes related to metabolic syndrome
  395. Association of soluble receptor for Advanced Glycation end-product with increasing central aortic stiffness in hypertensive patients
  396. Angiopoietin‐1 protects the endothelial cells against Advanced Glycation end product injury by strengthening cell junctions and inhibiting cell apoptosis
  397. … -6-methoxycyclohexa-2, 5-diene-1, 4-dione, isolated from Averrhoa carambola L.(Oxalidaceae) roots, on Advanced Glycation end-product-mediated renal injury in type …
  398. Differences in the modulating potential of Advanced Glycation end product (AGE) peptides versus AGE proteins
  399. DL‑3‑n‑butylphthalide protects endothelial cells against Advanced Glycation end product ‑induced injury by attenuating oxidative stress and inflammation responses
  400. Alagebrium chloride, a novel Advanced Glycation end-product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury …
  401. Formation of pentosidine cross-linking in myoglobin by glyoxal: detection of fluorescent Advanced Glycation end product
  402. Circulating soluble receptor for Advanced Glycation end product : Cross-sectional associations with cardiac markers and subclinical vascular disease in older …
  403. Effect of high Advanced Glycation end product diet on pulmonary inflammatory response and pulmonary function following gastric aspiration
  404. Rosiglitazone reduces angiotensin II and Advanced Glycation end product -dependent sustained nuclear factor-κB activation in cultured human proximal tubular …
  405. Isolation and identification of the 3-hydroxy-5-hydroxymethyl-pyridinium compound as a novel Advanced Glycation end product on glyceraldehyde-related Maillard …
  406. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits Advanced Glycation end-product (AGE) -elicited hepatic insulin resistance via peroxisome proliferator …
  407. Lysine‐Arginine Advanced Glycation End‐Product Cross‐links and the Effect on Collagen Structure: A Molecular Dynamics Study
  408. Minodronate, a nitrogen-containing bisphosphonate, inhibits Advanced Glycation end product -induced vascular cell adhesion molecule-1 expression in endothelial …
  409. Peel extract of water chestnut (Trapa bispinosa Roxb.) inhibits Glycation, degradesα-dicarbonyl compound, and breaks Advanced Glycation end product
  410. Advanced Glycation end-product-induced mitogenesis is dependent on Janus kinase 2-induced heat shock protein 70 in normal rat kidney interstitial fibroblast cells
  411. Effects of Advanced Glycation end product modification on proximal tubule epithelial cell processing of albumin
  412. Study of an unusual Advanced Glycation end-product (AGE) derived from glyoxal using mass spectrometry
  413. Increased Advanced Glycation end product and meat consumption is associated with childhood wheeze: analysis of the National Health and Nutrition Examination …
  414. Irbesartan inhibits Advanced Glycation end product (AGE) -induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular …
  415. Advanced Glycation end product in familial amyloidotic polyneuropathy (FAP)
  416. iRAGE as a novel carboxymethylated peptide that prevents Advanced Glycation end product -induced apoptosis and endoplasmic reticulum stress in vascular smooth …
  417. Coptis chinensis Polysaccharides Inhibit Advanced Glycation end product Formation
  418. Age-related accumulation of Advanced Glycation end-products-albumin, S100β, and the expressions of Advanced Glycation end product receptor differ in visceral and …
  419. Inhibitory effect of Arachis hypogaea (Peanut) and its phenolics against methylglyoxal-derived Advanced Glycation end product toxicity
  420. Novel inhibitory effects of glycyrrhizic acid on the accumulation of Advanced Glycation end product and its receptor expression
  421. The downregulation of thioredoxin accelerated Neuro2a cell apoptosis induced by Advanced Glycation end product via activating several pathways
  422. A significant inhibitory effect on Advanced Glycation end product formation by catechin as the major metabolite of lotus seedpod oligomeric procyanidins
  423. Serum Carboxymethyllysine, an Advanced Glycation end product , and Age-Related Macular Degeneration: The Age, Gene/Environment Susceptibility–Reykjavik …
  424. The neuroprotective role of rosiglitazone in Advanced Glycation end product treated human neural stem cells is PPARgamma-dependent
  425. Advanced Glycation end product levels were correlated with inflammation and carotid atherosclerosis in type 2 diabetes patients
  426. Skin Advanced Glycation end-product accumulation is negatively associated with calcaneal osteo-sono assessment index among non-diabetic adult …
  427. Kuwanon G protects HT22 cells from Advanced Glycation end product -induced damage
  428. Soluble receptor for Advanced Glycation end-product levels are related to albuminuria and arterial stiffness in essential hypertension
  429. Pentosidine, an Advanced Glycation end-product, may reflect clinical and morphological features of hand osteoarthritis
  430. Advanced Glycation end-product (AGE) -albumin from activated macrophage is critical in human mesenchymal stem cells survival and post-ischemic …
  431. Characterization of anti-Advanced Glycation end product antibodies to nonenzymatically lysine-derived and arginine-derived glycated products
  432. The antioxidant 3H-1, 2-dithiole-3-thione potentiates Advanced Glycation end-product-induced oxidative stress in SH-SY5Y cells
  433. Troxerutin suppresses the inflammatory response in Advanced Glycation end-product-administered chondrocytes and attenuates mouse osteoarthritis development
  434. Simultaneous determination of the Advanced Glycation end product N ɛ-carboxymethyllysine and its precursor, lysine, in exhaled breath condensate using isotope …
  435. Hydrogen-rich medium suppresses the generation of reactive oxygen species, elevates the Bcl-2/Bax ratio and inhibits Advanced Glycation end product
  436. Advanced Glycation end-product pentosidine is not a relevant marker of disease activity in patients with rheumatoid arthritis.
  437. Leptin and connective tissue growth factor in Advanced Glycation end‐product‐induced effects in NRK‐49F cells
  438. The role of autophagy in Advanced Glycation end product -induced proliferation and migration in rat vascular smooth muscle cells
  439. Agonism of GPR39 displays protective effects against Advanced Glycation end-product (AGE) -induced degradation of extracellular matrix in human SW1353 cells
  440. Free Advanced Glycation end product distribution in blood components and the effect of genetic polymorphisms
  441. Pioglitazone Inhibits Advanced Glycation end product -Induced TNF-E and MMP-13 Expression via the Antagonism of NF-TB Activation in Chondrocytes
  442. Silybin, a flavonolignan from milk thistle seeds, restrains the early and Advanced Glycation end product modification of albumin
  443. Methylglyoxal-hydroimidazolones (MG-Hs) instead of Nɛ-(carboxymethyl)-l-lysine (CML) is the major Advanced Glycation end-product during drying process in black …
  444. Age-dependent expression of Advanced Glycation end product receptor genes in the human heart
  445. … n-3 polyunsaturated fatty acids revert renal responses induced by a combination of 2 protocols that increase the amounts of Advanced Glycation end product
  446. Serum pentosidine, an Advanced Glycation end product , indicates poor outcomes after acute ischemic stroke
  447. Advanced Glycation end product is implicated in amyloid‐related kidney complications
  448. Programmed cell death protein 4 deficiency suppresses foam cell formation by activating autophagy in Advanced Glycation end‐product low‐density lipoprotein …
  449. Imaging receptor for Advanced Glycation end product expression in mouse model of hind limb ischemia
  450. TRC4149 a novel Advanced Glycation end product breaker improves hemodynamic status in diabetic spontaneously hypertensive rats
  451. Renoprotective and lipid‐lowering effects of LR compounds, Novel Advanced Glycation end product inhibitors, in streptozotocin‐induced diabetic rats
  452. Advanced Glycation end-product peptides are associated with impaired renal function, but not with biochemical markers of endothelial dysfunction and inflammation …
  453. C-Type Natriuretic Peptide Protects the Retinal Pigment Epithelium against Advanced Glycation end product –Induced Barrier Dysfunction
  454. RETRACTED: Pigment epithelium-derived factor inhibits Advanced Glycation end-product-induced angiogenesis and stimulates apoptosis in retinal endothelial cells
  455. The Receptor for Advanced Glycation end product (RAGE) Pathway in COVID-19
  456. Absence of Receptor for Advanced Glycation end product (RAGE) Reduces Inflammation and Extends Survival in the hSOD1 G93A Mouse Model of Amyotrophic …
  457. … and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of Advanced Glycation end product
  458. Grape seed procyanidin B2 inhibits Advanced Glycation end product ‐induced endothelial cell apoptosis through regulating GSK3β phosphorylation
  459. Angelica Acutiloba Root Alleviates Advanced Glycation End‐Product‐Mediated Renal Injury in Streptozotocin‐Diabetic Rats
  460. Circulating soluble Advanced Glycation end product is inversely associated with the significant risk of developing cancer: evidence from a meta-analysis
  461. … atherogenesis via inhibiting Advanced Glycation end product -induced receptor for Advancedglycosylation end product expression in apolipoprotein-E …
  462. Minimum stable structure of the receptor for Advanced Glycation end product possesses multi ligand binding ability
  463. Carboxymethyl lysine, an Advanced Glycation end product , and incident diabetes: a case–cohort analysis of the ARIC Study
  464. Advanced Glycation end-product accumulation reduces vitreous permeability
  465. Pigment epithelium-derived factor (PEDF) blocks Advanced Glycation end product (AGE) -induced angiogenesis in vitro
  466. Can Advanced Glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?
  467. The role of black soybean and purple sweet potato active compound on Advanced Glycation end-product in streptozotocin-induced type 2 diabetes mellitus rat
  468. Suppression of high-mobility group box-1 and receptor for Advanced Glycation end-product axis by polymyxin B–immobilized fiber hemoperfusion in septic shock …
  469. Low Advanced Glycation end product diet improves the central obesity, insulin resistance and inflammatory profiles in Iranian patients with metabolic syndrome: a …
  470. Inhibitory effect of zinc on the Advanced Glycation end product -induced apoptosis of mouse osteoblastic cells
  471. Inhibitors of Advanced Glycation end product (AGE) Formation and Accumulation
  472. Inhibitory effect of lotus seedpod oligomeric procyanidins on Advanced Glycation end product formation in a lactose-lysine model system
  473. Rivaroxaban inhibits oxidative and inflammatory reactions in Advanced Glycation end product -exposed tubular cells by blocking thrombin/protease-activated receptor …
  474. Blocking the receptor for Advanced Glycation end product activation attenuates autoimmune myocarditis
  475. Elevated soluble receptor for Advanced Glycation end product levels in patients with acute coronary syndrome and positive cardiac troponin I
  476. 2 ″, 4 ″-O-diacetylquercitrin, a novel Advanced Glycation end-product formation and aldose reductase inhibitor from Melastoma sanguineum
  477. Formation of Advanced Glycation end‐product‐modified superoxide dismutase‐1 (SOD1) is one of the mechanisms responsible for inclusions common to familial …
  478. Lower serum endogenous secretory receptor for Advanced Glycation end product level as a risk factor of metabolic syndrome among Japanese adult men: a 2-year …
  479. High serum concentrations of pentosidine, an Advanced Glycation end product , are associated with low normal value of ankle-brachial index in apparently healthy …
  480. Higher serum soluble receptor for Advanced Glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross …
  481. An interactive association of Advanced Glycation end-product receptor gene four common polymorphisms with coronary artery disease in northeastern Han …
  482. Relationship of a dominant Advanced Glycation end product , serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: the Baltimore Longitudinal …
  483. The effect of packed red blood cell storage on arachidonic acid and Advanced Glycation end-product formation
  484. The roles of protein Glycation, glycoxidation, and Advanced Glycation end-product formation in diabetes-induced atherosclerosis
  485. 2-ammonio-6-(3-oxidopyridinium-1-yl) hexanoate (OP-lysine) is a newly identified Advanced Glycation end product in cataractous and aged human lenses
  486. Advanced Glycation end product -induced astrocytic differentiation of cultured neurospheres through inhibition of Notch-Hes1 pathway-mediated neurogenesis
  487. Functional polymorphisms of the receptor for the Advanced Glycation end product promoter gene in inflammatory bowel disease: a case–control study
  488. The protective effects of bexarotene against Advanced Glycation end-product (AGE) -induced degradation of articular extracellular matrix (ECM)
  489. Singlet oxygen induced Advanced Glycation end-product photobleaching of in vivo human fingertip autofluorescence
  490. TRB3 mediates Advanced Glycation end product -induced apoptosis of pancreatic β-cells through the protein kinase C β pathway
  491. Involvement of caspase-10 in Advanced Glycation end-product-induced apoptosis of bovine retinal pericytes in culture
  492. Carboxymethyllysine, an Advanced Glycation end-product, promotes the invasion and migration of lung cancer A549 cells
  493. AdvancedGlycation-end-product-cholesterol-aggregated-protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-beta 1 …
  494. Advanced Glycation end product -modified β2-microglobulin is a component of amyloid fibrils of primary localized cutaneous nodular amyloidosis
  495. Immunochemical detection of N2-[1-(1-carboxy) ethyl] guanosine, an Advanced Glycation end product formed by the reaction of DNA and reducing sugars or L …
  496. Pioglitazone attenuates atherosclerosis in diabetic mice by inhibition of receptor for Advanced Glycation end-product (RAGE) signaling
  497. Advanced Glycation end product concentrations in follicular fluid of women undergoing IVF/ICSI with a GnRH agonist protocol
  498. Allium sativum aqueous extract inhibitory effect on Advanced Glycation end product
  499. Receptor for Advanced Glycation end product polymorphisms and type 2 diabetes: the CODAM study
  500. Caffeoylated phenylpropanoid glycosides from Brandisia hancei inhibit Advanced Glycation end product formation and aldose reductase in vitro and vessel …
  501. Antiglycative effect of Kaempferia parviflora Wall. Ex. Baker (Zingiberaceae): Prevention of Advanced Glycation end product formation.
  502. Mass spectrometry to detect the site specificity of AdvancedGlycation/lipoxidation end-product formation on protein: some challenges and solutions
  503. … medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in Advanced Glycation end product (AGE) -injected rats.
  504. Gelatin as a convenient surrogate protein to model the in vitro effects of Advanced Glycation end‐product formation
  505. Receptor of Advanced Glycation end product (RAGE) expression in the minor salivary glands of patients with Sjo˝ gren’s syndrome: a preliminary study
  506. Prostaglandin E2 inhibits Advanced Glycation end product -induced adhesion molecule expression, cytokine production, and lymphocyte proliferation in human …
  507. Reduced systemic Advanced Glycation end products in children receiving peritoneal dialysis with low glucose degradation product content
  508. Amelioration of experimental autoimmune uveoretinitis by inhibition of glyceraldehyde‐derived Advanced Glycation end‐product formation
  509. Paradox of circulating Advanced Glycation end product concentrations in patients with congestive heart failure and after heart transplantation
  510. … and biological activity of 4-aryl-3-benzoyl-5-phenylspiro [pyrrolidine-2.3′-indolin]-2′-one derivatives as novel potent inhibitors of Advanced Glycation end product
  511. Anti-glycative effect of yogurt: Prevention of Advanced Glycation end product formation
  512. Up-regulation of the receptor for Advanced Glycation end product (RAGE) in esophageal cancer and down-regulation in lung cancer and their relationship to …
  513. Nifedipine, a calcium-channel blocker, inhibits Advanced Glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured …
  514. An inhibitor of Advanced Glycation end product formation reducesNϵ-(carboxymethyl) lysine accumulation in glomeruli of diabetic rats
  515. Association of Advanced Glycation end-product accumulation with overactive bladder in community-dwelling elderly: A cross-sectional Sukagawa study
  516. Vardenafil, an inhibitor of phosphodiesterase-5, blocks Advanced Glycation end product (AGE) -induced up-regulation of monocyte chemoattractant protein-1 mRNA …
  517. DW1029M, a novel botanical drug candidate, inhibits Advanced Glycation end-product formation, rat lens aldose reductase activity, and TGF-β1 signaling
  518. Morphological adaptation of muscle collagen and receptor of Advanced Glycation end product (RAGE) in osteoarthritis patients with 12 weeks of resistance training …
  519. Identification of (−)-epigallocatechin (EGC) as a methylglyoxal (MGO)-trapping agent and thereby as an inhibitor of Advanced Glycation end product (AGE)
  520. A novel pleiotropic effect of atorvastatin on Advanced Glycation end product (AGE) -related disorders
  521. Advanced Glycation end product accumulation in rho0 cells without a functional respiratory chain
  522. A novel crosslinked type of Advanced Glycation end-product derived from lactaldehyde
  523. Role of peroxisome proliferators-activated receptor-gamma in Advanced Glycation end product -mediated functional loss of voltage-gated potassium channel …
  524. Receptor for Advanced Glycation end product blockade enhances the chemotherapeutic effect of cisplatin in tongue squamous cell carcinoma by reducing autophagy …
  525. Impact of diet-induced obesity in male mouse reproductive system: The role of Advanced Glycation end product –receptor for Advanced Glycation end product axis
  526. Receptor for Advanced Glycation end-product rs1800624 polymorphism contributes to increase breast cancer risk: Evidence from a meta-analysis
  527. Anti-glycative effect of Japanese sake (seishu): prevention of Advanced Glycation end product (AGE) formation
  528. RACK1 mediates the Advanced Glycation end product ‐induced degradation of HIF‐1α in nucleus pulposus cells via competing with HSP90 for HIF‐1α binding
  529. … activity are related to components of the metabolic syndrome, but not to circulating concentrations of the Advanced Glycation end-product Nɛ-carboxymethyl-lysine in …
  530. Effect of rice bran extract on in vitro Advanced Glycation end product formation
  531. Association analysis between genomic variants within Advanced Glycation end product specific receptor (AGER) gene and risk of breast cancer in Iranian …
  532. Levels of mature cross-links and Advanced Glycation end product cross-links in human vitreous
  533. Myocardial infarction coincides with increased expression of NO2X2 and the Advanced Glycation end product Ne-(carboxymethyl) lysine in the microvasculature of the …
  534. Advanced Glycation end product (AGE) inhibition as a possible pharmacotherapeutic strategy in the treatment of Alzheimer’s disease
  535. Processing Advanced Glycation end product ‐Modified Albumin by the Renal Proximal Tubule and the Early Pathogenesis of Diabetic Nephropathy
  536. Reasons to investigate the soluble receptor for Advanced Glycation end-product (sRAGE) pathway in aortic disease
  537. Effect of nicotine on Advanced Glycation end product -induced immune response in human monocytes
  538. INVESTIGATION OF CHANGES IN LEVELS OF SERUM ELEMENTS, LIPID PROFILE AND Advanced Glycation end product IN PATIENTS WITH …
  539. Production of single-chain Fv antibodies specific for GA-Pyridine, an Advanced Glycation end-product (AGE) , with reduced inter-domain motion
  540. Pioglitazone suppresses Advanced Glycation end product -induced expression of plasminogen activator inhibitor-1 in vascular smooth muscle cells
  541. The protection of 4, 4′-diphenylmethane-bis (methyl) carbamate from Cortex Mori on Advanced Glycation end product -induced endothelial dysfunction: Via inhibiting …
  542. Advanced Glycation end (AGE) product modification of laminin downregulates Kir4. 1 in retinal Müller cells
  543. Advanced Glycation end product Inhibitor Pyridoxamine Attenuates IVD Degeneration in Type 2 Diabetic Rats
  544. Therapeutic effects of antigen affinity-purified polyclonal anti-receptor of Advanced Glycation end-product (RAGE) antibodies on cholestasis-induced liver injury in rats
  545. Hypoxia‐induced increases in glucose uptake do not cause oxidative injury or Advanced Glycation end‐product (AGE) formation in vascular endothelial cells
  546. SOCS3 overexpression inhibits Advanced Glycation end product -induced EMT in proximal tubule epithelial cells
  547. Protective effects of physiological testosterone on Advanced Glycation end product ‑induced injury in human endothelial cells
  548. Expression of Advanced Glycation end‐product receptors in the cochlea
  549. Inhibition of Advanced Glycation end-product formation by lutein from Tagetes erecta
  550. Role of urotensin II in Advanced Glycation end product -induced extracellular matrix synthesis in rat proximal tubular epithelial cells
  551. Reduction of lipid peroxidation products and Advanced Glycation end‐product precursors by cyanobacterial aldo‐keto reductase AKR3G1—a founding member of the …
  552. Preventive effects of Rosa rugosa root extract on Advanced Glycation end product -induced endothelial dysfunction
  553. SUN-LB131 Association of Receptor for Advanced Glycation end product (RAGE) Gene Polymorphisms & Serum Levels of Soluble RAGE (sRAGE) With Metabolic …
  554. Nε-(Carboxymethyl)Lysine, a Major Advanced Glycation end product in Exhaled Breath Condensate as a Biomarker of Small Airway Involvement in Asthma
  555. The potential role of Advanced Glycation end product and iNOS in chronic renal failure-related testicular dysfunction
  556. Pentosidine, Advanced Glycation end product , in acute ischaemic stroke patients with and without atrial rhythm disturbances
  557. Advanced Glycation end-product-inhibited cell proliferation and protein expression of β-catenin and cyclin D1 are dependent on glycogen synthase kinase 3β in LLC …
  558. Domain I-IV of β2-glycoprotein I inhibits Advanced Glycation end product -induced angiogenesis by down-regulating vascular endothelial growth factor 2 …
  559. Association of serum carboxymethyl-lysine, a dominant Advanced Glycation end product , with anemia in adults: the Baltimore Longitudinal Study of Aging
  560. Isolation and identification of 5-methyl-imidazolin-4-one derivative as glyceraldehyde-derived Advanced Glycation end product
  561. Interferon-γ mediates the protective effects of soluble receptor for Advanced Glycation end-product in myocardial ischemia/reperfusion
  562. The Advanced Glycation end product Nϵ‐carboxymethyllysine and its precursor glyoxal increase serotonin release from Caco‐2 cells
  563. Reduction of Advanced Glycation end‐product (AGE) levels in nervous tissue proteins of diabetic Lewis rats following islet transplants is related to different durations of …
  564. … analysis of contractility in the ileum in response to flow and ramp distension in streptozotocin-induced diabetic rats—Association with Advanced Glycation end product
  565. Phenolic Compounds from the Leaves of Homonoia riparia and their Inhibitory Effects on Advanced Glycation end product Formation
  566. Abundance, localization, and functional correlates of the Advanced Glycation end‐product carboxymethyl lysine in human myocardium
  567. … evaluation of novel 2, 3, 5-triaryl-4H, 2, 3, 3a, 5, 6, 6a-hexahydropyrrolo [3, 4-d] isoxazole-4, 6-diones for Advanced Glycation end product formation inhibitory activity
  568. Possible involvement of altered RGD sequence in reduced adhesive and spreading activities of Advanced Glycation end product -modified fibronectin to vascular …
  569. Nitroxidized-Albumin Advanced Glycation end product and Rheumatoid Arthritis
  570. Detection and determination of glyceraldehyde-derived Advanced Glycation end product
  571. Impact of chronic renal failure and peritoneal dialysis fluids on Advanced Glycation end product and iNOS levels in penile tissue: an experimental study
  572. The marine natural product Scalarin inhibits the receptor for Advanced Glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic …
  573. Combination of medicinal herbs KIOM-79 reduces Advanced Glycation end product accumulation and the expression of inflammatory factors in the aorta of …
  574. Immunohistochemistry of Advanced Glycation end product N ε-(carboxymethyl) lysine in coronary arteries in relation to cardiac fibrosis and serum N-terminal …
  575. The Development of Maillard Reaction, and Advanced Glycation end product (AGE) -Receptor for AGE (RAGE) Signaling Inhibitors as Novel Therapeutic Strategies for …
  576. Pigment epithelium-derived factor (PEDF) inhibits diabetes-or Advanced Glycation end product (AGE) -induced platelet CD40 ligand overexpression in rats
  577. Role of peroxisome proliferators-activated receptor-gamma in Advanced Glycation end product -mediated functional loss of voltage-gated potassium channel in rat …
  578. GW28-e0833 Inhibition of myocardial ischemia/reperfusion apoptosis by soluble receptor for Advanced Glycation end-product (sRAGE) via interferon-induced …
  579. Advanced Glycation end product carboxymethyl-lysine and risk of incident peripheral artery disease in older adults: The Cardiovascular Health Study
  580. N ε-Carboxymethyllysine (CML), a Maillard reaction product, stimulates serotonin release and activates the receptor for Advanced Glycation end products (RAGE) in …
  581. Identification of N2-(1-carboxymethyl) guanine (CMG) as a guanine Advanced Glycation end product
  582. Endogenous secretory receptor for Advanced Glycation end product levels are inversely associated with HbA1c in type 2 diabetic patients
  583. On resin synthesis and cross-linking of collagen peptides containing the Advanced Glycation end-product pyrraline via Maillard condensation
  584. … -6-(2-formyl-5-hydroxymethyl-pyrrol-l-yl)-hexanoic acid (‘pyrraline’) as an early-stage product or Advanced Glycation end product in non-enzymic protein Glycation
  585. The Association Between Anemia and Skin Autofluorescence, a Marker for Advanced Glycation end product Accumulation
  586. Comment on: Thallas-Bonke et al.(2008) Inhibition of NADPH Oxidase Prevents Advanced Glycation end product –Mediated Damage in Diabetic Nephropathy …
  587. Can soluble receptor for Advanced Glycation end-product (sRAGE) levels in blood be used as a predictor of cardiovascular diseases?
  588. Blue native/SDS‐PAGE combined with iTRAQ analysis reveals Advanced Glycation end‐product‐induced changes of synaptosome proteins in C57 BL/6 mice
  589. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in Advanced Glycation end product (AGE) -related disorders
  590. Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in Advanced Glycation end product (AGE) -injected rats.
  591. Protective effect of Gymnema sylvestre L. against Advanced Glycation end‑product, sorbitol accumulation and aldose reductase activity in Homoeopathic Formulation
  592. Expression of receptor for Advanced Glycation end product mRNA by human peritoneal mesothelial cells
  593. Inhibitors of Advanced Glycation end products from coffee bean roasting by-product
  594. Genistein attenuates Advanced Glycation end product -induced expression of fibronectin and connective tissue growth factor
  595. Blockade by nifedipine of Advanced Glycation end product -induced CD40-CD40 ligand interaction in endothelial cells.
  596. Prevention of proliferative diabetic retinopathy and cataract in SDT rats with aminoguanidine, an anti-Advanced Glycation end product agent
  597. Ginsenoside derivatives inhibit Advanced Glycation end-product formation and glucose–fructose mediated protein Glycationin vitro via a specific structure–activity …
  598. Preparation of monoclonal antibodies against different epitopes on extracellular domain of human receptor for Advanced Glycation end product .
  599. Cold Storage Increases Albumin and AdvancedGlycationend product -Albumin Levels in Kidney Transplants: A Possible Cause for Exacerbated Renal …
  600. Inhibitory effect of caffeic acid on Advanced Glycation end product ‐induced renal fibrosis in vitro: A potential therapeutic target
  601. Prostaglandin E2 inhibits Advanced Glycation end product -induced adhesion molecule expression on monocytes, cytokine production, and lymphocyte proliferation …
  602. Inhibitory effect of receptor for Advanced Glycation end product ‑specific small interfering RNAs on the development of hepatic fibrosis in primary rat hepatic …
  603. Anti-Advanced Glycation end-product and free radical scavenging activity of plants from the yucatecan flora
  604. Combination therapy with nateglinide and telmisartan ameliorates insulin resistance in Zucker fatty rats by suppressing Advanced Glycation end product receptor axis
  605. … product peritoneal dialysis regimen is associated with lower plasma EN‐RAGE and HMGB‐1 proinflammatory ligands of receptor for Advanced Glycation end products
  606. Advanced Glycation end product LEVELS IN EYE LENSES, AORTA, AND TAIL TENDON IN TRANSPLANTED DIABETIC INBRED LEWIS RATS1
  607. Increased Advanced Glycation end product specific fluorescence in repeatedly heated used cooking oil
  608. Telmisartan blocks Advanced Glycation end product (AGE) -induced plasminogen activator inhibitor-1 (PAI-1) gene expression in endothelial cells via activation of …
  609. Chlorogenic acid isomers from Sorbus commixta of ulleung island origin and their inhibitory effects against Advanced Glycation end product (AGE) formation and …
  610. Correlation of endogenous secretory receptor for Advanced Glycation end product (esRAGE) with metabolic health related biomarkers of skeletal muscle
  611. Deterioration of Glutaraldehyde Crosslinked Heterograft Biomaterials due to Advanced Glycation end product Formation and Serum Albumin Infiltration
  612. Analysis of differentially expressed Advanced Glycation end product -modified proteins in diabetic rat kidney
  613. Advanced Glycation end product inhibitory effect of quercetin-3-O-rutinoside, isolated from Teucrium polium
  614. Role of myosin light chain and myosin light chain kinase in Advanced Glycation end product –induced endothelial hyperpermeability in vitro and in vivo
  615. Advanced Glycation end product (AGE) ‐immunoreactive materials in chronic prurigo patients receiving a long‐standing haemodialysis
  616. Prokaryotic expression of receptor for Advanced Glycation end product and screening of its interaction proteins [J]
  617. Abstract B26: A novel dietary Advanced Glycation end product (AGE) model to assess impact on tumor progression
  618. Effect of γ-Glutamyl Cysteine Derivatives from Garlic on Advanced Glycation End-Product (AGE) Formation during Food Processing
  619. Effects of arginine supplementation on exogenous Advanced Glycation end product -induced renal inflammatory mediator expression in rats
  620. Interrelationship of elevated serum Advanced Glycation End-product levels and malnutrition (Subjective Global Assessment) scores with the severity of retinopathy in …
  621. The receptor for Advanced Glycation end product (RAGE) binding to HMGB1 and subsequent NADPH oxidase activation mediates ectopic intestinal inflammation in …
  622. Expression of receptors of Advanced Glycation end product (RAGE) and types I, III and IV collagen in the vastus lateralis muscle of men in early stages of knee …
  623. Effect of Process Conditions on Advanced Glycation end product Formation in BSA-Glucose System [J]
  624. Advanced Glycation end-product cross-link breakers: A novel therapeutic pathway for cardiovascular disease
  625. A soluble receptor for Advanced Glycation end product levels in patients with systemic lupus erythematosus
  626. 2215-PUB: Serum Levels of the Advanced Glycation end product (AGE) Pentosidine Do Not Correlate with the Extent of Coronary Artery Disease Assessed by …
  627. THE THERAPEUTIC POTENTIAL OF NIGELLA SATIVA IN THE INHIBITION OF Advanced Glycation end product (AGE) FORMATION: A SYSTEMATIC …
  628. Anti-skin-aging Effect of Mori Folium through decreased Advanced Glycation end product (AGEs)
  629. Inhibition of Advanced Glycation end product formation by burdock root extract
  630. Diabetic nephropathy and low molecular weight Advanced Glycation end-product in urine
  631. Autophagy plays a protective role in Advanced Glycation end product -induced apoptosis of vascular endothelial cells [J]
  632. 135: Interruption of the Receptor for Advanced Glycation end product pathway attenuates pulmonary reperfusion injury
  633. … to” Methylglyoxal-hydroimidazolones (MG-Hs) instead of Nɛ-(carboxymethyl)-l-lysine (CML) is the major Advanced Glycation end-product during drying process in …
  634. EFFECTS OF ONE YEAR EXERCISE TRAINING WITH A DRUG TO BREAK Advanced Glycation END-PRODUCT CROSS-LINKS ON CARDIAC FUNCTION IN …
  635. Assessment of Serum Advanced Glycation End-Product Level and Its Effect on Periodontal Health Status in Type 2 Diabetic Patients with Chronic Periodontitis.
  636. Advanced Glycation end product (AGE) -Mediated Reactive Oxygen Species Production in Cultured Endothelial Cells is Dependent on NADPH Oxidase Activation.
  637. OxiSelect™ Advanced Glycation end product (AGE) ELISA Kit
  638. Effect of Advanced Glycation end product on Cellular Proliferation and Expression of Plasminogen Activator Inhibitor-1 in Rat Vascular Smooth Muscle Cell
  639. Pentosidine and soluble receptor for Advanced Glycation end-product (RAGE) are important prognostic factors independent of renal function in heart failure
  640. Garlic (Allium sativum) Modulates the Expression of the Receptor for Advanced Glycation end product (RAGE) Isoforms in Renal Tissues of Streptozotocin‐Induced …
  641. Transient cytosolic free calcium changes in cultured neonatal rat cardiac myocytes in response to Advanced Glycation end-product treatment
  642. OxiSelect™ Advanced Glycation end product (AGE) Competitive ELISA Kit
  643. Nervous System Pathophysiology: Accumulation of methylglyoxal increases the Advanced Glycation end-product levels in DRG and contributes to lumbar disk …
  644. OR-02 SAXAGLIPTIN PREVENTS INCREASED CORONARY ARTERIAL STIFFNESS AND Advanced Glycation end product EXPRESSION IN A …
  645. Changes of high mobility protein B1 and soluble Advanced Glycation end product receptor in heart failure
  646. Significantly High Level of Soluble Receptor for Advanced Glycation end product (sRAGE) in Serum: A Predictor of Acute Coronary Syndrome
  647. GW28-e0060 Changes of high mobility protein B1 and soluble Advanced Glycation end product receptor in elderly patients with congestive heart failure at high altitude
  648. OxiSelect™ Advanced Glycation end product (AGE) Competitive ELISA Kit, Trial Size
  649. Assessment of serum ɛN-carboxymethyllysine and soluble receptor of Advanced Glycation end product levels among type 2 diabetes mellitus patients with …
  650. Ellisras Longitudinal Study 2017: elevated serum levels of carboxymethyl-lysine, an Advanced Glycation end-product, are associated with higher odds of developing …
  651. An Advanced Glycation end product (AGE) -receptor for AGEs (RAGE) axis restores adipogenic potential of senescent preadipocytes through modulation of p53 protein …
  652. Antioxidant and anti-AGEs (Advanced Glycation end-product) activities of ethanolic extract of Ficus carica Linn from Indonesia
  653. Peel extract of water chestnut (Trapa bispinosa Roxb.) inhibits Glycation, degradesα-dicarbonyl compound, and breaks Advanced Glycation end product crosslinks
  654. Altered serum glyceraldehyde-derived Advanced Glycation end product (AGE) and
  655. High Serum Level of Pentosidine, an Advanced Glycation end product (AGE) , is a Risk Factor of Patients with Heart Failure
  656. Non-invasive skin autofluorescence, blood and urine assays of the Advanced Glycation end product (AGE) pentosidine as an indirect indicator of AGE content in …
  657. Neuroprotective effects of the Advanced Glycation end-product inhibitors LR90 and pyridoxamine in experimental diabetes.
  658. Advanced Glycation end product inhibitory assay-‘Achyranthes Aspera leaf’
  659. Advanced Glycation end product and Glycosaminoglycans Levels in Patients with Diabetic Ketoacidosis
  660. Leptin and connective tissue growyh factor in Advanced Glycation end-product efects in NRK-49F cells.
  661. … Structural, hemodynamic and clinical improvements among patients with Advancedheart failure treated with Alagebrium (a novel oral Advanced Glycation end-product …
  662. Effects of dietary AGE (Advanced Glycation end product ) on ovarian microenvironment and oocyte quality
  663. Biochemical and biophysical characterization of hemoglobin-Advanced Glycation end product and its relevance to diabetes mellitus
  664. Expression of Advanced Glycation end product (AGE) receptors in corneal endothelial cells
  665. The Effect of Advanced Glycation end product Inhibition on the Development of Diabetic Encephalopathy in Rats
  666. AB0291 Association between Pentosidine, an Advanced Glycation End-Product, and Disease Activity in Patients with Untreated Rheumatoid Arthritis. A Preliminary …
  667. Pentosidine, an Advanced Glycation end product , Is a Negative Predictor of Cortical Bone Geometric Endpoints in Children
  668. Correlation between receptor for Advanced Glycation end product gene polymorphism and left ventricular hypertrophy
  669. Promoting effect of receptor for Advanced Glycation end product in periodontitis
  670. Impact of interaction of Advanced Glycation end product and its receptor on podocytes apoptosis
  671. Advanced Glycation end product precursors in diabetes: a crucial link between oxidative stress and inflammation?
  672. Effects of Saengjihwangeum-ja Extracts on the Expression of Inflammatory Response in Human Monocyte Cells Induced by Advanced Glycation end product
  673. The effect of an insulin releasing agent, BTS 67 582, on Advanced Glycation end product formation in vitro
  674. Advanced Glycation end product and its Receptor RAGE promote the in-vitro wound healing of HCE corneal epithelial cells
  675. The Role of Soluble Subtype of the Receptor for Advanced Glycation end product (sRAGE) in Rheumatoid Arthrirtis Disease Activity and Treatment Follow-up
  676. Relationship Between Soluble Receptor of Advanced Glycation end product and Carotid Atherosclerosis in Patients Under Hemodialysis
  677. Analysis of the expression of soluble receptor for Advanced Glycation end product and its influencing factors in patients with acute cerebral infarction
  678. Effect of stimulation to alveolar macrophage by SiO_2 on Advanced Glycation end product receptor and ligand
  679. The differential effects of fructose and glucose on Advanced Glycation end-product formation and cellular damage in vitro
  680. Diet-induced obesity may initiate Advanced Glycation end-product-mediated inflammation in articular cartilage
  681. Association of diabetic retinopathy severity with lens fluorescence ratio reflecting Advanced Glycation end product level
  682. Advanced Glycation end product and Amadori Product Are Increased and Related to Apoptosis in the Human Diabetic Retina.
  683. Soluble Receptor For Advanced Glycation end products Are Decreased But Not The Levels Of Advanced Glycation end product Ne-(Carboxymethyl) Lysine In …
  684. Corni Fructus Inhibits Wrinkle Formation by Reduced Advanced Glycation end product (AGEs)
  685. Pre-Existing Emphysema Affects Soluble Receptor for Advanced Glycation End-Product Levels in Acute Respiratory Distress Syndrome
  686. Key functional domains of human cardiac troponin-C are susceptible to Advanced Glycation end-product formation in vitro
  687. Receptor for Advanced Glycation end product (RAGE) mediates retinal ganglion cell loss in experimental glaucoma
  688. The effect of oral metformin on vitreous Advanced Glycation end-product content in patients with proliferative diabetic retinopathy
  689. The Effects of Different Diets (High Fat and High Fructose Diet) on the Development of Insulin Resistance and Tissue Advanced Glycation end product Levels in Rats
  690. Altered Cell-surface Receptor Levels Result from Fructose Advanced Glycation end product -Induced Inflammation
  691. Evaluation of receptor for Advanced Glycation end product /high-mobility group box 1 (RAGE/HMGB1) expression status and its prognostic value in breast cancer
  692. Screening breaker of advancedGlycationend-product cross-links by enzyme-linked immunosorbent assay method in vitro
  693. Dialysis-related amyloidosis: role of Advanced Glycation end product -β-microglobulin in joint inflammation
  694. Effects of pro-inflammatory mediators on Advanced Glycation end product receptors in type-b synovial cells
  695. Expression and Clinical Meaning of Plasma Soluble Receptor of Advanced Glycation end product in Patients With Gestational Hypertension Heart Disease
  696. The Role of Glutathione Maintenance in Protection against Advanced Glycation end product Induced Neurite Degeneration in SH‐SY5Y Cells
  697. The effects of Buyang Huanwu decoction on Advanced Glycation end product receptor of hippocampus in Alzheimer’s disease mice
  698. Serum levels of soluble receptor for Advanced Glycation end product in type 2 diabetic patients: possible association with urinary albumin excretion
  699. The Advanced Glycation end-product inhibitor pyridoxamine traps intermediates formed during lipid peroxidation reactions in vitro and in vivo: Mechanism of action of …
  700. Effects of Advanced Glycation End-Product Inhibition and Protein Cross-Link Breaking in Diabetic Rats
  701. Correlation between p. 82G> S polymorphisms of receptor for Advanced Glycation end-product gene and susceptibility to inflammatory bowel diseases
  702. … and 3H-1, 2-Dithiole-3-Thione in Maintaining Glutathione Status and Protection Against Advanced Glycation end product Induced Neurite Degeneration in SH-SY5Y …
  703. Advanced Glycation end-product-induced mitogenesis and collagen production are dependent on angiotensin II and connective tissue growth factor in NRK-49F cells.
  704. Rhinacanthins-rich extract: A potent superoxide scavenger and Advanced Glycation end-product formation inhibitor
  705. Up-regulation of Receptors for Advanced Glycation end product in the Spinal Cord after Peripheral Nerve Injury
  706. INHIBITION OF Advanced Glycation END-PRODUCT FORMATION ON EYE LENS PROTEINS BY SALVIA OFFICINALIS EXTRACT
  707. Trichostatin A abrogates Advanced Glycation end-product-induced retinal pigment epithelium dysfunction in an in vivo model of diabetic eye disease
  708. N-(carboxymethyl) valine adduct in hemoglobin: A biomarker of Advanced Glycation end product formation and oxidative stress.
  709. Association of Soluble Receptor for Advanced Glycation end product (sRAGE) with increasing central aortic stiffness in hypertensive patients
  710. The expression of receptor for Advanced Glycation end product in gingival tissues of type 2 diabetic patients with periodontitis
  711. Can Different Diets (High Fat and High Fructose Diet) Affect Insulin Resistance, Tissue Advanced Glycation end product Levels in Rats’ Pancreas
  712. Advanced Glycation end product associated skin autofluorescence and serum corboxymethyl lysine levels in acromegaly
  713. The Glp-1 Analogue Liraglutide Inhibits the Advanced Glycation End-Product Cml and Nox2 in the Diabetic Heart and Brain
  714. Dynamics of Circulating Ligands and Soluble Receptor for Advanced Glycation End-Product in Liver Transplantation: 1746
  715. Response to Comment on: Thallas-Bonke et al.(2008) Inhibition of NADPH Oxidase Prevents Advanced Glycation end product –Mediated Damage in Diabetic …
  716. Biophysical Characterization of the Interaction between the Receptor for Advanced Glycation end product and High Mobility Group Box 1
  717. Enhanced Advanced Glycation end product Receptors are Associated With Plaque Neovascularization and Inflammation in Peripheral Atheroma From Patients With …
  718. Modulation of nicotine and Advanced Glycation end product (AGE) mediated effects by the antioxidant glutathione (G) in fibroblasts
  719. Effect of Advanced Glycation end product receptor signal transduction on MCP-1 expression of podocyte induced by carboxymethyllysine
  720. Change and clinical significance of high mobility group protein B1 and its Advanced Glycation end product receptor in patients with systemic lupus erythematosus
  721. Nucleophilic Compounds Block Advanced Glycation end product (AGE) Formation From Ascorbic Acid in the hSVCT2-enA Transgenic Mouse Model of Lenticular …
  722. Renal Fibrosis and Glomerulosclerosis in a New Mouse Model of Diabetic Nephropathy and its Regression by BMP-7 and Advanced Glycation End-Product …
  723. The Role of Brown Adipose Tissue (BAT) Activity inMice Devoid of Receptor for Advanced Glycation end product (RAGE)
  724. Advanced Glycation End-Product Inhibition With Alagebrium Slows Age-Related Large Vessel Arterial Stiffening in Healthy Elderly Humans
  725. A role for angiotensin-(1-7) to attenuate Advanced Glycation end product -induced myofibroblast transition in the NRK-52E renal proximal tubule cell line
  726. Accumulation of argpyrimidine, a methylglyoxal-derived Advanced Glycation end product , increases apoptosis of lens epithelial cells both in vitro and in vivo
  727. -374 T/A POLYMORPHISM IN THE RECEPTOR OF Advanced Glycation end product (AGER) GENE IS ASSOCIATED WITH ONSET OF DIABETES …
  728. Advanced Glycation end product (AGE) , soluble receptor for AGE (sRAGE) and inflammation in smokers and mild/moderate chronic obstructive pulmonary disease …
  729. Effects of grape seed proanthocyanidin extracts on Advanced Glycation end product receptor and connective tissue growth factor in the myocardium of diabetic rats
  730. Advanced Glycation end-product-induced mitogenesis is dependent on Janus kinase 2-induced heat shock protein 70 in normal rat kidney interstitial fibroblast cells.
  731. An Advanced Glycation end product (AGE) -Rich Diet Promotes Nε-Carboxymethyl-lysine Accumulation in the Cardiac Tissue and Tendons of Rats
  732. 2-Ammonio-6-(3-oxidopyridinium-1-yl) hexanoate (OP-lysine) is a newly identified Advanced Glycation end product in cataractous and aged human lenses. Vol. 279 …
  733. Liraglutide alleviates arteriosclerotic lesions and inhibits receptor for Advanced Glycation end-product expression in diabetic ApoE-/-mice
  734. Vaccination Using Advanced Glycation end product of Low-Density Lipoprotein Pulsed Dendritic Cells Reduces Atherosclerosis in Diabetic Apoe-/- Mice
  735. Functional and immunochemical characterization of Advanced Glycation end-product (AGE) -modified low-density lipoproteins (AGE-LDL).
  736. Treatment With Nitric Oxide (NO) Donors or Pioglitazone Improves CD34+ Cell Dynamics on Advanced Glycation end product (AGE) Modified Basement Membrane
  737. Circulating Levels and Dietary Intake of the Advanced Glycation End-product Marker Carboxymethyl Lysine in Chronic Kidney Disease Patients on …
  738. Advanced Glycation end-product-inhibited cell proliferation and protein expression of beta-catenin and cyclin D1 are dependent on glycogen synthase kinase 3 beta in …
  739. Design, Synthesis and Biological Evaluation of Novel Receptor for Advanced Glycation End-product (RAGE) Inhibitor
  740. Advanced Glycation end product Modification of Laminin Alters Kir4. 1 Expression in Retinal Glia Cells
  741. Expression of Receptor for Advanced Glycation end product mRNA and Protein in Cultured Hepatic Stellate Cells Inhibited by Specific Small Interfering RNA
  742. GW24-e1023 Advanced Glycation end product Modified Low Density Lipoprotein Activates Mast Cells via Toll-Like 4 Receptor Pathway
  743. Pioglitazone reduces expression of Advanced Glycation end product receptor mRNA in renal cortex of streptozotocin-induced diabetic rats
  744. The anti-ALS drug riluzole attenuates MCP-1 by high glucose, Advanced Glycation end product (AGE) or TNF-α in cultured human retinal pericytes
  745. Effect of glycaemic control on the diurnal blood pressure variation and endogenous secretory receptor for Advanced Glycation end product (esRAGE) levels in type 1 …
  746. Effect of mitogen-activated protein kinase kinase 6-p38 alpha signal pathway on receptor for Advanced Glycation end-product expression in alveolar epithelial cells …
  747. Development of New Antibody Based Theranostic Agents Targeting the Receptor for Advanced Glycation End-Product (Rage)
  748. Proteomic Analysis of Advanced Glycation End-Product (AGE) Modified Proteins in High Glucose-Exposed Retinal Müller Glia: Evidence for Age-Mediated Cell …
  749. Fundus Autofluorescence in a Rabbit Model of Age-Related Macular Degeneration Induced by Advanced Glycation end product Microspheres as Imitation Lipofuscin
  750. FAILURE OF PANCREAS TRANSPLANTATION TO PREVENT DEPOSITION OF AN Advanced Glycation END-PRODUCT IN TRANSPLANTED KIDNEYS …
  751. An Advanced Glycation end product (AGE) -receptor for AGEs (RAGE) axis restores adipogenic potential of senescent preadipocytes through modulation of p53 protein …
  752. … Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ: Advanced Glycation end product intervention reduce diabetes …
  753. … BY EPLERENONE: RELATIONSHIP BETWEEN MINERALOCORTICOID RECEPTOR, Advanced Glycation end product RECEPTOR AND CAVEOLIN-1 IN …
  754. Nᵋ-Carboxymethyllysine (CML), a Maillard reaction product, stimulates serotonin release and activates the receptor for Advanced Glycation end products (RAGE) in …
  755. L-Arginine inhibits in vitro nonenzymatic Glycationand Advancedglycosylated end product formation of human serum albumin
  756. Advanced Glycation end-products: a review
  757. Advanced Glycation end products : sparking the development of diabetic vascular injury
  758. Advanced Glycation end products and the kidney
  759. Advanced Glycation end-products and atherosclerosis
  760. Advanced Glycation end products : a Nephrologist’s perspective
  761. Advanced Glycation end-products and the progress of diabetic vascular complications
  762. Role of Advanced Glycation end products in diabetic nephropathy
  763. Effect of collagen turnover on the accumulation of Advanced Glycation end products
  764. Recent progress in Advanced Glycation end products and diabetic complications
  765. Advanced Glycation end products in diabetic corneas
  766. Angiogenesis induced by Advanced Glycation end products and its prevention by cerivastatin
  767. The role of Advanced Glycation end products in the development of atherosclerosis
  768. Advanced Glycation end products and the progressive course of renal disease
  769. Inhibition of protein Glycationand Advanced Glycation end products by ascorbic acid and other vitamins and nutrients
  770. Advanced Glycation end products in Alzheimer’s disease and other neurodegenerative diseases
  771. Advanced Glycation end-products and Advancedoxidation protein products in patients with diabetes mellitus
  772. Advanced Glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes
  773. Advanced Glycation end products and diabetic complications
  774. Advanced Glycation end products contribute to amyloidosis in Alzheimer disease
  775. The biology of the receptor for Advanced Glycation end products and its ligands
  776. Advanced Glycation end products increase retinal vascular endothelial growth factor expression.
  777. Advanced Glycation end products and endothelial dysfunction in type 2 diabetes
  778. Understanding RAGE, the receptor for Advanced Glycation end products
  779. Advanced Glycation end products , oxidant stress and vascular lesions
  780. Implication of an increased oxidative stress in the formation of Advanced Glycation end products in patients with end-stage renal failure
  781. Survey of the distribution of a newly characterized receptor for Advanced Glycation end products in tissues
  782. Renal catabolism of Advanced Glycation end products : the fate of pentosidine
  783. Advanced Glycation end products and mortality in hemodialysis patients
  784. Advanced Glycation end products and diabetic complications: a general overview
  785. Glucose, Advanced Glycation end products , and diabetes complications: what is new and what works
  786. Randomized trial of an inhibitor of formation of Advanced Glycation end products in diabetic nephropathy
  787. Enhanced cellular oxidant stress by the interaction of Advanced Glycation end products with their receptors/binding proteins
  788. Advanced Glycation end products and nutrition
  789. Determination of Advanced Glycation end products in serum by fluorescence spectroscopy and competitive ELISA
  790. Receptor for advancedGlycationend products
  791. Regulation of vascular endothelial growth factor expression by Advanced Glycation end products
  792. Differential accumulation of Advanced Glycation end products in the course of diabetic retinopathy
  793. Advanced Glycation end products and bone loss during aging
  794. Advanced Glycation end products and diabetic nephropathy
  795. Role of Advanced Glycation end products and their receptors in development of diabetic neuropathy
  796. Breakers of Advanced Glycation end products restore large artery properties in experimental diabetes
  797. A role for Advanced Glycation end products in diminished bone healing in type 1 diabetes
  798. Advanced Glycation end products up-regulate gene expression found in diabetic glomerular disease
  799. Advanced Glycation end products (AGEs)and diabetic vascular complications
  800. Modification of low density lipoprotein by Advanced Glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency
  801. Restriction of dietary glycotoxins reduces excessive Advanced Glycation end products in renal failure patients
  802. Advanced Glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for Advanced Glycation end products (RAGE)
  803. Advanced Glycation end products , their receptors and diabetic angiopathy
  804. Advanced Glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation
  805. Association between serum levels of soluble receptor for Advanced Glycation end products and circulating Advanced Glycation end products in type 2 diabetes
  806. In vitro kinetic studies of formation of antigenic Advanced Glycation end products (AGEs) : novel inhibition of post-Amadori Glycationpathways
  807. Importance of Advanced Glycation end products in diabetes-associated cardiovascular and renal disease
  808. The relationship between accumulation of Advanced Glycation end products and expression of vascular endothelial growth factor in human diabetic retinas
  809. Cellular receptors for Advanced Glycation end products . Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions.
  810. A breaker of Advanced Glycation end products attenuates diabetes-induced myocardial structural changes
  811. Vascular hypertrophy in experimental diabetes. Role of Advanced Glycation end products .
  812. Toxic Advanced Glycation end products (TAGE) theory in Alzheimer’s disease
  813. Accumulation of Advanced Glycation end products as a molecular mechanism for aging as a risk factor in osteoarthritis
  814. Differential effects between amphoterin and Advanced Glycation end products on colon cancer cells
  815. Advanced Glycation end products induce glomerular sclerosis and albuminuria in normal rats
  816. Reduction of the accumulation of Advanced Glycation end products by ACE inhibition in experimental diabetic nephropathy
  817. Characterization of Advanced Glycation end products for biochemical studies: side chain modifications and fluorescence characteristics
  818. Advanced Glycation end products in nondiabetic patients with coronary artery disease
  819. Advanced Glycation end products in age-related macular degeneration
  820. Involvement of Advanced Glycation end-products (AGEs)in Alzheimer’s disease
  821. Serum levels of Advanced Glycation end products are increased in patients with type 2 diabetes and coronary heart disease.
  822. RAGE: a novel cellular receptor for Advanced Glycation end products
  823. Possible participation of Advanced Glycation end products in the pathogenesis of osteoporosis in diabetic patients
  824. Soluble receptor for Advanced Glycation end products : from disease marker to potential therapeutic target
  825. Neurotoxicity of Advanced Glycation end-products for cultured cortical neurons
  826. Glycationin food and metabolic transit of dietary AGEs (Advanced Glycation end-products): studies on the urinary excretion of pyrraline
  827. Role of Advanced Glycation end products (AGEs)in thrombogenic abnormalities in diabetes
  828. … association between serum levels of Advanced Glycation end products and the soluble form of receptor for Advanced Glycation end products in nondiabetic subjects
  829. Advanced Glycation end-products pentosidine and Nϵ-carboxymethyllysine are elevated in serum of patients with osteoporosis
  830. Increased serum levels of Advanced Glycation end-products and diabetic complications
  831. Characterization and functional analysis of the promoter of RAGE, the receptor for Advanced Glycation end products
  832. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for Advanced Glycation end products .
  833. Serum levels of Advanced Glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes.
  834. Advanced Glycation end products in human optic nerve head
  835. Association between acute-phase reactants and Advanced Glycation end products in type 2 diabetes
  836. Plasma levels of soluble receptor for Advanced Glycation end products and coronary artery disease in nondiabetic men
  837. Detection of noncarboxymethyllysine and carboxymethyllysine Advanced Glycation end products (AGE) in serum of diabetic patients
  838. The receptor for Advanced Glycation end products is induced by the Glycationproducts themselves and tumor necrosis factor-α through nuclear factor-κB, and …
  839. Increased levels of Advanced Glycation end products in human cataractous lenses
  840. Expression of receptors for Advanced Glycation end products in peripheral occlusive vascular disease
  841. Lipid peroxidation and Advanced Glycation end products in the brain in normal aging and in Alzheimer’s disease
  842. Advanced Glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy.
  843. Purification and characterization of mouse soluble receptor for Advanced Glycation end products (sRAGE)
  844. Relationship of serum Advanced Glycation end products with deterioration of periodontitis in type 2 diabetes patients
  845. Receptor for Advanced Glycation end-products is a marker of type I cell injury in acute lung injury
  846. Soluble receptor for Advanced Glycation end products in patients with decreased renal function
  847. Advanced Glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study
  848. Genotoxicity of Advanced Glycation end products in mammalian cells
  849. Identification of galectin-3 as a high-affinity binding protein for Advanced Glycation end products (AGE) : a new member of the AGE-receptor complex
  850. The receptor for Advanced Glycation end products is highly expressed in the skin and upregulated by Advanced Glycation end products and tumor necrosis …
  851. beta 2-Microglobulin modified with Advanced Glycation end products is a major component of hemodialysis-associated amyloidosis.
  852. Advanced Glycation end products in renal failure
  853. FEEL-1 and FEEL-2 are endocytic receptors for Advanced Glycation end products
  854. Expression of Advanced Glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease
  855. Activation of receptor for Advanced Glycation end products : a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
  856. RAGE (receptor for Advanced Glycation end products ): a central player in the inflammatory response
  857. Advanced Glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses
  858. Immunochemical approach to characterize Advanced Glycation end products of the Maillard reaction: evidence for the presence of a common structure
  859. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through Advanced Glycation end products
  860. Skin autofluorescence, a measure of cumulative metabolic stress and Advanced Glycation end products , predicts mortality in hemodialysis patients
  861. Advanced Glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury
  862. Blockade of receptor for Advanced Glycation end-products restores effective wound healing in diabetic mice
  863. Impairment of vascular endothelial nitric oxide synthase activity by Advanced Glycation end products
  864. The breakdown of pre‐existing Advanced Glycation end products is associated with reduced renal fibrosis in experimental diabetes
  865. Induction of Advanced Glycation end products and alterations of the tensile properties of articular cartilage
  866. The role of Advanced Glycation end products in retinal microvascular leukostasis
  867. Advanced Glycation end products and nephrotoxicity of high-protein diets
  868. Receptor for Advanced Glycation end products (RAGE) regulates sepsis but not the adaptive immune response
  869. Scavenger receptors that recognize Advanced Glycation end products
  870. Immunochemical evidence for the presence of Advanced Glycation end products in human lens proteins and its positive correlation with aging.
  871. Increased Advanced Glycation end products in atherosclerotic lesions of patients with end-stage renal disease
  872. Specific fluorescence assay for Advanced Glycation end products in blood and urine of diabetic patients
  873. Decreased plasma levels of soluble receptor for Advanced Glycation end-products in patients with essential hypertension
  874. Receptor for Advanced Glycation end products -binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis
  875. Expression of receptors for Advanced Glycation end‐products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer
  876. Methylglyoxal-derived hydroimidazolone Advanced Glycation end-products of human lens proteins
  877. Immunohistochemical and ultrastructural detection of Advanced Glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal …
  878. Increased accumulation of skin Advanced Glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy
  879. Age-related changes in cells and tissues due to Advanced Glycation end products (AGEs)
  880. Advanced Glycation end products induce blood–retinal barrier dysfunction in normoglycemic rats
  881. Advanced Glycation end products in Human Cancer Tissues: Detection of Nε‐(Carboxymethyl)lysine and Argpyrimidine
  882. Immunological evidence that non-carboxymethyllysine Advanced Glycation end-products are produced from short chain sugars and dicarbonyl compounds in …
  883. Receptor for Advanced Glycation end‐products is a marker of type I lung alveolar cells
  884. Age-and stage-dependent accumulation of Advanced Glycation end products in intracellular deposits in normal and Alzheimer’s disease brains
  885. Enzymatic digestion and mass spectrometry in the study of Advanced Glycation end products /peptides
  886. RAGE‐mediated neutrophil dysfunction is evoked by Advanced Glycation end products (AGEs)
  887. Advanced Glycation end products (AGEs)co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats.
  888. Diabetes increases formation of Advanced Glycation end products on Sarco (endo) plasmic reticulum Ca2+-ATPase
  889. Accumulation of Advanced Glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration.
  890. Advanced Glycation end products in clinical nephrology
  891. Increased serum concentrations of Advanced Glycation end products : a marker of coronary artery disease activity in type 2 diabetic patients
  892. The receptor for Advanced Glycation end products (RAGE) is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of rage …
  893. Immunohistochemical distribution of the receptor for Advanced Glycation end products in neurons and astrocytes in Alzheimer’s disease
  894. Crosslinking by Advanced Glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which …
  895. Rapid formation of Advanced Glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway
  896. Oxidation conspires with Glycationto generate noxious Advanced Glycation end products in renal failure.
  897. Activation of the receptor for Advanced Glycation end products triggers a p21 ras-dependent mitogen-activated protein kinase pathway regulated by oxidant …
  898. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for Advanced Glycation end products (RAGE) activation
  899. Receptor for Advanced Glycation end products , inflammation, and accelerated periodontal disease in diabetes: mechanisms and insights into therapeutic modalities
  900. Increased levels of serum Advanced Glycation end‐products in women with polycystic ovary syndrome
  901. Thiazolidinediones reduce endothelial expression of receptors for Advanced Glycation end products
  902. Advanced Glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS
  903. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for Advanced Glycation end products
  904. Receptor for Advanced Glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development
  905. Serum levels of low molecular weight Advanced Glycation end products in diabetic subjects
  906. N ε-(carboxymethyl) lysine adducts of proteins are ligands for receptor for Advanced Glycation end products that activate cell signaling pathways and modulate …
  907. Tomato paste fraction inhibiting the formation of Advanced Glycation end-products
  908. Receptor for Advanced Glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but …
  909. Advanced Glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial …
  910. Influence of Advanced Glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of β-amyloid peptide
  911. Advanced Glycation end products and Advancedoxidation protein products in hemodialyzed patients
  912. Role of Advanced Glycation end products (AGEs)and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
  913. The receptor for Advanced Glycation end-products has a central role in mediating the effects of Advanced Glycation end-products on the development of vascular …
  914. Advanced Glycation end products activate Smad signaling via TGF‐β‐dependent and‐independent mechanisms: implications for diabetic renal and vascular disease
  915. Advanced Glycation end products in uremia
  916. Articular chondrocytes express the receptor for Advanced Glycation end products : potential role in osteoarthritis
  917. Role of Advanced Glycation end products in adynamic bone disease in patients with diabetic nephropathy
  918. Advanced Glycation end products -induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes
  919. Role of Advanced Glycation end-products (AGE) in late diabetic complications
  920. Circulating levels of soluble receptor for Advanced Glycation end products in Alzheimer disease and vascular dementia
  921. Receptor for Advanced Glycation end products is involved in impaired angiogenic response in diabetes
  922. Advanced Glycation end products induce crosslinking of collagen in vitro
  923. Accumulation of Advanced Glycation end products , measured as skin autofluorescence, in renal disease
  924. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by Advanced Glycation end products
  925. The receptor for Advanced Glycation end products and its ligands: a new inflammatory pathway in lung disease?
  926. Advanced Glycation end products in neurodegeneration: more than early markers of oxidative stress?
  927. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic Advanced Glycation end-products: comparison with aminoguanidine
  928. Markedly elevated levels of plasma Advanced Glycation end products in patients with liver cirrhosis–amelioration by liver transplantation
  929. Co-expression of receptor for Advanced Glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer
  930. Enhanced expression of receptor for Advanced Glycation end products in chronic kidney disease
  931. Alternative routes for the formation of immunochemically distinct Advanced Glycation end-products in vivo
  932. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for Advanced Glycation end products blocks hyperpermeability in diabetic …
  933. Expression profiling of endogenous secretory receptor for Advanced Glycation end products in human organs
  934. 3-Deoxyglucosone, a promoter of Advanced Glycation end products in fluids for peritoneal dialysis
  935. Receptor for Advanced Glycation end products (AGEs)has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins
  936. Advanced Glycation end products in end-stage renal disease and their removal
  937. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and Advanced Glycation end products .
  938. Novel splice variants of the receptor for Advanced Glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in …
  939. Receptor for Advanced Glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis
  940. Advanced Glycation end products induce expression of vascular endothelial growth factor by retinal Müller cells
  941. … system of human phagocytes generates Nε-(carboxymethyl)lysine on proteins: a mechanism for producing Advanced Glycation end products at sites of …
  942. Modulation of soluble receptor for Advanced Glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy
  943. … prevents macro-and microvascular endothelial dysfunction and oxidative stress following a meal rich in Advanced Glycation end products in individuals with type 2 …
  944. Nε-(Carboxymethyl)lysine Protein Adduct Is a Major Immunological Epitope in Proteins Modified with Advanced Glycation end products of the Maillard Reaction
  945. Inflammation-induced chondrocyte hypertrophy is driven by receptor for Advanced Glycation end products
  946. Reduced cell replication and induction of apoptosis by Advanced Glycation end products in rat Schwann cells
  947. Advanced Glycation end‐products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone
  948. Enhanced interaction of Advanced Glycation end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in …
  949. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of Advanced Glycation end products
  950. Circulating soluble receptor for Advanced Glycation end products is inversely associated with glycemic control and S100A12 protein
  951. Formation of Advanced Glycation end products during CAPD
  952. Cd36, a member of the class b scavenger receptor family, as a receptor for Advanced Glycation end products
  953. Advanced Glycation end products -driven angiogenesis in vitro: induction of the growth and tube formation of human microvascular endothelial cells through …
  954. Advanced Glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus
  955. Decreased levels of soluble receptor for Advanced Glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control
  956. Increased methylglyoxal and Advanced Glycation end products in kidney from spontaneously hypertensive rats
  957. Advanced Glycation end products and vascular structure and function
  958. The receptor for Advanced Glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site
  959. Possible involvement of Advanced Glycation end-products in bone resorption
  960. Receptor for Advanced Glycation end products and age-related macular degeneration
  961. Advanced Glycation end products (AGEs)on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the …
  962. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of Advanced Glycation end products : biochemical …
  963. Anti-hypertensive agents inhibit in vivo the formation of Advanced Glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model
  964. Advanced Glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages
  965. Accumulation of fructosyl-lysine and Advanced Glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats
  966. Evaluation of Advanced Glycation end products and carbonyl compounds in patients with different conditions of oxidative stress
  967. Macrophage scavenger receptor mediates the endocytic uptake and degradation of Advanced Glycation end products of the Maillard reaction
  968. Proteins modified by malondialdehyde, 4-hydroxynonenal, or Advanced Glycation end products in lipofuscin of human retinal pigment epithelium
  969. Down-regulation of the receptor for Advanced Glycation end-products (RAGE) supports non-small cell lung carcinoma
  970. Advanced Glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway
  971. Identification of polymorphisms in the receptor for Advanced Glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups.
  972. Chronic diabetes increases Advanced Glycation end products on cardiac ryanodine receptors/calcium-release channels
  973. Induction of 1, 2-dicarbonyl compounds, intermediates in the formation of Advanced Glycation end-products, during heat-sterilization of glucose-based peritoneal …
  974. Plasma levels of Advanced Glycation end products in healthy, long-term vegetarians and subjects on a western mixed diet
  975. Corneal Advanced Glycation end products increase in patients with proliferative diabetic retinopathy
  976. Expression of receptor for Advanced Glycation end products and HMGB1/amphoterin in colorectal adenomas
  977. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for Advanced Glycation end products
  978. Advanced Glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells
  979. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for Advanced Glycation end products
  980. Inflammation and Advanced Glycation end products in uremia: Simple coexistence, potentiation or causal relationship?
  981. Effects of Advanced Glycation end-products on the proliferation and differentiation of osteoblast-like cells
  982. Effect of Advanced Glycation end-products on gene expression and synthesis of TNF-α and endothelial nitric oxide synthase by endothelial cells
  983. Expression of the receptor of Advanced Glycation end products in gingival tissues of type 2 diabetes patients with chronic periodontal disease: a study utilizing …
  984. Advanced Glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells
  985. Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by Advanced Glycation end products
  986. Age‐related decrease in susceptibility of human articular cartilage to matrix metalloproteinase–mediated degradation: The role of Advanced Glycation end products
  987. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for Advanced Glycation end-products
  988. N‐Glycans on the receptor for Advanced Glycation end products influence amphoterin binding and neurite outgrowth
  989. Advanced Glycation end-products in diabetic nephropathy
  990. Advanced Glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent …
  991. Glyceraldehyde-derived Advanced Glycation end products in Alzheimer’s disease
  992. Advanced Glycation end-products in patients with chronic alcohol misuse
  993. Receptor for Advanced Glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E–null mice
  994. Enhancing effect of Advanced Glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus
  995. Familial amyloid polyneuropathy: receptor for Advanced Glycation end products -dependent triggering of neuronal inflammatory and apoptotic pathways
  996. Impaired retinal angiogenesis in diabetes: role of Advanced Glycation end products and galectin-3
  997. Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of Advanced Glycation end products .
  998. … production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: Role of the receptor for Advanced Glycation end products
  999. Effect of Advanced Glycation end products on accelerated apoptosis of retinal capillary cells under in vitro conditions
  1000. Glyoxalase I deficiency is associated with an unusual level of Advanced Glycation end products in a hemodialysis patient
  1001. Immunohistochemical localisation of Advanced Glycation end products in pulmonary fibrosis.
  1002. Advanced Glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with …
  1003. Accumulation of Advanced Glycation end products of the Maillard reaction with age in human hippocampal neurons
  1004. Advanced Glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells
  1005. Naphthopyrone glucosides from the seeds of Cassia tora with inhibitory activity on Advanced Glycation end products (AGEs)formation
  1006. Immunohistochemical localization of Advanced Glycation end products , pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer’s disease and aged …
  1007. Glycolaldehyde, a reactive intermediate for Advanced Glycation end products , plays an important role in the generation of an active ligand for the macrophage …
  1008. Positive association of serum levels of Advanced Glycation end products with thrombogenic markers in humans
  1009. High serum levels of Advanced Glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a …
  1010. Expression of receptor for Advanced Glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells.
  1011. Advanced Glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications
  1012. Immunohistochemical localization of different epitopes of Advanced Glycation end products in human atherosclerotic lesions
  1013. Advanced Glycation end‐products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes
  1014. In vitro formation of Advanced Glycation end products in peritoneal dialysis fluid
  1015. Activation of receptor for Advanced Glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes
  1016. Key role of Src kinase in S100B-induced activation of the receptor for Advanced Glycation end products in vascular smooth muscle cells
  1017. The receptor for Advanced Glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via …
  1018. Immunochemical detection of Advanced Glycation end products in lens crystallins from streptozocin-induced diabetic rat
  1019. Advanced Glycation end products in human senile and diabetic cataractous lenses
  1020. Interaction of the receptor for Advanced Glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation
  1021. Accumulation of Advanced Glycation end products in women with preeclampsia: possible involvement of placental oxidative and nitrative stress
  1022. Soluble receptor for Advanced Glycation end products triggers a proinflammatory cytokine cascade via β2 integrin Mac‐1
  1023. Characterization of Advanced Glycation end products : mass changes in correlation to side chain modifications
  1024. Up‐regulated expression of the receptor for Advanced Glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts
  1025. High levels of dietary Advanced Glycation end products transform low-dersity lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in …
  1026. Membrane proteins of human erythrocytes are modified by Advanced Glycation end products during aging in the circulation
  1027. Plasma levels of Advanced Glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality
  1028. … in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to Advanced Glycation end-products through binding of …
  1029. Involvement of beta 2-microglobulin modified with Advanced Glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human …
  1030. Advanced Glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques.
  1031. Histones from diabetic rats contain increased levels of Advanced Glycation end products
  1032. Generation of active oxygen species from Advanced Glycation end-products (AGEs)during ultraviolet light A (UVA) irradiation and a possible mechanism for cell …
  1033. Identification of pentosidine as a native structure for Advanced Glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related …
  1034. Toxic action of Advanced Glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy
  1035. Effects of Advanced Glycation End-products on the Proliferation and Fibronectin Production of Smooth Muscle Cells
  1036. The role of galectin-3 in endocytosis of Advanced Glycation end products and modified low density lipoproteins
  1037. Acid-stable fluorescent Advanced Glycation end products : vesperlysines A, B, and C are formed as crosslinked products in the Maillard reaction between lysine or …
  1038. Effect of Advanced Glycation end products on lens epithelial cells in vitro
  1039. Possible participation of Advanced Glycation end products in the pathogenesis of colorectal cancer in diabetic patients
  1040. Type II alveolar epithelial cells in lung express receptor for Advanced Glycation end products (RAGE) gene
  1041. Expression of a novel secreted splice variant of the receptor for Advanced Glycation end products (RAGE) in human brain astrocytes and peripheral blood …
  1042. Advanced Glycation end-products in diabetic nephropathy.
  1043. Effect of buformin and metformin on formation of Advanced Glycation end products by methylglyoxal
  1044. Association of expression of receptor for Advanced Glycation end products and invasive activity of oral squamous cell carcinoma
  1045. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for Advanced Glycation end products (AGE)
  1046. Upregulation of mesangial growth factor and extracellular matrix synthesis by Advanced Glycation end products via a receptor-mediated mechanism
  1047. Advanced Glycation end products induce angiogenesis in vivo
  1048. Advanced Glycation end products in diabetic complications
  1049. Expression and function of receptors for Advanced Glycation end products in bovine corneal endothelial cells
  1050. Advanced Glycation end products -cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the …
  1051. Modification of enzymatic antioxidants in retinal microvascular cells by glucose or Advanced Glycation end products
  1052. Deposition of Advanced Glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat.
  1053. Advanced Glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes
  1054. High levels of soluble receptor for Advanced Glycation end products may be a marker of extreme longevity in humans
  1055. Relationship between the expression of Advanced Glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy
  1056. Receptor for Advanced Glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation
  1057. Candesartan reduced Advanced Glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice
  1058. Advanced Glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes
  1059. Inhibition of human endothelial cell nitric oxide synthesis by Advanced Glycation end-products but not glucose: relevance to diabetes
  1060. Accumulation of Advanced Glycation end products decreases collagen turnover by bovine chondrocytes
  1061. Advanced Glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived Advanced
  1062. Synergistic action of Advanced Glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic …
  1063. β2-Microglobulin modified with Advanced Glycation end products modulates collagen synthesis by human fibroblasts
  1064. Advanced Glycation end products (AGEs) , free radicals and diabetes
  1065. The role of reactive oxygen species in TNFα-dependent expression of the receptor for Advanced Glycation end products in human umbilical vein endothelial …
  1066. Identification of the Advanced Glycation end products Nε-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis
  1067. Advanced Glycation end products can induce glial reaction and neuronal degeneration in retinal explants
  1068. Elevation of Nε-(carboxymethyl) lysine-modified Advanced Glycation end products in chronic liver disease is an indicator of liver cirrhosis
  1069. β2-Microglobulin modified with Advanced Glycation end products delays monocyte apoptosis
  1070. From benefit to damage. Glutamate and Advanced Glycation end products in Alzheimer brain
  1071. Constituents of the roots of Pueraria lobata inhibit formation of Advanced Glycation end products (AGEs)
  1072. Atorvastatin decreases serum levels of Advanced Glycation end products (AGEs)in patients with type 2 diabetes
  1073. Below the Radar: Advanced Glycation end products that Detour “around the side”: Is HbA1c not an accurate enough predictor of long term progression and …
  1074. Roles of Advanced Glycation end-products in the progression of diabetic nephropathy
  1075. Advanced Glycation end products induce choroidal endothelial cell proliferation, matrix metalloproteinase-2 and VEGF upregulation in vitro
  1076. Increased expression of receptor for Advanced Glycation end products by synovial tissue macrophages in rheumatoid arthritis
  1077. Effects of a diet rich in Advanced Glycation end products in the rat remnant kidney model
  1078. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early Advanced Glycation end-products (AGEs)and a proinflammatory response
  1079. cDNA cloning of a novel secreted isoform of the human receptor for Advanced Glycation end products and characterization of cells co-expressing cell-surface …
  1080. Pigment epithelium-derived factor prevents Advanced Glycation end products -induced monocyte chemoattractant protein-1 production in microvascular …
  1081. Thiamine corrects delayed replication and decreases production of lactate and Advanced Glycation end-products in bovine retinal and human umbilical vein …
  1082. Inhibition of Advanced Glycation end‐products protects against retinal capillary basement membrane expansion during long‐term diabetes
  1083. Advanced Glycation end products induce secretion of chemokines and apoptosis in human first trimester trophoblasts
  1084. Serum levels of Advanced Glycation end products are associated with in-stent restenosis in diabetic patients
  1085. Puerariafuran, a new inhibitor of Advanced Glycation end products (AGEs)isolated from the roots of Pueraria lobata
  1086. … acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with Advanced Glycation end products
  1087. AdvancedGlycationend products in insulin-resistant states
  1088. [11] Advanced Glycation end products : Detection and reversal
  1089. Genotoxicity of Advanced Glycation end products : involvement of oxidative stress and of angiotensin II type 1 receptors
  1090. Increased serum levels of Advanced Glycation end products (AGEs)in children and adolescents with IDDM
  1091. High‐fat diet enhances visceral Advanced Glycation end products , nuclear O‐Glc‐Nac modification, p38 mitogen‐activated protein kinase activation and apoptosis
  1092. Increased expression of Advanced Glycation end-products and their receptor, and activation of nuclear factor kappa-B in lacrimal glands of diabetic rats
  1093. Advanced Glycation end products and oxidative stress are increased in chronic allograft nephropathy
  1094. What’s the RAGE?: The receptor for Advanced Glycation end products (RAGE) and the dark side of glucose
  1095. Are food Advanced Glycation end products toxic in biological systems?
  1096. The endothelial cell binding site for Advanced Glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide
  1097. Role of vitamin E-coated membrane in reducing Advanced Glycation end products in hemodialysis patients: a pilot study
  1098. Bimodal effect of Advanced Glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous …
  1099. Advanced Glycation end products in Diabetes‐Associated Atherosclerosis and Renal Disease: Interventional Studies
  1100. Advanced Glycation end products and receptor for Advanced Glycation end products in AA amyloidosis
  1101. Effect of Advanced Glycation end-products on cell proliferation and cell death
  1102. Decreased levels of Advanced Glycation end-products in patients with Gilbert syndrome.
  1103. Advanced Glycation end products increase collagen-specific chaperone protein in mouse diabetic nephropathy
  1104. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of Advanced Glycation end products
  1105. Nitric oxide inhibits the formation of Advanced Glycation end products
  1106. Blockade of the receptor for Advanced Glycation end products attenuates acetaminophen‐induced hepatotoxicity in mice
  1107. Advanced Glycation end‐products in sickle cell anaemia
  1108. The receptor for Advanced Glycation end products mediates the chemotaxis of rabbit smooth muscle cells
  1109. Advanced Glycation end products (AGEs)and their receptor (RAGE) system in diabetic retinopathy
  1110. Advanced Glycation end-products induce apoptosis of bovine retinal pericytes in culture: involvement of diacylglycerol/ceramide production and oxidative stress …
  1111. Advanced Glycation end products co-localized with astrocytes and microglial cells in Alzheimer’s disease brain
  1112. Advanced Glycation end products -induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages
  1113. Advanced Glycation end products and their recognition by macrophage and macrophage-derived cells
  1114. Pigment epithelium-derived factor (PEDF) prevents diabetes-or Advanced Glycation end products (AGE) -elicited retinal leukostasis
  1115. Significance of proximal tubular metabolism of Advanced Glycation end products in kidney diseases
  1116. Are Advanced Glycation end products cardiovascular risk factors in patients with CRF?
  1117. Telmisartan inhibits expression of a receptor for Advanced Glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of …
  1118. Low-molecular but not high-molecular Advanced Glycation end products (AGEs)are removed by high-flux dialysis.
  1119. Impact of metabolic control and serum lipids on the concentration of Advanced Glycation end products in the serum of children and adolescents with type 1 diabetes …
  1120. Immunochemical detection of Advanced Glycation end products in renal cortex from STZ-induced diabetic rat
  1121. Advanced Glycation end products in children with chronic renal failure and type 1 diabetes
  1122. Identification of the receptor for Advanced Glycation end products in synovial tissue of patients with rheumatoid arthritis
  1123. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of Advanced Glycation end-products in renal transplant …
  1124. Advanced Glycation end-products (AGEs)induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal …
  1125. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and Advanced Glycation end products
  1126. CD36-mediated endocytic uptake of Advanced Glycation end products (AGE) in mouse 3T3-L1 and human subcutaneous adipocytes
  1127. Advanced Glycation end-products and peritoneal sclerosis
  1128. A developmental nephron deficit in rats is associated with increased susceptibility to a secondary renal injury due to Advanced Glycation end-products
  1129. Suppression of nNOS expression in rat enteric neurones by the receptor for Advanced Glycation end‐products
  1130. Advanced Glycation end‐products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor‐induced ICAM‐1 expression …
  1131. Activation of astrocytes by Advanced Glycation end products : cytokines induction and nitric oxide release
  1132. Advanced Glycation end products : a highly complex set of biologically relevant compounds detected by mass spectrometry
  1133. Identification of mouse orthologue of endogenous secretory receptor for Advanced Glycation end-products: structure, function and expression
  1134. Plasma levels of Advanced Glycation end products in children with renal disease
  1135. Estimation of age of human cadavers by immunohistochemical assessment of Advanced Glycation end products in the hippocampus
  1136. Autofluorescence characterization of Advanced Glycation end products of hemoglobin
  1137. Regulation of receptor for Advanced Glycation end products during bleomycin-induced lung injury
  1138. Transition Metal–Catalyzed Oxidation of Ascorbate in Human Cataract Extracts: Possible Role of Advanced Glycation end products
  1139. The receptor for Advanced Glycation end products (RAGE) is elevated in women with preeclampsia
  1140. … Nε-(carboxymethyl) lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of Advanced Glycation end products
  1141. Glycationand Advanced Glycation end-products in laboratory experiments in vivo and in vitro
  1142. Kinetics of nonenzymatic Glycationof ribonuclease A leading to Advanced Glycation end products . Paradoxical inhibition by ribose leads to facile isolation of protein …
  1143. Induction of aldose reductase in cultured human microvascular endothelial cells by Advanced Glycation end products
  1144. The role of metal-catalyzed oxidation in the formation of Advanced Glycation end products : an in vitro study on collagen
  1145. Age-dependent accumulation of Advanced Glycation end-products in adult Drosophila melanogaster
  1146. Interaction between β2-microglobulin and Advanced Glycation end products in the development of dialysis related-amyloidosis
  1147. Effect of Advanced Glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells.
  1148. Advanced Glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells …
  1149. Are Advanced Glycation end-products associated with amyloidosis in Alzheimer’s disease?
  1150. Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for Advanced Glycation end-products
  1151. Advanced Glycation end products modulate the maturation and function of peripheral blood dendritic cells
  1152. The amphoterin (HMGB1)/receptor for Advanced Glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration …
  1153. Incadronate disodium inhibits Advanced Glycation end products -induced angiogenesis in vitro
  1154. Receptor for Advanced Glycation end products is a promising target of diabetic nephropathy
  1155. Two immunochemical assays to measure Advanced Glycation end-products in serum from dialysis patients
  1156. Expression of the receptor for Advanced Glycation end products in Huntington’s disease caudate nucleus
  1157. Expression of receptor for Advanced Glycation end products (RAGE) in human biliary cancer cells.
  1158. Selective formation of certain Advanced Glycation end products in spinal cord astrocytes of humans and mice with superoxide dismutase-1 mutation
  1159. Pathophysiology of Advanced Glycation end-products in renal failure
  1160. Chemoselective synthesis of peptides containing major Advanced Glycation end‐products of lysine and arginine
  1161. Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of Advanced Glycation end products in human tissues.
  1162. Immunohistochemical study of Advanced Glycation end products in aging and Alzheimer’s disease brain
  1163. Inhibitory effect of metformin on formation of Advanced Glycation end products
  1164. Acute modulation of albumin microvascular leakage by Advanced Glycation end products in microcirculation of diabetic rats in vivo.
  1165. Dysfunction of dermal fibroblasts induced by Advanced Glycation end-products (AGEs)and the contribution of a nonspecific interaction with cell membrane and AGEs
  1166. Relationship between autofluorescence and Advanced Glycation end products in diabetic lenses
  1167. Role of Advanced Glycation end products in aging collagen
  1168. Peroxisome proliferator-activated receptor γ down-regulates receptor for Advanced Glycation end products and inhibits smooth muscle cell proliferation in a diabetic …
  1169. Role of megalin in endocytosis of Advanced Glycation end products : implications for a novel protein binding to both megalin and Advanced Glycation end products
  1170. Receptor for Advanced Glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis
  1171. The breakdown of preformed Advanced Glycation end products reverses erectile dysfunction in streptozotocin‐induced diabetic rats: Preventive versus curative …
  1172. Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by Advanced Glycation end products links oxidative stress to altered retinal …
  1173. The effects of valsartan on the accumulation of circulating and renal Advanced Glycation end products in experimental diabetes
  1174. Genomic damage in end-stage renal failure: potential involvement of Advanced Glycation end products and carbonyl stress
  1175. Advanced Glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction
  1176. Low‐Molecular Weight Advanced Glycation end products : Markers of Tissue AGE Accumulation and More?
  1177. Nifedipine inhibits gene expression of receptor for Advanced Glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation.
  1178. Activated protein C, a natural anticoagulant protein, has antioxidant properties and inhibits lipid peroxidation and Advanced Glycation end products formation
  1179. Substrates modified by Advanced Glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet …
  1180. Serum or cerebrospinal fluid levels of glyceraldehyde-derived Advanced Glycation end products (AGEs)may be a promising biomarker for early detection of …
  1181. In vitro effect of Advanced Glycation end‐products on human polymorphonuclear superoxide production
  1182. Removal of Advanced Glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis
  1183. C-Reactive protein upregulates receptor for Advanced Glycation end products expression in human endothelial cells
  1184. Immunohistochemical localization of Advanced Glycation end products in pinguecula
  1185. Susceptibility of brain microvascular endothelial cells to Advanced Glycation end products -induced tissue factor upregulation is associated with intracellular reactive …
  1186. Advanced Glycation end products in Descemet’s membrane and their effect on corneal endothelial cell
  1187. Low molecular weight Advanced Glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis
  1188. Advanced Glycation end products (AGE) -modified proteins and their potential relevance to atherosclerosis
  1189. Phosphatidylinositol 3′-kinase-dependent activation of renal mesangial cell Ki-Ras and ERK by Advanced Glycation end products
  1190. Selective inhibition by grape seed proanthocyanidin extracts of cell adhesion molecule expression induced by Advanced Glycation end products in endothelial cells
  1191. Inhibitor for Advanced Glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats
  1192. Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of Advanced Glycation end products
  1193. Serum levels of glucose-derived Advanced Glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal …
  1194. Differential expression of receptors for Advanced Glycation end‐products in peritoneal mesothelial cells exposed to glucose degradation products
  1195. The− 374A allele of the receptor for Advanced Glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with …
  1196. Isolation and characterization of Advanced Glycation end products derived from the in vitro reaction of ribose and collagen
  1197. Aminoguanidine inhibits Advanced Glycation end products formation on beta2-microglobulin.
  1198. Possible significance of Advanced Glycation end products in serum in end-stage renal disease and in late complications of diabetes
  1199. Advanced Glycation and lipoxidation end products : role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism
  1200. Immunohistochemical distribution and quantitative biochemical detection of Advanced Glycation end products in fetal to adult rats and in rats with …
  1201. Generation of active oxygen species from Advanced Glycation end-products (AGE) under ultraviolet light A (UVA) irradiation
  1202. Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of Advanced Glycation end products
  1203. Advanced Glycation end products Stimulate an Enhanced Neutrophil Respiratory Burst Mediated Through the Activation of Cytosolic Phospholipase A2 and …
  1204. Modification of β2m with Advanced Glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum
  1205. Role of Advanced Glycation end products and growth factors in peritoneal dysfunction in CAPD patients
  1206. Advanced Glycation end-products (AGEs)in hyperglycemic patients
  1207. Inhibition of matrix-induced bone differentiation by Advanced Glycation end-products in rats
  1208. Distribution of the receptor for Advanced Glycation end products gene polymorphisms in patients with chronic periodontitis: a preliminary study
  1209. Presence of dopa and amino acid hydroperoxides in proteins modified with Advanced Glycation end products (AGEs) : amino acid oxidation products as a possible …
  1210. Induction of macrophage growth by Advanced Glycation end products of the Maillard reaction.
  1211. Dietary bread crust Advanced Glycation end products bind to the receptor for AGEs in HEK‐293 kidney cells but are rapidly excreted after oral administration to healthy …
  1212. Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and Advanced Glycation end-products) for atherogenesis in …
  1213. Effects of Advanced Glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells
  1214. Blockade of angiotensin II receptors reduces the expression of receptors for Advanced Glycation end products in human endothelial cells
  1215. Immunohistochemical detection of Advanced Glycation end products in dialysis-related amyloidosis
  1216. Skin autofluorescence, a marker of Advanced Glycation end products and oxidative stress, is increased in recently preeclamptic women
  1217. Monocyte/macrophage response to β2-microglobulin modified with Advanced Glycation end products
  1218. Renal accumulation and clearance of Advanced Glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and …
  1219. Advanced Glycation end products /Peptides: An in Vivo Investigation
  1220. Receptor for Advanced Glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing
  1221. Advanced Glycation end products : specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis
  1222. Detection of N epsilon-(carboxymethyl) lysine (CML) and non-CML Advanced Glycation end-products in the anterior horn of amyotrophic lateral sclerosis spinal cord.
  1223. Hepatic clearance of Advanced Glycation end products (AGEs) —myth or truth?
  1224. 3-Deoxyosone-related Advanced Glycation end products in foods and biological systems
  1225. Immunohistochemical study of human Advanced Glycation end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with …
  1226. Mechanisms involved in the stimulatory effect of Advanced Glycation end products on growth of rat aortic smooth muscle cells
  1227. Induction of reactive oxygen species and cell survival in the presence of Advanced Glycation end products and similar structures
  1228. … and reduced viability of Alzheimer’s disease neuronal cybrids is reproduced by β-amyloid peptide acting through receptor for Advanced Glycation end products (RAGE …
  1229. Advanced Glycation end products and hyperglycaemia
  1230. Developmental expression of receptor for Advanced Glycation end products (RAGE), amphoterin and sulfoglucuronyl (HNK‐1) carbohydrate in mouse cerebellum and …
  1231. Advanced Glycation end products impair the scavenger function of rat hepatic sinusoidal endothelial cells
  1232. Rheumatoid arthritis: links with cardiovascular disease and the receptor for Advanced Glycation end products
  1233. Receptor for Advanced Glycation end products plays a more important role in cellular survival than in neurite outgrowth during retinoic acid-induced …
  1234. Expression and purification of the soluble isoform of human receptor for Advanced Glycation end products (sRAGE) from Pichia pastoris
  1235. The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind Advanced Glycation end products , an interaction that may play a role in the …
  1236. Inhibition of nitric oxide synthase activity by early and Advanced Glycation end products in cultured rabbit proximal tubular epithelial cells
  1237. Accurate mass measurements by Fourier transform mass spectrometry in the study of Advanced Glycation end products /peptides
  1238. Benfotiamine inhibits intracellular formation of Advanced Glycation end products in vivo
  1239. Effect of high-dose thiamine and pyridoxine on Advanced Glycation end products and other oxidative stress markers in hemodialysis patients: a randomized placebo …
  1240. Advanced Glycation end products -modified proteins and oxidized LDL mediate down-regulation of leptin in mouse adipocytes via CD36
  1241. β2-Microglobulin modified with Advanced Glycation end products induces interleukin-6 from human macrophages: Role in the pathogenesis of hemodialysis …
  1242. Amyloidosis, Advanced Glycation end products and Alzheimer disease
  1243. Increased serum levels of Advanced Glycation end products in NIDDM patients with diabetic complications
  1244. New hypothesis on etiopathogenesis of Alzheimer syndrome. Advanced Glycation end products (AGEs)
  1245. Signalling pathways involved in retinal endothelial cell proliferation induced by Advanced Glycation end products : inhibitory effect of gliclazide
  1246. N-Terminal pyrazinones: a new class of peptide-bound Advanced Glycation end-products
  1247. Beraprost sodium, a prostaglandin I 2 analogue, protects against Advanced Glycation end products -induced injury in cultured retinal pericytes
  1248. Neurotoxicity of acetaldehyde-derived Advanced Glycation end products for cultured cortical neurons
  1249. The-429 T/C and-374 T/A gene polymorphisms of the receptor of Advanced Glycation end products gene are not risk factors for diabetic retinopathy in Caucasians with …
  1250. Advanced Glycation end products modulate transcriptional regulation in mesangial cells
  1251. Effects of Advanced Glycation end products on hyaluronan photolysis: a new mechanism of diabetic vitreopathy
  1252. Receptors for Advanced Glycation end-products (AGE) —expression by endothelial cells in non-diabetic uraemic patients
  1253. a-Series gangliosides mediate the effects of Advanced Glycation end products on pericyte and mesangial cell proliferation: a common mediator for retinal and renal …
  1254. Graded sensitiveness of the various retinal neuron populations on the glyoxal-mediated formation of Advanced Glycation end products and ways of protection
  1255. Advanced Glycation end-products downregulating intervertebral disc cell production of proteoglycans in vitro
  1256. Amino acids injure mesangial cells by Advanced Glycation end products , oxidative stress, and protein kinase C
  1257. Advanced Glycation end products stimulate tumor necrosis factor-alpha and interleukin-1 beta secretion by peritoneal macrophages in patients on continuous …
  1258. Endocytic uptake of Advanced Glycation end products by mouse liver sinusoidal endothelial cells is mediated by a scavenger receptor distinct from the macrophage …
  1259. Augmentation of the neutrophil respiratory burst through the action of Advanced Glycation end products : a potential contributor to vascular oxidant stress
  1260. Reactive oxygen species accelerate production of vascular endothelial growth factor by Advanced Glycation end products in RAW264. 7 mouse macrophages
  1261. Aminoguanidine inhibits albuminuria, but not the formation of Advanced Glycation end-products in skin collagen of diabetic rats
  1262. The induction of surface β-amyloid binding proteins and enhanced cytotoxicity in cultured PC-12 and IMR-32 cells by Advanced Glycation end products
  1263. Immunochemical evidence for increased formation of Advanced Glycation end products and inhibition by aminoguanidine in diabetic rat lenses
  1264. In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for Advanced Glycation end products
  1265. Potential benefit of inhibitors of Advanced Glycation end products in the progression of type II diabetes: a study with aminoguanidine in C57/BLKsJ diabetic mice
  1266. Advanced Glycation end products of the Maillard reaction in aortic pepsin-insoluble and pepsin-soluble collagen from diabetic rats
  1267. Enhanced plasma levels of Advanced Glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after …
  1268. Advanced Glycation end products induce death of retinal neurons via activation of nitric oxide synthase
  1269. Effects of eparlestat on plasma levels of Advanced Glycation end products in patients with type 2 diabetes.
  1270. Antibodies to Advanced Glycation end products in children with diabetes mellitus
  1271. The human and rat recombinant receptors for Advanced Glycation end products have a high degree of homology but different pharmacokinetic properties in rats
  1272. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by Advanced Glycation end products
  1273. Nuclear factor-κB and Advanced Glycation end-products expression in lacrimal glands of aging rats
  1274. Cytotoxicity of acetaldehyde‐derived Advanced Glycation end‐products (AA‐AGE) in alcoholic‐induced neuronal degeneration
  1275. Rapid determination of Advanced Glycation end products of proteins using MALDI-TOF-MS and PERL script peptide searching algorithm
  1276. Pathogenic role of Advanced Glycation end-products (AGEs) : an overview
  1277. The–429 T/C and–374 T/A gene polymorphisms of the receptor of Advanced Glycation end products gene (RAGE) are not risk factors for coronary artery disease in …
  1278. Damaging effects of Advanced Glycation end-products in the murine macrophage cell line J774A. 1
  1279. Advanced Glycation end products induce actin rearrangement and subsequent hyperpermeability of endothelial cells THIS ARTICLE HAS BEEN RETRACTED
  1280. The effect of Advanced Glycation end-products and aminoguanidine on TNFα production by rat peritoneal macrophages
  1281. Early and Advanced Glycation end-products are increased in dietary copper deficiency
  1282. Gene polymorphisms (G82S, 1704G/T, 2184A/G and 2245G/A) of the receptor of Advanced Glycation end products (RAGE) in plaque psoriasis
  1283. Advanced Glycation end-products as a potential target for treatment of cardiovascular disease
  1284. Advanced Glycation end-products in the peritoneal fluid and in the peritoneal membrane of continuous ambulant peritoneal dialysis patients
  1285. Mechanism of Advanced Glycation end products -induced hyperpermeability in endothelial cells
  1286. Advanced Glycation end products in adolescents and young adults with diabetic angiopathy
  1287. Ribozyme targeting of receptor for Advanced Glycation end products in mouse mesangial cells
  1288. In vitro nonenzymatic Glycationof DNA nucleobases: an evaluation of Advanced Glycation end products under alkaline pH
  1289. Effect of Advanced Glycation end products on oxidative stress in endothelial cells in culture: a warning on the use of cells studied in serum-free media
  1290. Chemistry and Biological Effects of Melanoidins and Glyceraldehyde‐Derived Pyridinium as Advanced Glycation end products
  1291. Expression of receptors for Advanced Glycation end-products in occlusive vascular and renal disease
  1292. Advanced Glycation end products and the pathogenesis of diabetic nephropathy
  1293. Advanced Glycation end products of the Maillard reaction and their relation to aging
  1294. Detection of DNA‐bound Advanced Glycation end‐products by immunoaffinity chromatography coupled to HPLC‐diode array detection
  1295. Induction of an aging mRNA retinal pigment epithelial cell phenotype by matrix-containing Advanced Glycation end products in vitro
  1296. Pathological significance and mechanism of Advanced Glycation end-products [J]
  1297. Differential expression of receptors for Advanced Glycation end products on monocytes in patients with IDDM
  1298. Inhibitory effects of amlodipine and fluvastatin on the deposition of Advanced Glycation end products in aortic wall of cholesterol and fructose-fed rabbits
  1299. Advanced Glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce …
  1300. Distribution of Advanced Glycation end products in the cerebellar neurons of dogs
  1301. A food chemist’s view of Advanced Glycation end-products
  1302. Screening of Korea Traditional Herbal Medicines with Inhibitory Activity on Advanced Glycation end products (AGEs)Formation
  1303. Identification of Advanced Glycation end products of the Maillard reaction in Pick’s disease
  1304. Influence of hemodialysis membrane permeability on serum levels of Advanced Glycation end products (AGEs)and homocysteine metabolites.
  1305. Angiogenic effects of Advanced Glycation end products of the Maillard reaction on cultured human umbilical cord vein endothelial cells
  1306. Identification of monoclonal antibody of Advanced Glycation end products
  1307. Advanced Glycation end products potentiate the stimulatory effect of glucose on macrophage lipoprotein lipase expression
  1308. Serum levels of 3-deoxyglucosone and tissue contents of Advanced Glycation end products are increased in streptozotocin-induced diabetic rats with nephropathy
  1309. Serum levels of Advanced Glycation end products in poorly metabolically controlled children with diabetes mellitus: relation to HbA1c.
  1310. Pentosidine in Advanced Glycation end-products (AGEs)during UVA irradiation generates active oxygen species and impairs human dermal fibroblasts
  1311. Overexpression of receptor of Advanced Glycation end products hypersensitizes cells for amyloid beta peptide-induced cell death
  1312. Immunolocalization and quantification of Advanced Glycation end products in retinal neovascular membranes and serum: a possible role in ocular neovascularization
  1313. Study of the− 429 T/C and− 374 T/A receptor for Advanced Glycation end products promoter polymorphisms in diabetic and nondiabetic subjects with macrovascular …
  1314. Advanced Glycation end products in peritoneal dialysis
  1315. Analysis of serum of patients with Alzheimer’s disease for the level of Advanced Glycation end products
  1316. Hemodialysis techniques and Advanced Glycation end products
  1317. Cardiovascular risk in patients with end-stage renal disease: a potential role for Advanced Glycation end products
  1318. Hereditary ceruloplasmin deficiency increases Advanced Glycation end products in the brain
  1319. AU-rich elements in the mRNA 3′-untranslated region of the rat receptor for Advanced Glycation end products and their relevance to mRNA stability
  1320. Local application of Advanced Glycation end products and intimal hyperplasia in the rabbit collared carotid artery
  1321. Association of Advanced Glycation end products with A549 cells, a human pulmonary epithelial cell line, is mediated by a receptor distinct from the scavenger receptor …
  1322. Immunolocalization of lipid peroxidation/Advanced Glycation end products in amyloid A amyloidosis
  1323. Advanced Glycation end products : a possible link to angiotensin in an animal model
  1324. Inhibition by Advanced Glycation end products (AGEs)of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells.
  1325. Ultrastructural changes and immunohistochemical localization of nitric oxide synthase, Advanced Glycation end products and NF-κB in aorta of streptozotocin treated …
  1326. Glyceraldehyde-derived Advanced Glycation end-products preferentially induce VEGF expression and reduce GDNF expression in human astrocytes
  1327. Importance of Advanced Glycation end products –AGE products
  1328. Advanced Glycation end products inhibit tubulogenesis and migration of kidney epithelial cells in an ezrin-dependent manner
  1329. Advanced Glycation end products (AGEs) ‐induced expression of TGF‐β1 is suppressed by a protease in the tubule cell line LLC‐PK1
  1330. … of erythroleukaemia cell differentiation by extracellular high-mobility group-box protein 1 is independent of the receptor for Advanced Glycation end-products
  1331. Advanced Glycation end-products/peptides: a preliminary investigation by LC and LC/MS
  1332. Advanced Glycation end products impair protein turnover in LLC-PK1: Amelioration by trypsin
  1333. Suppressive effects of tea polyphenol and conformational changes with receptor for Advanced Glycation end products (RAGE) expression in human hepatoma cells.
  1334. Increased expression of tissue factor and receptor for Advanced Glycation end products in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus …
  1335. High glucose and Advanced Glycation end products induce phospholipid hydrolysis and phospholipid enzyme inhibition in bovine retinal pericytes
  1336. Pathological significance and mechanism of Advanced Glycation end-products
  1337. Ultrastructural localization of Advanced Glycation end products and beta2-microglobulin in dialysis amyloidosis.
  1338. Diabetic nephropathy and Advanced Glycation end products
  1339. Effect of intraperitoneal administration of heparin on Advanced Glycation end-products in CAPD
  1340. Determination of Advanced Glycation end products
  1341. … factor and interleukin-18 in maintenance hemodialysis patients: comparative study of Advanced Glycation end products , carboxymethyllysine and pentosidine
  1342. Glycosphingolipid changes induced by Advanced Glycation end-products
  1343. Mass spectrometry of Advanced Glycation end products
  1344. N‐phenacylthiazolium bromide decreases renal and increases urinary Advanced Glycation end products excretion without ameliorating diabetic nephropathy in …
  1345. Advanced Glycation end-products in anterior chamber aqueous of cataractous patients
  1346. Advanced Glycation end products quench nitric oxide in vitro
  1347. Oleate, not ligands of the receptor for Advanced Glycation end-products, promotes proliferation of human arterial smooth muscle cells
  1348. Advanced Glycation end products accelerate atherosclerosis via enhancement of oxidative stress
  1349. Advanced Glycation end products are involved in microvascular permeability changes observed in microcirculation of diabetic rats in vivo
  1350. Advanced Glycation end products induce specific glycoprotein alterations in retinal microvascular cells
  1351. Cloning and characterization of the canine receptor for Advanced Glycation end products
  1352. Phototransformations of Advanced Glycation end products in the human eye lens due to ultraviolet A light irradiation
  1353. Ultrastructural changes and immunohistochemical localization of Advanced Glycation end products in the heart of streptozotocin-treated Mongolian gerbils
  1354. Advanced Glycation end-products prepared in solution under high pressure contain epitopes distinct from those formed in the dry reaction at high temperature
  1355. Advanced Glycation end-products in corneas of patients with keratoconus
  1356. Studies on Advanced Glycation end products by recent mass spectrometric techniques
  1357. Amyloid, Advanced Glycation end products , and dialysis related arthropathy
  1358. Constituents of the stems of Rumex japonicus with Advanced Glycation end products (AGEs)and rat lens aldose reductase (RLAR) inhibitory activity
  1359. Experimental effect of Puerarin on the formation of Advanced Glycation end products and expression of RAGE in the arota of diabetic rats [J]
  1360. Advanced Glycation end products stimulate plasminogen activator activity via GM-CSF in RAW 264.7 cells
  1361. Advanced Glycation end products , their receptors and diabetic angiopathy
  1362. Molecular heterogeneity of amyloid β2-microglobulin and modification with Advanced Glycation end products
  1363. Proliferation-inhibiting effect of Advanced Glycation end products modified human serum albumin to vascular endothelial cell ecv304
  1364. Advanced Glycation end-products reduce the viability of human peritoneal mesothelial cells
  1365. Protective effects of carnosine and relative compounds on DNA cleavage by Advanced Glycation end products
  1366. Intraperitoneal infusion of glucose-based dialysate in the rat—an animal model for the study of peritoneal Advanced Glycation end-products formation and effect on …
  1367. Relationship between vascular endothelial growth factors and Advanced Glycation end products in the human vitreous
  1368. Nitric oxide, Advanced Glycation end products , and uremia
  1369. Role of lipid peroxidation products in the formation of Advanced Glycation end products : An in vitro study on collagen
  1370. Localization of Advanced Glycation end products of Maillard reaction in bovine tissues and their endocytosis by macrophage scavenger receptors
  1371. … radical trapping and carbonyl group trapping anti-AGE agent: a pyridoxamine analogue for inhibiting Advanced Glycation (AGE) and lipoxidation (ALE) end products
  1372. Advanced Glycation end products and β2-microglobulin. The story unfolds
  1373. Advanced Glycation and lipoxidation end products : reactive carbonyl compounds‐related uraemic toxicity
  1374. In vitro-prepared Advanced Glycation end-products and the modulating potential of their low-molecular weight degradation products in IRPTC-A rat proximal-tubular …
  1375. Lipid peroxidation, Advanced Glycation end products and antioxidant status in patients on dialysis
  1376. The relation between impaired wound healing and Advanced Glycation end products [J]
  1377. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of Advanced Glycation end products in renal failure
  1378. Formation of Advanced Glycation end (AGE) products in diabetes: Prevention by pyruvate and a-keto glutarate
  1379. Advanced Glycation end products inhibit production of nitric oxide by human endothelial cells through activation of the p38 signal pathway
  1380. Expression of receptor for Advanced Glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 …
  1381. Effects of Advanced Glycation end products on Ezrin‐Dependent Functions in LLC‐PK1 Proximal Tubule Cells
  1382. Induction of GM-CSF production of macrophages by Advanced Glycation end products of the Maillard reaction
  1383. Immunohistochemical study with anti‐Advanced Glycation end‐products antibody in murine amyloidosis
  1384. Advanced Glycation end products in hemodialyzed patients with diabetes mellitus correlate with leptin and leptin/body fat ratio
  1385. Decrease in the glyceraldehyde derived Advanced Glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease
  1386. Increased levels of circulating Advanced Glycation end products in a model of acute renal insufficiency in rats
  1387. … renal biopsy samples in patients with diabetic nephropathy in non‐insulin dependent diabetes mellitus using monoclonal antibody to Advanced Glycation end products
  1388. Protective effect of inducible type nitric oxide synthase against intracellular oxidative stress caused by Advanced Glycation end-products in vascular smooth muscle …
  1389. Crossline-like structure accumulates as fluorescent Advanced Glycation end products in renal tissues of rats with diabetic nephropathy
  1390. Hepatocyte growth factor protects against apoptosis induced by Advanced Glycation end products in endothelial cells.
  1391. Experimental effect of Puerarin on the formation of Advanced Glycation end products and expression of RAGE in the arota of diabetic rats
  1392. RAGE engagement and vascular cell derangement by short chain sugar-derived Advanced Glycation end products
  1393. Evidence for accumulation of Advanced Glycation end products in acute renal failure
  1394. Advanced Glycation end products (AGEs)and renal failure
  1395. Recombinant human interleukin-10 inhibits proliferation of vascular smooth muscle cells stimulated by Advanced Glycation end products and neointima hyperplasia …
  1396. Advanced Glycation end products stimulate human endothelial cells to produce monocyte chemoattractant protein-1
  1397. Immunochemical determination of Advanced Glycation end products in erythrocyte peripheral-membrane proteins from diabetic patients
  1398. Effects of Advanced Glycation end-products on cell cycle distribution and apoptosis in neonatal rat cardiac myocytes
  1399. Activation of smad signaling and collagenⅠ synthesis in NRK52E cells induced by Advanced Glycation end products
  1400. Inhibitory effect of dilazep hydrochloride on the formation of Advanced Glycation end products
  1401. Activation of receptor for Advanced Glycation end products : a mechanism for monocyte-mediated inflammation in chronic renal failure
  1402. The Mechanism of Advanced Glycation end products -Induced Morphological Changes of Tight Junction in Endothelial Cell
  1403. Inhibitory effect of peptide-free forms of Advanced Glycation end products on the proliferation and extracellular matrix protein production of cultured cells
  1404. Advanced Glycation end products and coronary heart disease in type 2 diabetes.
  1405. Formation and ways of detecting Advanced Glycation end-products in isolated human glomerular basement membrane and human serum albumin nonenzymatically …
  1406. Advanced Glycation end products induce apoptosis and expression of apoptotic genes in cultured bovine retinal capillary pericytes
  1407. Intracellular changes in astrocytes and NG 108-15 neuroblastoma X glioma cells induced by Advanced Glycation end products
  1408. Sodium sulfite and N-acetylcysteine: new additives to dialysate for inhibiting formation of glucose degradation products and Advanced Glycation end-products
  1409. Mass Spectrum in the Study of Advanced Glycation end products
  1410. Diabetic erythrocytes bearing Advanced Glycation end products induce vascular dysfunctions
  1411. … Use of Solid Phase Extraction Cartridges as a Pre-Fractionation Step in the Quantisation of Intermolecular Collagen Crosslinks and Advanced Glycation End-Products
  1412. Effect of Advanced Glycation end products on rat aortic vascular smooth muscle cells
  1413. In vitro glycoxidation of insoluble fibrous type I collagen: solubilization and Advanced Glycation end products
  1414. Expression and function of receptors for Advanced Glycation end products in bovine corneal endothelial cells
  1415. Expression of receptors for Advanced Glycation end products at surface of peripheral blood monocytes and relationship thereof to plasma proinflammatory cytokines in …
  1416. Advanced Glycation end products in intervertebral discs and hip joint capsules: Correlation with senile amyloid?
  1417. Effects of flavone from leaves of Diospyros kaki on adventitial fibroblast proliferation induced by Advanced Glycation end-products in vitro
  1418. Effects of Advanced Glycation End-products on Expression of Peroxisome Proliferator Activated Receptor-γ mRNA in Cultured Human Vascular Endothelial Cells [J]
  1419. A modulatory role for Advanced Glycation end-products (AGEs)in retinal microvascular leukostasis
  1420. Molecular mechanism of diabetic retinopathy: role of Advanced Glycation end products (AGEs)and their receptor (RAGE) in the pathogenesis of diabetic retinopathy
  1421. Advanced Glycation end products -induced TNF-α and IL-6 production by peripheral lymphocytes of diabetic patients [J]
  1422. Effects of tonifying shen recipe on Advanced Glycation end products , amyloid-beta peptide in telencephalon and hippocampus of ovariectomized rats
  1423. Screening of natural resources with inhibitory activity on free radicals and Advanced Glycation end products (AGEs)formation
  1424. Effects of Advanced Glycation end products on oxidative stress in endothelial cells
  1425. Immunohistochemistry of Advanced Glycation end products in neurofilamentous axonal spheroids induced by β-β′-iminodipropionitrile in lower motor neurons of rat
  1426. The pathobiological effect of β_2-microglobulin modified with Advanced Glycation end products on human type B synovial cells [J]
  1427. Effects of Advanced Glycation end products on changes of glomerulus of STZ-induced diabetic rat
  1428. Recombinant human interleukin-10 inhibits proliferation of rat vascular smooth muscle cells stimulated by Advanced Glycation end products [J]
  1429. The Effect of Advanced Glycation end products on Macrophage Matrix Metalloproteinase-9 Activity and the Intervention Effect of Simvastatin
  1430. AGE (Advanced Glycation end products ) receptors in age–related macular degeneration
  1431. Advanced Glycation end products and pseudoexfoliation–correlation between clinical outcome and histological findings
  1432. Effects of Advanced Glycation end products on the expression of plasminogen activator inhibitor-1 in rat mesangial cells [J]
  1433. Advanced Glycation end-products and diabetic renal disease
  1434. The changes of Advanced Glycation end products in a rat liver fibrosis model and the interventional effect of aminoguanidin
  1435. Effect of Advanced Glycation end products (AGEs)on proliferation of vascular endothelial cells cultured in vitro
  1436. Evaluation of Advanced Glycation End–Products in Diabetic and Inherited Canine Cataracts
  1437. Effect of Wenjintong Composita on mRNA expression of receptor of the Advanced Glycation end products in sciatic nerve of streptozotocin-induced diabetic rats
  1438. Advanced Glycation end products induce apoptosis in corneal endothelium
  1439. Effects of carvedilol and metoprolol on plasma Advanced Glycation end products (AGE) and Advancedoxidation protein products (AOPP) in patients with chronic heart …
  1440. Inhibitory effect of pycnogenol on generation of Advanced Glycation end products in vitro
  1441. Expression of Advanced Glycation end products receptors on human joint synovial cells
  1442. Elevated Level of Imidazolone and Pyrraline, Major Components of Advanced Glycation end products , in the Vitreous Fluid of Patients With Diabetic Retinopathy
  1443. Effects of Advanced Glycation end products on activity and expression of eNOS in human umbilical vein endothelial cells
  1444. Effects of Advanced Glycation end products and hypoxia on endothelin-1 secretion by bovine retinal microvascular pericytes
  1445. Non-invasive assessment of Advanced Glycation end products , markers of oxidative stress, in recently preeclamptic women
  1446. In vitro effects of flavone from leaves of Diospyros kaki on rat cardiac myocyte apoptosis induced by hypoxia-reoxygenation and Advanced Glycation end products .
  1447. Effect of Different Advanced Glycation end products on Proliferation of Vascular Smooth Muscle Cell
  1448. Advanced Glycation end products in Nephrology
  1449. A new model of age-related macular degeneration induced by Advanced Glycation end products
  1450. Dietary Copper Deficiency Causes Elevation of Early and Advanced Glycation End-Products
  1451. Effects of Advanced Glycation end products on the activity of NF-kappaB and the expression of fibronectin mRNA in the endothelial cells in aged rats
  1452. Polymorphism 2184A/G in the gene encoding Receptor of Advanced Glycation end products (RAGE) is a newly identified risk factor for diabetic nephropathy
  1453. Influence of Advanced Glycation end-products in the development of atherosclerosis
  1454. Relation between dialysis-related amyloidosis and Advanced Glycation end products (AGEs)
  1455. Advanced Glycation end products -induced TNF-? and IL-6 production by peripheral lymphocytes of diabetic patients
  1456. Structure and function of the metal-binding protein S100B and its interaction with the receptor for Advanced Glycation end products
  1457. Monocyte/macrophage receptors for proteins modified by Advanced Glycation end products : role in normal tissue remodeling and in pathology
  1458. The Correlation Between Serum Advanced Glycation end products and Nitric Oxide Levels in Type 2 Diabetes and Chronic Complications of Diabetes
  1459. Alterations of retinal microvascular cell glycoproteins by Advanced Glycation end products
  1460. Immunohistochemical localization of Advanced Glycation end products in pinguecula.
  1461. Inhibitory effects of extracts from Ginkgo biloba and grape seed on the generation of Advanced Glycation end products in vitro
  1462. Pattern of CTGF mRNA expression induced by Advanced Glycation end products in mesangial cells [J]
  1463. Advanced Glycation end-products-LDL stimulates adhesion molecule expression by human aortic endothelial cells
  1464. Accelerated Aging in Glaucoma: Immunohistochemical Assessment of Advanced Glycation End–Products in the Human Retina and Optic Nerve Head
  1465. Effects of perindopril on expression of transformation growth factor-β type receptorⅡ in cultured human vascular endothelial cells by Advanced Glycation end products
  1466. Advanced Glycation end products and senile dementia
  1467. Recombinant Lapemis hardwickii phospholipase A2 inhibits rat vascular smooth muscle cell proliferation stimulated by Advanced Glycation end products
  1468. Advanced Glycation end products Act As A Skin Tumor Initiator in Mice
  1469. Enzyme-linked immunosorbent assay development for Advanced Glycation end products and brochocin-C.
  1470. Role of peroxisome proliferators activated receptor gamma in mediating proliferation of rat vascular smooth muscle cells induced by Advanced Glycation end products
  1471. Effects of Advanced Glycation end products on protein and mRNA expression of macrophage inflammatory protein-1α in cultured human umbilical vein endothelial …
  1472. The correlation between the Advanced Glycation end products (AGEs-P) and diabetic retinopathy
  1473. Proteolysis of the receptor for Advanced Glycation end products by matrix metalloproteinases
  1474. Effects of Advanced Glycation end products on osteoblastic cells
  1475. Advanced Glycation end-products induce global endothelial activation
  1476. Interaction of reactive oxygen species in atherogenetic properties of Advanced Glycation end products in diabetes
  1477. Effects of crocetin on formation of Advanced Glycation end products and expression of releptor for Advanced Glycation and prodmts protein in diabetic rats
  1478. Advanced Glycation end products in urine: Are some sugar-derived products better than others?
  1479. Effect of quercetin on generation of Advanced Glycation end products in vitro
  1480. 39. Synthesis of Labelled Advanced Glycation end products Using N-Succinimidyl 4-[18F] Fluorobenzoate
  1481. Effects of Advanced Glycation end products on Rat Bladder Fibroblast
  1482. Effect of Advanced Glycation end products on inflammation in cultured cardiomyocytes
  1483. Diet and diabetes, Advanced Glycation end products or AGEs
  1484. Deposition of Advanced Glycation end products in Climatic Droplet Keratopathy
  1485. Advanced Glycation end products (AGEs)related complications in diabetic nephropathy
  1486. Hypertension and Atherosclerosis: Advanced Glycation end products —A Common Link
  1487. PREVENTION OF THE MAILLARD REACTION AND REVERSIBLE DESTRUCTION OF Advanced Glycation end products (AGE) BY NOVEL ORGANIC …
  1488. EFFECTS OF Advanced Glycation end products (AGEs)ON ADHESION AND MULTIPLICATION IN E. coli
  1489. Effects of Advanced Glycation end products on the expression of ICAM-1 and VCAM-1 in ECV-304 cells
  1490. Effects of Advanced Glycation end products on expression and activity of PAI-1 in rat renal cortex
  1491. The effect of exogenous Advanced Glycation end products on the alteration of visual evoked potential in the rats
  1492. Expression of receptor for Advanced Glycation end products (RAGE) and its ligands S100/calgranulins and amphoterin is increased in the vitreous cavity of patients …
  1493. Immunological Approach to Advanced Glycation end products of The Maillard Reaction
  1494. Role of Advanced Glycation end products (AGE) in the development of diabetic microangiopathies and the beneficial effects of AGE inhibitors
  1495. Effects of Advanced Glycation end-products on skin keratinocytes by NF-? B activation
  1496. Advanced Glycation end products accumulate in the diabetic gallbladder
  1497. THE ACCUMULATION OF Advanced Glycation end products IN THE EXTRINSIC MAMBRANE FRACTIONS OF HUMAN CATARACTOUS LENSES [J]
  1498. Advanced Glycation end products are Associated With Diabetic Peripheral Macrovascular Complications
  1499. Inhibition of Inflammation due to Advanced Glycation End‐products by Pentoxifylline
  1500. Serum levels of Advanced Glycation end products are associated with in-stent restenosis in diabetic patients
  1501. Endocytosis of Advanced Glycation end products in Bovine Choriocapillary Endothelial Cells
  1502. Effects of Advanced Glycation end products on activi ty and expression of matrix metalloproteinase-2 in renal cortex of rats
  1503. Impaired glucose tolerance, angiopathy and Advanced Glycation end products
  1504. Effects of vitamin E on secretion of inflammatory mediators of human monocytes by Advanced Glycation end products
  1505. The presence and activity of the receptor for Advanced Glycation end products in osteoblasts
  1506. Glycationof basement membranes: Location of Advanced Glycation end products within type IV collagen and their effect on degradation by matrix proteases.
  1507. Advanced Glycation end products MODIFIED PROTEIN UP-REGULATES EXPRESSION OF ADHESION MOLECULES ON HUMAN ENDOTHELIAL CELLS
  1508. Role of Advanced Glycation end products (AGEs)in diabetic cardiovascular and renal disease
  1509. Gly82Ser polymorphism in the receptor for Advanced Glycation end products (RAGE) gene is not associated with the progression of diabetic nephropathy and …
  1510. Biodistribution of the 18F-labelled Advanced Glycation end products Nε-carboxymethyllysine (CML) and Nε-carboxyethyllysine (CEL)
  1511. 298 INVERSE RELATIONSHIP BETWEEN Advanced Glycation end products AND GLUTATHIONE IN SICKLE CELL ANEMIA
  1512. EXPRESSION AND REGULATION OF THE BINDING PROTEINS FOR Advanced Glycation end products ON HUMAN JOINT SYNOVIAL CELLS
  1513. Glyoxalase I deficiency is associated with an unusual level of Advanced Glycation end products in a hemodialysis patient
  1514. Response to ‘Do Advanced Glycation end products and glucose induce similar signaling events in mesangial cells?’
  1515. Advanced Glycation end products cross-links and diabetic-induced endothelium dysfunction
  1516. Advanced Glycation end products (AGEs)Reduce Vesicular Transport in RPE Cells
  1517. EFFECTS OF VITAMIN C AND VITAMIN E ON RECEPTORS OF Advanced Glycation end products IN EXPERIMENTAL DIABETIC RATS [J]
  1518. Advanced Glycation end products (AGE) enhance vascular endothelial growth factor (VEGF) production in promonocytic leukaemia THP-1 cells
  1519. Induction of Age-related Macular Degeneration (AMD) by Advanced Glycation End (AGE) Products and S100B
  1520. The Accumulation of Advanced Glycation end products in the Retinal Pigment Epithelium and in Bruch’s membrane of human donors.
  1521. Heparin blocks the binding of Advanced Glycation end products to its receptors on human monocytes
  1522. Advanced Glycation end products and Loss of Pericytes in Early Diabetic Retinopathy
  1523. Advanced Glycation end products AND AdvancedOXIDATION PROTEIN PRODUCTION IN PATIENTS WITH AA AMYLOIDOSIS
  1524. 3.3 INHIBITON OF PROTEIN GlycationAND Advanced Glycation end products BY FOODSTATE® VITAMIN C AND OTHER VITAMINS AND …
  1525. Effects of Advanced Glycation end products on peroxisome proliferator activated receptor-? mRNA expression in rat renal cortex
  1526. Advanced Glycation end products induce proliferation of vascular smooth muscle cells and antagonism of drugs
  1527. Effects of Advanced Glycation end products on the expression of plasminogen activator inhibitor-1 in rat mesangial cells
  1528. Formation of Advanced Glycation end products by glyceraldehyde and glyceraldehyde-3-phosphate with proteins.
  1529. P9 Participation of Advanced Glycation end products in actinic elastosis
  1530. Advanced Glycation end products (AGEs)lower the clearance function of hepatic scavenger endothelial cells (SEC)
  1531. Diabetic erythrocytes bearing Advanced Glycation end products (AGE) bind to the receptor for age and increase vascular permeability
  1532. ; EFFECT OF HIGH CONCENTRATION GLUCOSE AND Advanced Glycation end products ONMIP-1α mRNA EXPRESSION IN CULTURED HUMAN …
  1533. Effect of high concentration glucose and Advanced Glycation end products on MIP-1# alpha# mRNA expression in cultured human umbilical vein endothelial cells
  1534. Relationship between the Advanced Glycation end products content and expressions of RAGE, ICAM-1 in vascular tissue of diabetic rats
  1535. Biodistribution of the {sup 18} F-labelled Advanced Glycation end products N {sup {epsilon}}-carboxymethyllysine (CML) and N {sup {epsilon}}-carboxyethyllysine (CEL …
  1536. Effects of Advanced Glycation end products on the survival and the morphology of bovine retinal endothelial cells and pericytes
  1537. Advanced Glycation end products (AGEs)Induce Glomerular Sclerosis and Albuminuria in Normal Rats
  1538. Effects of Advanced Glycation end products on glycosphingolipids of retinal pericytes
  1539. < SYMPOSIUM: Biology of Aging and Age-associated Skin Disorders> POSSIBLE ROLES OF Advanced Glycation END-PRODUCTS IN PROMOTING SKIN …
  1540. Effects of Advanced Glycation end products on protein and mRNA expression of macrophage inflammatory protein-1? in cultured human umbilical vein endothelial …
  1541. Advanced Glycation end products -induced inflammatory reaction in human monocytes: cellular receptor pathway & intracellu-lar signaling
  1542. Vector construction for the intracellular domain of human receptor for Advanced Glycation end-products and expression of the fusion protein
  1543. Effects of Wen-Jin-Tong on the formation of Advanced Glycation end products and expressions of RAGE and ICAM-1 in cardiovascular tissues of diabetic rats
  1544. The Receptor for Advanced Glycation end products Is Induced by the GlycationProducts Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by …
  1545. Advanced Glycation end products Induce Expression of Vascular Endothelial Growth Factor by Retinal Müller Cells.
  1546. Mechanism of migration of vascular adventitial fibroblasts enhanced by Advanced Glycation end-products and the inhibition effect of candesartan
  1547. Advanced Glycation end products MEDIATE ANG II-DEPENDENT PRO-INFLAMMATORY RESPONSES IN A TRANSGENIC RAT MODEL: 2C. 5
  1548. Effects of Probenecid on the Elimination of the Advanced Glycation End-products Ne-Carboxymethyllysine (CML) and Ne-Carboxyethyllysine (CEL) Using …
  1549. Rapid Communication: Blockade of Angiotensin II Receptors Reduces the Expression of Receptors for Advanced Glycation end products in Human Endothelial Cells
  1550. Immunohistochemical demonstration of Advanced Glycation end products in synovial amyloid deposits of patients on long-term hemodialysis
  1551. Advanced Glycation end products Increases U937 Macrophages Expression of Scavenger Receptor Class B Type I
  1552. Inhibitory effects of extracts from {sl Ginkgo biloba} and grape seed on the generation of Advanced Glycation end products {sl in vitro}
  1553. Effects of tetramethylpyrazine on the expression of nuclear factorkappa B induced by Advanced Glycation end products in retinal pigment epithelium
  1554. Naphthopyrone Glucosides from the Seeds of Cassia tora with Inhibitory Activity on Advanced Glycation end products (AGEs)Formation
  1555. MOLECULAR ANALYSIS OF RECEPTOR FOR Advanced Glycation END-PRODUCTS ISOFORMS EXPRESSED IN TISSUES AND CELL LINES.: 123
  1556. Effect of aminoguanidine on mRNA expression of specific receptor of the Advanced Glycation end products in diabetic kidney tissue in rats
  1557. Puerarin reduces serum levels of Advanced Glycation end products and monocyte chemoattractant protein-1 in diabetic rats
  1558. Advanced Glycation end products -induced MCP-1 expression via its receptor RAGE in mouse podocytes
  1559. N-acetylcysteine inhibits Advanced Glycation end products -induced VCAM-1 expression in mouse cardiac microvascular endothelial cells
  1560. Inhibition of green tea polyphenols on proliferation of rat vascular smooth muscle cells stimulated by Advanced Glycation end products
  1561. Localization of Advanced Glycation end products (AGE) in actinic elastosis.
  1562. Advanced Glycation end products induce actin rearrangement and subsequent hyperpermeability in endothelial cells
  1563. Macrophage Scavenger Receptor Mediates The Endocytic Uptake of Advanced Glycation end products (AGEs)
  1564. Galectin-3,[Beta]-Galactoside-Binding Lectin, as a Receptor for Advanced Glycation end products
  1565. Modification of enzymatic antioxidants in bovine retinal capillary pericytes by Advanced Glycation end products
  1566. A 24-nor-Triterpenoid from the Steins of Rumex japonicus with Advanced Glycation End-products (AGEs)Inhibitory Activity
  1567. Receptor for Advanced Glycation end products (RAGE) in Pulmonary Fibrosis
  1568. Ginkgo biloba extract attenuates Advanced Glycation end products -induced TGF-? _1, CTGF mRNA expression and oxidative stress in NRK-49F cells
  1569. Regulation of adhesion molecule expression on retinal capillary endothelium by exposure to high glucose: a role for Advanced Glycation end–products (AGEs) ?
  1570. Effects of Advanced Glycation end-products on expression of acyl coenzyme A: cholesterol acyltransferase-1 in THP-1 macrophages
  1571. Role of Advanced Glycation end products in TGF-β1 and Fibronectin Expression in Mesangial Cells Cultured under High Glucose
  1572. Angiotensin-Converting Enzyme Inhibition Influences Serum Levels of Advanced Glycation end products in Patients with Coronary Artery Disease: Results from a …
  1573. Insulin Accelerates the Endocytic Uptake and Degradation of Advanced Glycation End-Products Mediated by The Macrophage Scavenger Receptor
  1574. Functional Hyperhomocysteinemia in Healthy Vegetar-ians: No Association with Advanced Glycation end products , Markers of Protein Oxidation, or Lipid …
  1575. Advanced Glycation end products (AGEs)exacerbate NAFLD progression to liver fibrosis via receptor for AGEs (RAGE) in high fat fed mice
  1576. Identification of N ε carboxymethyl lysine as a native structure for Advanced Glycation end products in circulation and amyloid fibrils in chronic hemodialysis patients
  1577. Advanced Glycation end products and thiobarbituric acid reactive substance in gingival tissues of diabetic and non-diabetic patients with chronic periodontitis
  1578. The inflammatory and immunogenic properties of the receptor for Advanced Glycation end products and its ligand, high mobility group box chromosomal …
  1579. Screening and identification of proteins that interact with receptor for Advanced Glycation end products (RAGE) via T7 select phage display system
  1580. Inhibition of Diabetic Leukostasis and Blood–Retinal Barrier Breakdown With a Soluble Form of a Receptor for Advanced Glycation end products
  1581. SUPPRESSION OF Advanced Glycation AND LIPOXIDATION end products BY AN ANGIOTENSIN II TYPE-1 RECEPTOR BLOCKER IN ESSENTIAL …
  1582. Superoxide Mediates Through ERK Signaling TGF-β1 Expression in Rat Kidney Proximal Tubule Epithelial Cells Treated with Advanced Glycation end products
  1583. Effects of Advanced Glycation end products on expression of scavenger receptor class B type I (SR-BI) in U937 macrophages
  1584. Essential role of receptor for Advanced Glycation end products (RAGE) in the inflammatory response and mucosal injury after hemorrhagic shock (HS)
  1585. … System (RAS) Inhibits Increased Matrix Metalloproteinase-9 Expression and Apoptosis Induced by Advanced Glycation end products (AGE) and Attenuates Receptor …
  1586. Small Interfering RNA (siRNA) Targeting Receptor for Advanced Glycation end products (RAGE) Downregulates Stromal Cell Derived Factor 1 (SDF-1) in …
  1587. The role of Advanced Glycation end products in progression and complications of diabetes
  1588. Advanced Glycation end products in foods and a practical guide to their reduction in the diet
  1589. Advanced Glycation end‐products and the kidney
  1590. Dietary Advanced Glycation end products and aging
  1591. Does accumulation of Advanced Glycation end products contribute to the aging phenotype?
  1592. Advanced Glycation end products and insulin resistance
  1593. The road to Advanced Glycation end products : a mechanistic perspective
  1594. Advanced Glycation end products , diabetes and ageing
  1595. Role of Advanced Glycation end products in diabetic neuropathy
  1596. Advanced Glycation end‐products (AGEs)and heart failure: pathophysiology and clinical implications
  1597. Advanced Glycation end products , oxidative stress and diabetic nephropathy
  1598. Advanced Glycation end products and diabetic foot disease
  1599. Possible involvement of Advanced Glycation end-products (AGEs)in the pathogenesis of Alzheimer’s disease
  1600. Mechanisms of disease: Advanced Glycation end-products and their receptor in inflammation and diabetes complications
  1601. Advanced Glycation end-products: implications for diabetic and non-diabetic nephropathies
  1602. Advanced Glycation end-products and arterial stiffness in hypertension
  1603. Advanced Glycation end-products (AGEs) : involvement in aging and in neurodegenerative diseases
  1604. The role of Advanced Glycation end products in retinal ageing and disease
  1605. Advanced Glycation end products (AGEs)and their involvement in liver disease
  1606. Advanced Glycation end-products and bone fractures
  1607. Calcitriol blunts the deleterious impact of Advanced Glycation end products on endothelial cells
  1608. Advanced Glycation end products and cardiovascular disease
  1609. Food-derived Advanced Glycation end products (AGEs) : a novel therapeutic target for various disorders
  1610. Collagen, cross-linking, and Advanced Glycation end products in aging human skeletal muscle
  1611. Trends in Advanced Glycation end products research in diabetes mellitus and its complications
  1612. Plasma receptor for Advanced Glycation end products and clinical outcomes in acute lung injury
  1613. Soluble form of a receptor for Advanced Glycation end products (sRAGE) as a biomarker.
  1614. The receptor for Advanced Glycation end products (RAGE) and the lung
  1615. Significance of Advanced Glycation end products in aging-related disease
  1616. A role for the receptor for Advanced Glycation end products in idiopathic pulmonary fibrosis
  1617. Rutin metabolites: novel inhibitors of nonoxidative Advanced Glycation end products
  1618. Role of Advanced Glycation end products (AGEs)and oxidative stress in diabetic retinopathy
  1619. Clinical and prognostic value of Advanced Glycation end-products in chronic heart failure
  1620. Receptor for Advanced Glycation end products (RAGEs) and experimental diabetic neuropathy
  1621. Elevated levels of serum Advanced Glycation end products in patients with non‐alcoholic steatohepatitis
  1622. The role of the receptor for Advanced Glycation end-products in lung fibrosis
  1623. Advanced Glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways
  1624. Dietary Advanced Glycation end products –a risk to human health? A call for an interdisciplinary debate
  1625. Receptor for Advanced Glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes
  1626. The extracellular region of the receptor for Advanced Glycation end products is composed of two independent structural units
  1627. Role of Advanced Glycation end products in hypertension and atherosclerosis: therapeutic implications
  1628. Advanced Glycation end products in renal failure: an overview
  1629. Receptor for Advanced Glycation end products activation injures primary sensory neurons via oxidative stress
  1630. Soluble receptor for Advanced Glycation end products : a new biomarker in diagnosis and prognosis of chronic inflammatory diseases
  1631. Advanced Glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease
  1632. Inhibitory effects of Chrysanthemum species extracts on formation of Advanced Glycation end products
  1633. Advanced Glycation end products increases matrix metalloproteinase-1,-3, and-13, and TNF-α in human osteoarthritic chondrocytes
  1634. Advanced Glycation end products accumulate in the reproductive tract of men with diabetes
  1635. Advanced Glycation end products enhance the proliferation and activation of hepatic stellate cells
  1636. Structural basis for pattern recognition by the receptor for Advanced Glycation end products (RAGE)
  1637. Receptor for Advanced Glycation end products is subjected to protein ectodomain shedding by metalloproteinases
  1638. Advanced Glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells
  1639. Single oral challenge by Advanced Glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects
  1640. Elevated serum Advanced Glycation end products and poor grip strength in older community-dwelling women
  1641. Elevation of soluble form of receptor for Advanced Glycation end products (sRAGE) in diabetic subjects with coronary artery disease
  1642. Advanced Glycation end-products enhance calcification in vascular smooth muscle cells
  1643. Effect of pyridoxamine (K-163), an inhibitor of Advanced Glycation end products , on type 2 diabetic nephropathy in KK-Ay/Ta mice
  1644. Expression of high-mobility group box 1 and of receptor for Advanced Glycation end products in chronic obstructive pulmonary disease
  1645. Advanced Glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes
  1646. Plasma Advanced Glycation end products are decreased in obese children compared with lean controls
  1647. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for Advanced Glycation end products (RAGE) and RAGE ligands
  1648. Advanced Glycation end products strongly activate platelets
  1649. Role of soluble receptor for Advanced Glycation end products on endotoxin-induced lung injury
  1650. Effects of Advanced Glycation end products on the expression of COX-2, PGE2 and NO in human osteoarthritic chondrocytes
  1651. Endothelial dysfunction in patients with chronic kidney disease results from Advanced Glycation end products (AGE) -mediated inhibition of endothelial nitric oxide …
  1652. Advanced Glycation end-products induce tubular CTGF via TGF-β–independent Smad3 signaling
  1653. Protection against loss of innate defenses in adulthood by low Advanced Glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1
  1654. Advanced Glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes
  1655. Homodimerization is essential for the receptor for Advanced Glycation end products (RAGE)-mediated signal transduction
  1656. Advanced Glycation end products and receptor–oxidative stress system in diabetic vascular complications
  1657. Interactions between Advanced Glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors …
  1658. Immunohistochemical localization of Advanced Glycation end-products (AGEs)and their receptor (RAGE) in polycystic and normal ovaries
  1659. Role of Toll-like receptors 2 and 4, and the receptor for Advanced Glycation end products in high-mobility group box 1–induced inflammation in vivo
  1660. Serum levels of sRAGE, the soluble form of receptor for Advanced Glycation end products , are associated with inflammatory markers in patients with type 2 …
  1661. Increased serum Advanced Glycation end‐products is a distinct finding in lean women with polycystic ovary syndrome (PCOS)
  1662. Advanced Glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species
  1663. Advanced Glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women
  1664. Advanced Glycation end products as biomarkers and gerontotoxins–a basis to explore methylglyoxal-lowering agents for Alzheimer’s disease?
  1665. Accumulation of Advanced Glycation end products and chronic complications in ESRD treated by dialysis
  1666. Advanced Glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK
  1667. The receptor for Advanced Glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival
  1668. Receptor for Advanced Glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications
  1669. Accelerated aging in glaucoma: immunohistochemical assessment of Advanced Glycation end products in the human retina and optic nerve head
  1670. Advanced Glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways
  1671. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for Advanced Glycation end products
  1672. Role of Advanced Glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice
  1673. Effects of atorvastatin on serum soluble receptors for Advanced Glycation end-products in type 2 diabetes
  1674. Plasma levels of receptor for Advanced Glycation end products , blood transfusion, and risk of primary graft dysfunction
  1675. Convergence and amplification of toll-like receptor (TLR) and receptor for Advanced Glycation end products (RAGE) signaling pathways via high mobility group B1 …
  1676. Advanced Glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway
  1677. Involvement of Advanced Glycation end products in the pathogenesis of diabetic complications: the protective role of regular physical activity
  1678. Receptor for Advanced Glycation end products : fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial …
  1679. Association between circulating soluble receptor for Advanced Glycation end products and atherosclerosis: observations from the Dallas Heart Study
  1680. Advanced Glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor
  1681. Deletion of the receptor for Advanced Glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse
  1682. Receptor for Advanced Glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress
  1683. Receptor for Advanced Glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication
  1684. Astragalosides isolated from the root of astragalus radix inhibit the formation of Advanced Glycation end products
  1685. Chondroprotective effects and mechanisms of resveratrol in Advanced Glycation end products -stimulated chondrocytes
  1686. Higher plasma soluble receptor for Advanced Glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in …
  1687. Alternative splicing of the murine receptor for Advanced Glycation end‐products (RAGE) gene
  1688. … enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for Advanced Glycation end products
  1689. Dihydrochalcones: Implication in resistance to oxidative stress and bioactivities against Advanced Glycation end-products and vasoconstriction
  1690. Effects of Advanced Glycation end products on renal fibrosis and oxidative stress in cultured NRK-49F cells
  1691. Receptor for Advanced Glycation end products (RAGE)—soluble form (sRAGE) and gene polymorphisms in patients with breast cancer
  1692. Cancer malignancy is enhanced by glyceraldehyde-derived Advanced Glycation end-products
  1693. In skeletal muscle Advanced Glycation end products (AGEs)inhibit insulin action and induce the formation of multimolecular complexes including the receptor …
  1694. Advanced Glycation end products (AGEs)activate mast cells
  1695. The combination of high glucose and Advanced Glycation end-products (AGEs)inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced …
  1696. Distribution of the receptor for Advanced Glycation end products in the human male reproductive tract: prevalence in men with diabetes mellitus
  1697. Advanced Glycation end products in senile diabetic and nondiabetic patients with cataract
  1698. Role of the receptor for Advanced Glycation end products in hepatic fibrosis
  1699. Thiazolidinedione increases serum soluble receptor for Advanced Glycation end-products in type 2 diabetes
  1700. Advanced Glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2
  1701. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for Advanced Glycation end products
  1702. Advanced Glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase
  1703. Plasma protein Advanced Glycation end products , carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with …
  1704. Inhibitors of aldose reductase and Advanced Glycation end-products formation from the leaves of Stelechocarpus cauliflorus RE Fr.
  1705. Immunological detection of fructose-derived Advanced Glycation end-products
  1706. Receptor for Advanced Glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo
  1707. Receptor for Advanced Glycation end products : its role in Alzheimer’s disease and other neurological diseases
  1708. Advanced Glycation end-products induce cell cycle arrest and hypertrophy in podocytes
  1709. Decreased formation of Advanced Glycation end-products in peritoneal fluid by carnosine and related peptides
  1710. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for Advanced Glycation end products ) immunoglobulin …
  1711. Inhibitors of Advanced Glycation end products (AGEs) : potential utility for the treatment of cardiovascular disease
  1712. … of Advanced Glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of Advanced
  1713. Circulating soluble receptor for Advanced Glycation end products is inversely associated with body mass index and waist/hip ratio in the general population
  1714. The expression of receptor for Advanced Glycation end products is associated with angiogenesis in human oral squamous cell carcinoma
  1715. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for Advanced Glycation end products
  1716. The receptor for Advanced Glycation end products impairs host defense in pneumococcal pneumonia
  1717. Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by Advanced Glycation end products
  1718. Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for Advanced Glycation end-products (RAGE)
  1719. Nox1-based NADPH oxidase-derived superoxide is required for VSMC activation by Advanced Glycation end-products
  1720. Solution Structure of the Variable-Type Domain of the Receptor for Advanced Glycation end products : New Insight into AGE−RAGE Interaction,
  1721. Advanced Glycation end-products affect transcription factors regulating insulin gene expression
  1722. Receptor for Advanced Glycation end products is detrimental during influenza A virus pneumonia
  1723. Opposing effects of bisphosphonates and Advanced Glycation end-products on osteoblastic cells
  1724. Decrease in serum levels of Advanced Glycation end-products by short-term lifestyle modification in non-diabetic middle-aged females
  1725. Receptor for Advanced Glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer
  1726. Receptors for Advanced Glycation end-products targeting protect against hyperoxia-induced lung injury in mice
  1727. A novel function of the receptor for Advanced Glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC
  1728. Receptor for Advanced Glycation end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury
  1729. Advanced Glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells
  1730. Association of polymorphism in the receptor for Advanced Glycation end products (RAGE) gene with circulating RAGE levels
  1731. Induction of apoptosis of β cells of the pancreas by Advanced Glycation end‐products, important mediators of chronic complications of diabetes mellitus
  1732. Glycationend products on stored red blood cells increase endothelial reactive oxygen species generation through interaction with receptor for Advanced Glycation end …
  1733. Anti-receptor for Advanced Glycation end products therapies as novel treatment for abdominal aortic aneurysm
  1734. Advanced Glycation end products and their circulating receptors and level of kidney function in older community-dwelling women
  1735. Possible involvement of Advanced Glycation end products in periodontal diseases
  1736. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for Advanced Glycation end products (sRAGE) in diabetes
  1737. ERM protein moesin is phosphorylated by Advanced Glycation end products and modulates endothelial permeability
  1738. S100B Interaction With the Receptor for Advanced Glycation end products (RAGE) A Novel Receptor-Mediated Mechanism for Myocyte Apoptosis Postinfarction
  1739. Hypoxia-inducible factor-1 mediates neuronal expression of the receptor for Advanced Glycation end products following hypoxia/ischemia
  1740. Soluble receptor for Advanced Glycation end products in physiological and pathological pregnancy
  1741. Receptor for Advanced Glycation end products —soluble form and gene polymorphisms in chronic haemodialysis patients
  1742. Role of the receptor for Advanced Glycation end products (RAGE) in inflammation
  1743. Serum levels of soluble receptor for Advanced Glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk …
  1744. Decreased plasma levels of soluble receptor for Advanced Glycation end products in mild cognitive impairment
  1745. Advanced Glycation end products Inhibit Glucose-Stimulated Insulin Secretion through Nitric Oxide-Dependent Inhibition of Cytochrome c Oxidase and Adenosine …
  1746. Citrus Fruit Extracts Reduce Advanced Glycation end products (AGEs) – and H2O2-Induced Oxidative Stress in Human Adipocytes
  1747. Glutaraldehyde is an effective cross-linker for production of antibodies against Advanced Glycation end-products
  1748. Soluble Receptor for Advanced Glycation end products (RAGE) is a prognostic factor for heart failure
  1749. Short-term low calorie diet intervention reduces serum Advanced Glycation end products in healthy overweight or obese adults
  1750. The formation of intracellular glyceraldehyde-derived Advanced Glycation end-products and cytotoxicity
  1751. … increase is associated with skeletal muscle immunostaining for Advanced Glycation end products , receptor for Advanced Glycation end products , and oxidation injury
  1752. Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for Advanced Glycation end products and potentiates inflammation with highly homologous but …
  1753. Advanced Glycation end products in patients with cerebral infarction
  1754. Serum levels of soluble form of receptor for Advanced Glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in …
  1755. The role of Advanced Glycation end-products (AGEs)in the development of vascular diabetic complications
  1756. Soluble receptors for Advanced Glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention
  1757. Advanced Glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina
  1758. Evidence for activation of Toll-like receptor and receptor for Advanced Glycation end products in preterm birth
  1759. Effect of taurine-conjugated ursodeoxycholic acid on endoplasmic reticulum stress and apoptosis induced by Advanced Glycation end products in cultured mouse …
  1760. Smooth muscle cell pathophysiology and Advanced Glycation end products (AGEs)
  1761. An in vitro model to test the contribution of Advanced Glycation end products to bone biomechanical properties
  1762. The receptor for Advanced Glycation end products (RAGE) system in women with intraamniotic infection and inflammation
  1763. Mitigating effects of antioxidant properties of Artemisia campestris leaf extract on hyperlipidemia, Advanced Glycation end products and oxidative stress in alloxan …
  1764. Association of the Gly82Ser polymorphism in the receptor for Advanced Glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory …
  1765. Gly82Ser polymorphism of the receptor for Advanced Glycation end products is associated with an increased risk of gastric cancer in a Chinese population
  1766. Do Advanced Glycation end products contribute to the development of long-term diabetic complications?
  1767. Low serum level of the endogenous secretory receptor for Advanced Glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of …
  1768. Advanced Glycation end products inhibit the expression of collagens type I and III by human gingival fibroblasts
  1769. Advanced Glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy
  1770. Circulating Advanced Glycation end products (AGEs)and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte …
  1771. Advanced Glycation end products induce in vitro cross‐linking of α‐synuclein and accelerate the process of intracellular inclusion body formation
  1772. Advanced Glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?
  1773. Receptor for Advanced Glycation end-products (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix
  1774. Olmesartan blocks inflammatory reactions in endothelial cells evoked by Advanced Glycation end products by suppressing generation of reactive oxygen species
  1775. Plasma levels of Advanced Glycation end products are associated with haemolysis‐related organ complications in sickle cell patients
  1776. Plasma receptor for Advanced Glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation
  1777. Receptor for Advanced Glycation end products Facilitates Host Defense during Escherichia coli–Induced Abdominal Sepsis in Mice
  1778. Metformin reduces endothelial cell expression of both the receptor for Advanced Glycation end products and lectin-like oxidized receptor 1
  1779. … -to-basolateral transport of amyloid-β peptides through blood-brain barrier cells is mediated by the receptor for Advanced Glycation end-products and is restricted by P …
  1780. Elevated levels of the receptor for Advanced Glycation end products , a marker of alveolar epithelial type I cell injury, predict impaired alveolar fluid clearance in …
  1781. Ribosylation rapidly induces α-synuclein to form highly cytotoxic molten globules of Advanced Glycation end products
  1782. Monocyte CD147 is induced by Advanced Glycation end products and high glucose concentration: possible role in diabetic complications
  1783. Biologic variability in plasma glucose, hemoglobin A1c, and Advanced Glycation end products associated with diabetes complications
  1784. Identifying Advanced Glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in …
  1785. Blockade of PKC-beta protects HUVEC from Advanced Glycation end products induced inflammation
  1786. Effect of circulating soluble receptor for Advanced Glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in …
  1787. Plasma concentrations of high-mobility group box protein 1, soluble receptor for Advanced Glycation end-products and circulating DNA in patients with acute …
  1788. Glycated albumin, a precursor of Advanced Glycation end‐products, up‐regulates NADPH oxidase and enhances oxidative stress in human endothelial cells …
  1789. Flavan-3-ols having a γ-lactam from the roots of Actinidia arguta inhibit the formation of Advanced Glycation end products in vitro
  1790. Transport of the Advanced Glycation end products alanylpyrraline and pyrralylalanine by the human proton-coupled peptide transporter hPEPT1
  1791. … elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for Advanced Glycation end products
  1792. Receptor for Advanced Glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease
  1793. Restricted intake of dietary Advanced Glycation end products retards renal progression in the remnant kidney model
  1794. Amyloid β interaction with receptor for Advanced Glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood …
  1795. The inhibition of Advanced Glycation end-products-induced retinal vascular permeability by silver nanoparticles
  1796. Advanced Glycation end products (AGEs)and cardiovascular disease (CVD) in diabetes
  1797. Soluble receptor for Advanced Glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer
  1798. Serum levels of soluble form of receptor for Advanced Glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects
  1799. Precursor of Advanced Glycation end products mediates ER-stress-induced caspase-3 activation of human dermal fibroblasts through NAD (P) H oxidase 4
  1800. Pigment-epithelium-derived factor suppresses expression of receptor for Advanced Glycation end products in the eye of diabetic rats
  1801. Receptor for Advanced Glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma
  1802. Developmental expression of the receptor for Advanced Glycation end-products (RAGE) and its response to hyperoxia in the neonatal rat lung
  1803. Skin-autofluorescence, a measure of tissue Advanced Glycation end-products (AGEs) , is related to diastolic function in dialysis patients
  1804. … ribonuclear protein K and microRNA-16 in cyclooxygenase-2 RNA stability induced by S100b, a ligand of the receptor for Advanced Glycation end products
  1805. Effect of long‐term orlistat treatment on serum levels of Advanced Glycation end‐products in women with polycystic ovary syndrome
  1806. Possible link of food-derived Advanced Glycation end products (AGEs)to the development of diabetes
  1807. Advanced Glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells
  1808. Increased serum Advanced Glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy
  1809. Soluble receptor for Advanced Glycation end products in multiple sclerosis: a potential marker of disease severity
  1810. Blockage of receptor for Advanced Glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice
  1811. Advanced Glycation end products in pregnancies complicated with diabetes mellitus or preeclampsia
  1812. Diagnostic utility of serum or cerebrospinal fluid levels of toxic Advanced Glycation end-products (TAGE) in early detection of Alzheimer’s disease
  1813. Low levels of soluble receptor for Advanced Glycation end products in non-ST elevation myocardial infarction patients
  1814. PPARγ-mediated Advanced Glycation end products regulation of neural stem cells
  1815. Soluble receptor for Advanced Glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and …
  1816. Advanced Glycation end products (AGEs)and their receptors (RAGEs) in diabetic vascular disease
  1817. Advanced Glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow …
  1818. Receptor for Advanced Glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse
  1819. Advanced Glycation end products of DNA: Quantification of N2-(1-Carboxyethyl)-2′-deoxyguanosine in Biological Samples by Liquid Chromatography …
  1820. Expression of the receptor for Advanced Glycation end products in oligodendrocytes in response to oxidative stress
  1821. Expression of the receptor of Advanced Glycation end products in the gingival tissue of smokers with generalized periodontal disease and after nornicotine induction in …
  1822. Advanced Glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells
  1823. Positive association of serum levels of Advanced Glycation end products and high mobility group box–1 with asymmetric dimethylarginine in nondiabetic chronic …
  1824. A neutralizing antibody against receptor for Advanced Glycation end products (RAGE) reduces atherosclerosis in uremic mice
  1825. Androgens associated with Advanced Glycation end-products in postmenopausal women
  1826. Advanced Glycation and lipoxidation end products –amplifiers of inflammation: the role of food
  1827. A novel role for the Receptor for Advanced Glycation End-products in neural progenitor cells derived from adult SubVentricular Zone
  1828. Advanced Glycation end-products suppress neuropilin-1 expression in podocytes
  1829. Combined immunoelectron microscopic and computer-assisted image analyses to detect Advanced Glycation end-products in human myocardium
  1830. Olmesartan blocks Advanced Glycation end products (AGEs) -induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression
  1831. Internalization of the receptor for Advanced Glycation end products (RAGE) is required to mediate intracellular responses
  1832. The role of the receptor for Advanced Glycation end-products in a murine model of silicosis
  1833. Advanced Glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia
  1834. Serum level of Advanced Glycation end-products (AGEs)is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population
  1835. Role of maltol in Advanced Glycation end products and free radicals: in‐vitro and in‐vivo studies
  1836. Analysis of DNA-bound Advanced Glycation end-products by LC and mass spectrometry
  1837. Expression of Advanced Glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis
  1838. Angiotensin II receptor blocker inhibits abnormal accumulation of Advanced Glycation end products and retinal damage in a rat model of type 2 diabetes
  1839. Analysis and biological relevance of Advanced Glycation end‐products of DNA in eukaryotic cells
  1840. Cloning, characterisation, and comparative quantitative expression analyses of receptor for Advanced Glycation end products (RAGE) transcript forms
  1841. Effect of taurine on Advanced Glycation end products -induced hypertrophy in renal tubular epithelial cells
  1842. Inhibition of Advanced Glycation end products (AGEs) : An implicit goal in clinical medicine for the treatment of diabetic nephropathy?
  1843. Induction of receptor for Advanced Glycation end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis …
  1844. Diabetic threesome (hyperglycaemia, renal function and nutrition) and Advanced Glycation end products : evidence for the multiple-hit agent?
  1845. Detection of feto-maternal infection/inflammation by the soluble receptor for Advanced Glycation end products (sRAGE): results of a pilot study
  1846. Hepatic expression of galectin-3 and receptor for Advanced Glycation end products in patients with liver disease
  1847. Receptor for Advanced Glycation end products in donor lungs is associated with primary graft dysfunction after lung transplantation
  1848. Serum amyloid A activates nuclear factor-kappaB in rheumatoid synovial fibroblasts through binding to receptor of Advanced Glycation end-products.
  1849. … cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for Advanced Glycation end products and of connective tissue …
  1850. Immunohistochemical demonstration of Advanced Glycation end products and the effects of Advanced Glycation end products in ossified ligament tissues in vitro
  1851. Constituents of the flowers of Platycodon grandiflorum with inhibitory activity on Advanced Glycation end products and rat lens aldose reductase in vitro
  1852. Receptor for Advanced Glycation end products and neuronal deficit in the fatal brain edema of diabetic ketoacidosis
  1853. Pigment epithelium-derived factor inhibits Advanced Glycation end products -induced retinal vascular permeability
  1854. Plasma levels of soluble receptor for Advanced Glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic …
  1855. Inhibitors of Aldose Reductase and Formation of Advanced Glycation End-Products in Moutan Cortex (Paeonia suffruticosa)
  1856. Receptor for Advanced Glycation end products (RAGE) mediates neuronal differentiation and neurite outgrowth
  1857. Ectodomain shedding of the receptor for Advanced Glycation end products : a novel therapeutic target for Alzheimer’s disease
  1858. Expression of receptor for Advanced Glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma
  1859. Adverse effects of Advanced Glycation end products on embryonal development
  1860. Fluorescent Advanced Glycation end products in the detection of factual stages of cartilage degeneration.
  1861. Expression of senescence-associated β-galactosidase (SA-β-Gal) by human skin fibroblasts, effect of Advanced Glycation end-products and fucose or rhamnose-rich …
  1862. Receptor for Advanced Glycation end products is upregulated in optic neuropathy of Alzheimer’s disease
  1863. Levels of soluble receptor for Advanced Glycation end products in acute ischemic stroke without a source of cardioembolism
  1864. Assaying soluble forms of receptor for Advanced Glycation end products
  1865. C-reactive protein (CRP) up-regulates expression of receptor for Advanced Glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells …
  1866. Grape seed proanthocyanidin extracts inhibit vascular cell adhesion molecule expression induced by Advanced Glycation end products through activation of …
  1867. Peroxyl radicals are essential reagents in the oxidation steps of the Maillard reaction leading to generation of Advanced Glycation end products
  1868. Specific siRNA targeting the receptor for Advanced Glycation end products inhibits experimental hepatic fibrosis in rats
  1869. … epithelium‐derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of Advanced Glycation end products
  1870. Inhibition of L-arginine metabolizing enzymes by L-arginine-derived Advanced Glycation end products
  1871. Inhibitory effect of GSPE on RAGE expression induced by Advanced Glycation end products in endothelial cells
  1872. Advanced Glycation end products ‐induced apoptosis attenuated by PPARδ activation and epigallocatechin gallate through NF‐κB pa